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Annex 1: Expert consultation 
Introduction  
This document is a consultation document for the expert group of the ‘Study on impact 
analysis of policy options for strengthened EU cooperation on HTA’. It includes background 
information as well as a range of questions regarding the identified policy options for 
cooperation on HTA on EU level and possible impacts.  
As a member of the expert group established for the duration of this project we kindly 
invite you to respond to these questions to support us in ensuring the quality, feasibility 
and relevance of the policy options on HTA cooperation. 
The document is structured in 4 parts:  
1. Background information to this study 
2. Description on baseline scenario and related questions 
3. Information on policy options and related questions 
4. Questions regarding impacts for assessing the policy options 
 
 Background information 
The European Commission (EC) is exploring options for a new, sustainable mechanism for 
HTA in Europe after 2020. Consequently, the Directorate General for Health and Food 
Safety (DG SANTE) of the European Commission started an impact assessment process 
and launched a public consultation on 21 October 2016(1).    
In the framework of this process, the EC commissioned the consortium of Sogeti, the 
Austrian Public Health Institute (GÖ FP) and the London School of Economics and Political 
Science (LSE Health) to conduct an impact analysis of policy options for strengthened EU 
cooperation on HTA in order to support the Impact Assessment process of the EC 
with data and evidence.  
Possible policy options for cooperation on HTA on EU level have been identified within the 
Inception Impact Assessment published by the EC(2). These are further developed by the 
Commission in the course of the study and expert input is required to ensure their validity 
and reliability.  
In the course of the study a systematic literature review as well as a desk research of HTA 
and its use in EU Member States will be performed. A detailed case study covering 40 
health technologies including pharmaceuticals, medical devices and other technologies 
(such as screening programs) will be conducted to assess the status quo. Data for this 
case study will be retrieved by literature review and an additional survey process to 
complement information retrieved.  
Moreover, data will be collected to assess the impacts that the different possible 
implementation mechanisms for the five policy options in question (so called business 
models) will have on all relevant stakeholder groups. Data collection will be performed by 
a thorough literature research as well as a survey addressing all stakeholder groups.  
We like to emphasize that the data collection will be from a public health perspective 
focusing on facts and figures to underpin the different policy options, not on opinions of 
any stakeholder group. 
 
                                   
(1) http://ec.europa.eu/health/technology_assessment/consultations/cooperation_hta_en.htm 
(2) An inception impact assessment has been published: http://ec.europa.eu/smart-
regulation/roadmaps/docs/2016_sante_144_health_technology_assessments_en.pdf  
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 Description of Baseline Scenario  
The baseline scenario is defined as the status quo of European HTA cooperation in 2016 
taking the possible developments until 2020 (end of EUnetHTA Joint Action 3) into 
account. This status quo is characterized by 
- a heterogeneous situation regarding the relevance of HTA in the national decision 
making processes;  
- strictly voluntary cooperation between the European Commission and the EU Member 
States through (1) Joint Actions (Scientific and technical- developing methodologies 
and tool and performing joint assessments) and (2) HTA Network (providing strategic 
guidance).  
- No guarantees that any joint output is taken up in national HTA activities.   
 
Planned Work until 2020 – expected outcomes 
The general objective of the EUnetHTA Joint Action 3 (2016 – 2020) is to support 
voluntary cooperation at scientific and technical level between Health Technology 
Assessment Bodies to validate the model for joint work to be continued after EU funding 
under the Health Programme. The cooperation between national and regional HTA Bodies 
is to meet the provisions set out by Article 15 of Directive 2011/24/EU1 on patient’s right 
in cross-border healthcare and to create synergy with the strategic HTA Network set up 
under this Directive.  
The Joint Action 3 is aiming to establish an inventory on the available methodological 
documents and tools and, consequently, identifying gaps and adjusting or maintaining 
existing guidelines and tools. Moreover, all tools should be integrated in an Online 
Handbook for HTA-Doers, early dialogue communication should be provided and a tool 
for post-launch evidence generation and a prioritisation process for the topics of Joint 
Assessments should be developed.  
In EUnetHTA Joint Action 3 a higher number of joint production work, than in the last Joint 
Actions; namely 51 Joint Assessments(3) (33 on pharmaceuticals and 18 on other 
technologies) and 29 so called “Collaborative Assessments”(4) (4 on pharmaceuticals 
and 25 on other technologies) are planned.  
Until 2020 the Joint Action is financed by the 3rd Health Programme and Member States’ 
contributions in kind. A new Joint Action is not foreseen, as it is a mechanism that should 
pilot new cooperation mechanisms, but not fund them on a long term.  Therefore, it is 
anticipated that after expiration, and without further EU action, Member States would 
depend solely on their national/regional HTA procedures and budgets. Although Member 
States will be free to cooperate regarding HTA it is not sure on what scale joint work might 
continue.  
 
Questions addressing the Baseline Scenario: 
                                   
(3) A Joint Assessment is defined as a prioritized topic, submission-based (using the submission templates as were developed in 
EUnetHTA JA2), an authoring team of 2-3 agencies and at least 5 dedicated reviewers, English as working language, use of HTA 
Core Model and Guidelines, EUnetHTA procedures on stakeholder involvement (scoping meeting with manufacturer etc.), internal 
and external quality assurance. A Joint Assessment can be a REA or a Full HTA.  
 
(4) A collaborative assessment is defined by a lower level of centralized work organization, but equal criteria in quality assurance: 
the collaborative assessments shall include at least 3-5 partners, however in justified cases two partners would be acceptable. 
Such constitutes a less centralised topic selection/priority selection process. English as working language, use of HTA Core Model 
and Guidelines, not necessarily submission based, internal QA by review by at least 2 other EUnetHTA partners (support by WP 4) 
+ QA by external peer review, stakeholder involvement at 1 point in time (further criteria to be agreed upon). 
 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
  4 
 
1) Are you missing important aspects in the description of the Baseline Scenario? If 
yes, please state them shortly: 
 
 
 
 
2) If there is no further financing by the EU after 2020, do you expect that the EU 
cooperation work will continue?  
 
 
 
3) If yes, on what scale? Do you expect the following outputs to be produced through 
a MS-driven cooperation?  
 
Outputs Yes Partly (please elaborate) No 
Maintenance of common tools and 
procedures 
   
Performing joint Early Dialogues    
Performing joint Relative Effectiveness 
Assessments(5) 
   
Performing joint Full Health Technology 
Assessments(6)  
 
   
 
 
  
                                   
(5) REA can take place at time of market access, or later (re-assessment) 
(6)  Full HTA can take place at time of market access, or later (re-assessment) 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
  5 
Key characteristics of policy options for cooperation on HTA after 2020 
The different policy options for cooperation on HTA after 2020 are defined along several 
key characteristics focusing on 1. HTA output, 2. participation and uptake organizational 
aspects, 3. organizational aspects, 4. funding aspects as well as 5. timelines. These are 
described in the following.  
1) The scope of the cooperation is defined by several outputs(7) produced in joint 
collaboration, comprising: 
 Maintenance of common tools and procedures, incl. common submission 
templates, an IT system with planned and ongoing assessments, common 
methodologies (e.g EUnetHTA Core Model), a joint prioritization process, and 
cooperation regarding data requirements and Horizon Scanning  
 Performing joint Early Dialogues 
 Performing joint Relative Effectiveness Assessments (REA can take place at time of 
market access, or later (re-assessment)  
 Performing joint Full Health Technology Assessments (Full HTA can take place at 
time of market access, or later (re-assessment)) 
2) The engagement in participation and uptake(8) of jointly produced outputs can be either 
voluntary or mandatory:  
 voluntary participation/ voluntary uptake (V/V): both participating in the production 
of outputs and uptake of the respective output is entirely voluntary  
 voluntary participation/mandatory uptake (V/M): the participation in the production 
of joint work is voluntary, meaning that Member States can decide to opt-in(9) to 
the joint cooperation. However, once a Member State has opted-in the uptake of 
the joint work into the national setting is mandatory  
 mandatory participation/mandatory uptake (M/M): both participation in the 
production of outputs and the uptake of these into the national setting are 
mandatory 
For each of the policy options different combinations of voluntary or mandatory 
participation and uptake per output are possible.  
                                   
(7) The scope of the activities may differ for pharmaceuticals, medical devices and other technologies. 
(8) Please note that Up-take concerns the using or considering of the results and findings of the HTA cooperation, reaching from 
jointly developed submission templates to outcomes in full HTA. The subsequent pricing and reimbursement decision remains 
purely on national level. Also providers / developers need to adhere to this process. 
(9) Opt-in by MS is by output, not by individual products e.g. once a MS has opted in for joint REA, they take part in all joint REAs 
– but not necessarily as an author.  
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 3) For organizing the production of these joint HTA outputs a number of different 
implementation mechanism are conceivable: 
 Project based cooperation: there is voluntary cooperation, but no permanent 
coordination mechanism (i.e. Secretariat). 
 MS secretariat (rotating): a permanent Secretariat is established, which will be 
rotating between the Member States. 
 Existing EU agency: a permanent Secretariat is integrated in in an already existing 
EU agency. This Secretariat will coordinate the work of national experts in HTA 
bodies, to carry out the assessments.  
 New EU agency: a permanent Secretariat is integrated in a NEW EU agency. This 
Secretariat will coordinate the work of national experts in HTA bodies, to carry out 
the assessments.  
4) For financing the joint cooperation several funding mechanisms are conceivable: 
 EU funding, either through Public Health program or another financial instrument 
 Funding by Member States joining the collaboration 
 Funding through industry fees 
 
5) Timelines: 
Timelines for implementation of the proposed policy options post 2020 reach from 
immediately, without delay, for option 1 (i.e. 2021) to appropriate transitional periods for 
implementing options 4 or 5 in a new legal framework). 
 
Table 1 provides an overview of each policy option and the envisaged implementation 
funding mechanism. A short summary for each policy option can be found afterwards.  
Please note that the final policy option does not have to be exactly one that was presented 
but it can combine elements. (E.g. It is possible to have option X, but combine it with the 
implementation model of option Y.) So at this point it needs to be ensured that 5 policy 
options cover all elements (e.g. all feasible implementation models should be covered), in 
a combination that is logical.  
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Not covered – no structure for implementation, no fees, MS can organise on a voluntary basis 
 Covered in the legislative proposal Implementation mechanism 
Table 1: Overview of Policy Options 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   
(10) Early Dialogue: Here mandatory uptake means that the MS cannot repeat an ED that was done at EU level. Technology providers need to agree to Early Dialogue before it commences. 
(11) Either at time of market or re-assessment 
(12) A gradual introduction of products during a transitory period that allows to manage the workload while the structures/implementation model are being developed. 
 Baseline Non-legislative Legislative 
 PO 1 PO 2 PO 3 PO 4 PO 5 
No EU action 
after 2020 
 
Voluntary 
cooperation 
through Public 
Health 
Programme 
Legislation 
covering 
common tools 
and early 
dialogues 
 
Legislation covering  
Joint work on REA  
Plus 
common tools and early 
dialogues 
Legislation 
covering  
Joint work on Full 
HTA (incl. REA) 
Plus 
common tools and 
early dialogues 
4.1 
REA V/M 
4.2  
REA M/M 
O
u
tp
u
ts
 
Common tools, 
incl. templates, 
methodology 
V/V V/M M/M M/M M/M M/M 
Early 
dialogue(10) 
V/V V/M V/M V/M M/M M/M 
Joint REA(11) V/V V/M V/V V/M M/M M/M 
Joint Full HTA(9) V/V V/V V/V V/V V/V V/M 
Implementation No EU input Project based  
cooperation 
MS secretariat  
(rotating) 
Existing EU 
agency 
Existing EU 
agency 
New EU agency 
Financing None from EU EU+MS EU+MS+fees from industry for early dialogues, joint REA and full HTA 
 Scope  All medicines, 
medical and 
other 
technologies 
Tools: all 
medicines, MDs  , 
other 
technologies 
(phasing in), ED: 
industry 
submission 
Tools and ED see PO 3. REA: 
certain categories of medicines 
(centrally authorised, high 
value/budget impact, agreement 
between MS), certain categories of 
MDs (similar criteria) and other 
technologies (agreement and 
prioritisation between MS) – 
phasing in(12) 
Tools and ED see 
PO 3, REA see 
PO4. For others: 
ad hoc agreement 
and prioritisation 
between MS 
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Short description of policy options: 
Policy Option 1. Baseline scenario - No EU action after 2020: 
 Non-regulatory framework 
 Participation/uptake entirely voluntary 
 No EC action & no EU funding. MS are free to cooperate in any kind 
Policy Option 2. Voluntary cooperation supported by the Public Health 
Programme: 
 Non-regulatory framework 
 Participation entirely voluntary 
 Mandatory uptake of (some of the) common (IT-) tools, templates, methodologies 
+ Early Dialogue + joint REA EU contribution can only be obtained if contractually 
agreed by the participants.  
 Voluntary uptake of joint Full HTA 
 Coordination organised on a project basis 
 EU & MS funding but perhaps no long-term stability, as budgets have to be 
negotiated between EU and MS 13.  
 Scope: All medicines, medical and other technologies 
Policy Option 3. Legislation covering Common Tools and Early Dialogues: 
 Regulatory framework will be established 
 Mandatory participation and uptake in common (IT-) tools, templates, 
methodologies (question: what about registries for collection of data) 
 Opt-in (foreseen in legislation) in early dialogues and reassessments, mandatory 
uptake for those who opted in   
 Voluntary participation in and uptake of joint REA + joint Full HTA  
 Coordination organised by a rotating secretariat run by MSs 
 Funding by EU, MS and by other sources (e.g. company fees for early dialogues or 
registries for reassessment) 
 Scope: for tools: all medicines, MDs, other technologies (phasing in), for early 
dialogue:  industry submission 
Policy Option 4.1. Opt-in for Joint REA plus option 3: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies – see option 3 
 Opt-in (foreseen in legislation) in joint REA and early dialogues and mandatory 
uptake by those who opted in 
 Voluntary participation and uptake of joint Full HTA  
 Coordination organised in an existing EU agency 
 Funding by EU, MS and other sources (e.g. company fees – including for joint 
REAs) 
 Scope: for tools and ED see policy option 3. For REA: certain categories of 
medicines (centrally authorised, high value/budget impact, agreement between 
MS), certain categories of MDs (similar criteria) and other technologies (agreement 
and prioritisation between MS) – phasing in period foreseen 
Policy Option 4.2. Mandatory Joint REA plus option 3: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies + early dialogues +  joint REA 
                                   
(13) Through the Multiannual Financial framework (MFF) 
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 Voluntary participation in and uptake of joint Full HTA 
 Coordination organised in an existing EU agency 
 Funding by EU, MS and other sources (e.g. company fees – including for joint 
REAs) 
 Scope: for tools and ED see policy option 3. For REA: certain categories of 
medicines (centrally authorised, high value/budget impact, agreement between 
MS), certain categories of MDs (similar criteria) and other technologies (agreement 
and prioritisation between MS) – phasing in period foreseen 
Policy Option 5: Option 4.2 and Opt-in for Full HTA: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies + Early Dialogue +  joint REA – option 4.2 
 Opt-in (foreseen in legislation) participation in joint Full HTA and mandatory uptake 
for those who opted in 
 Coordination organised in a new EU agency  
 Funding by EU, MS and other sources (e.g. company fees – including for Full HTA) 
 Scope: for tools and ED see policy option 3. For REA see  policy option 4. For 
others: ad hoc agreement and prioritisation between MS. 
 
Questions regarding the policy options:  
We kindly invite you to comment on the respective Policy Options described in the 
previous section (Table 2 and short description above).  
Feedback is guided by the questions within Table 2. For closed questions, please indicate 
your opinion by using ‘X’. Within free text fields please keep you answer as short as 
possible.  
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Table 2: Questions regarding the policy options (note: please keep your answers as short as possible) 
– In this section you are invited to respond irrespective of the policy options presented in table 2 apart 
from questions directly referring to table 2. 
Question PO 2 PO 3 PO 4.1 and 4.2 PO 5 
 IMPLEMENTATION 
Is the 
Implementation 
Mechanism described 
in Table 2 suitable 
for this policy 
option?  
yes no yes no yes No yes no 
          
If not, which 
implementation 
mechanism would 
you consider more 
suitable for the 
respective policy 
option and why? 
     
Which 
Implementation 
mechanism do you 
consider the most 
preferable for HTA 
bodies?  
(single choice: please 
insert ‘X’) 
Project based  
cooperation 
 Project based  
cooperation 
 Project based  
cooperation 
  Project based  
cooperation 
 
MS secretariat  
(rotating) 
 MS secretariat  
(rotating) 
 MS secretariat  
(rotating) 
  MS secretariat  
(rotating) 
 
Existing EU 
agency 
 Existing EU 
agency 
 Existing EU 
agency 
  Existing EU 
agency 
 
New EU agency  New EU agency  New EU agency   New EU agency  
Which 
Implementation 
mechanism do you 
consider the most 
preferable for 
Industry?  
(single choice: please 
insert ‘X’) 
Project based  
cooperation 
 Project based  
cooperation 
 Project based  
cooperation 
  Project based  
cooperation 
 
MS secretariat  
(rotating) 
 MS secretariat  
(rotating) 
 MS secretariat  
(rotating) 
  MS secretariat  
(rotating) 
 
Existing EU 
agency 
 Existing EU 
agency 
 Existing EU 
agency 
  Existing EU 
agency 
 
New EU agency  New EU agency  New EU agency   New EU agency  
Is there another 
implementation 
mechanism not 
stated yet that you 
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Question PO 2 PO 3 PO 4.1 and 4.2 PO 5 
consider relevant? 
 SCOPE 
For which product 
group do you think 
the respective Policy 
option is feasible?  
(multiple choice: please 
insert ‘X’) 
Centrally 
authorised plus 
high 
value/budget 
impact 
pharmaceuticals, 
based on 
agreement 
between MS 
 Centrally 
authorised plus 
high 
value/budget 
impact 
pharmaceuticals, 
based on 
agreement 
between MS 
 Centrally 
authorised plus 
high 
value/budget 
impact 
pharmaceuticals, 
based on 
agreement 
between MS 
  Centrally 
authorised plus 
high 
value/budget 
impact 
pharmaceuticals, 
based on 
agreement 
between MS 
 
Other 
pharmaceuticals 
 Other 
pharmaceuticals 
 Other 
pharmaceuticals 
  Other 
pharmaceuticals 
 
Medical Devices  Medical Devices  Medical Devices   Medical Devices  
Other 
technologies 
 Other 
technologies 
 Other 
technologies 
  Other 
technologies 
 
 FINANCING OF POLICY OPTIONS 
Do you think the 
financing mechanism 
is feasible for the 
respective policy 
option? 
yes no yes no yes no yes no 
          
If not, which 
financing mechanism 
do you consider more 
suitable for the 
respective policy 
option and why? 
 
     
 INCENTIVES, BARRIERS 
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Question PO 2 PO 3 PO 4.1 and 4.2 PO 5 
What incentives 
would be needed for 
HTA bodies to 
engage within the 
respective policy 
option? 
     
What incentives 
would be needed for 
industry to engage 
within the respective 
policy option? 
     
What barriers can be 
expected for HTA 
bodies to engage 
within the respective 
policy option? 
     
What barriers can be 
expected for industry 
to engage within this 
policy option? 
     
 VOLUNTARY AND MANDATORY PARTICIPATION AND UPTAKE 
For each policy 
option, is the 
combination of 
voluntary and 
mandatory 
participation and 
uptake reasonable? 
 
 
yes no yes no yes no yes no 
          
If not, what would 
you change within 
the policy option 
with regards to 
voluntary/mandatory 
participation and 
uptake? 
     
 OTHER ASPECTS 
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Question PO 2 PO 3 PO 4.1 and 4.2 PO 5 
Is there a relevant 
aspect missing 
within the matrix of 
policy options (Table 
2)? If yes, please 
explain. 
     
Additional Comments      
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1. Impacts of the respective policy options 
Within this study we aim to collect and provide key input for assessing the impact of 
different identified policy options for EU cooperation on HTA beyond 2020 from the 
perspective of different stakeholders. A range of general impacts to be considered are 
stated within the Impact Assessment guidelines provided by the EC. A first set of 
indicators to assess these impacts was established. To ensure that all relevant impacts 
and indicators for all stakeholder groups are covered, we kindly ask you to go through 
Table 3 and: 
 
1. Rate the indicator with regard to its relevance for assessing the policy options’ 
impacts  
2. Comment on the indicator 
3. Add sources of information or references to literature if known 
4. Add indicators you consider being relevant but are missing in Table 3 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
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Table 3: Impacts to assess policy options  
Impact Indicator 
Rating of relevance 
++=high relevance 
+ =low relevance 
0 =no relevance 
Comment 
Sources of 
information / 
references to 
literature 
Economic Impacts 
Operating costs and 
conduct  
Costs of performing a 
health technology 
assessment for 
technology developers 
(incl. pharmaceutical and 
medical device industry 
and SMEs) 
   
Costs of performing a 
health technology 
assessment for HTA 
bodies 
   
Transaction costs for 
technology developer 
(costs for preparing 
multiple dossiers for HTA 
assessment bodies in 
different MS) 
   
Changes in timelines 
affecting technology 
developers’ revenue 
   
Administrative 
burden 
Duplication of 
assessments per 
technology on EU level 
   
Changes in administrative 
costs for industry 
induced by the respective 
policy option 
   
Changes in administrative 
costs for MS induced by 
the respective policy 
option 
   
SME’s growth 
Cost of performing a 
technology assessment 
for SME technology 
developers 
   
Revenue of SME 
technology developers 
Revenue of SME 
technology developers 
   
Impact on EU Health 
Technology sector 
competitiveness 
Predictability of HTA 
framework attracting 
investments  
   
Technology developers 
capacity to innovate 
(positively/negatively 
affecting investment 
decisions/R&D) 
   
Functioning of the 
internal market and 
Fragmentation of  HTA 
system 
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Impact Indicator 
Rating of relevance 
++=high relevance 
+ =low relevance 
0 =no relevance 
Comment 
Sources of 
information / 
references to 
literature 
competition 
Effects on the 
attractiveness of the 
European market at 
international level 
   
Innovation and 
research 
Incentives for Industry to 
innovate 
   
Diversity of research in 
the field of HTA 
   
Consumer and 
households/patients 
Involvement of patients in 
the HTA process 
   
Time for access to market 
   
Level of consumer/patient 
information on the 
technology 
   
Price patients pay for 
good/service 
   
Macroeconomic 
environment 
Consequences on 
economic growth and 
employment 
   
Social Impacts 
Employment and 
labour markets 
Influence on jobs related 
to health technology 
sector 
   
Governance, 
participation and 
good administration 
Responsibilities of public 
institutions and 
administration in HTA on 
MS level 
   
Public’s access to 
information on the 
decision-making process 
   
Involvement of 
stakeholders in HTA 
governance issues 
   
Access to and effects 
on social protection 
and health systems 
and Sustainability of 
health systems 
Financing of expensive 
treatments with little or 
no added value 
   
Negotiation power for MS 
in setting prices 
   
Access to health 
technologies (especially 
pharmaceuticals and 
medical devices) 
   
Public health and 
safety 
Availability of health 
technologies on the 
market 
   
Additional indicators 
that should be 
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Impact Indicator 
Rating of relevance 
++=high relevance 
+ =low relevance 
0 =no relevance 
Comment 
Sources of 
information / 
references to 
literature 
investigated:  
 
Additional indicators 
that should be 
investigated:  
 
 
   
Additional indicators 
that should be 
investigated:  
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Annex 2: Search strategy 
Search strategy Medline, Cochrane via OVID 
 
Search date: 11.11. 2016  
 
Databases:  
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 
to Present,  
EBM Reviews - Cochrane Database of Systematic Reviews  
EBM Reviews - ACP Journal Club  
EBM Reviews - Database of Abstracts of Reviews of Effects  
EBM Reviews - Cochrane Central Register of Controlled Trials  
EBM Reviews - Cochrane Methodology Register  
EBM Reviews - Health Technology Assessment  
EBM Reviews - NHS Economic Evaluation Database 2nd Quarter 2015 
 
1  (health adj2 technology adj2 assessment).ti,ab. 3608 
2  (European adj2 public adj2 assessment adj2 report).af. 37 
3  "relative effectiveness assessment*".af. 10 
4  joint assessment.af. 244 
5  (outcome adj2 assessment).ti,ab. 5602 
6  (outcome adj2 assessment).ti. 855 
7  (clinical adj2 assessment).ti,ab. 28074 
8  (process adj2 assessment).ti,ab. 2892 
9  (health adj2 services adj2 research).ti,ab. 3267 
10  (evidence adj2 based adj2 medicine).ti,ab. 11324 
11  exp Technology Assessment, Biomedical/ 11026 
12  Decision Making, Organizational/ 11623 
13  (international adj2 comparison*).ab,ti. 2515 
14  (international adj2 cooperation*).ab,ti. 1618 
15  health policy.ab,ti. 14596 
16  (european adj2 cooperation*).af. 116 
17  (european adj2 collaboration*).af. 236 
18  Health Policy/ 61143 
19  International Cooperation/ 44957 
20  1 or 2 or 3 or 4 or 7 or 8 or 9 or 10 or 11 58616 
21  12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 127090 
22  20 and 21 2205 
23  limit 22 to yr="2012 - 2016"  495 
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Search strategy Embase 
 
Search date: 11.11. 2016  
 
Databases: Embase 
 
1 (health adj2 technology adj2 assessment).ti,ab. 3728 
2 (European adj2 public adj2 assessment adj2 report).af. 30 
3 "relative effectiveness assessment*".af. 24 
4 joint assessment.af. 367 
5 (outcome adj2 assessment).ti,ab. 5870 
6 (outcome adj2 assessment).ti. 1023 
7 (clinical adj2 assessment).ti,ab. 37347 
8 (process adj2 assessment).ti,ab. 3799 
9 (health adj2 services adj2 research).ti,ab. 3600 
10 (evidence adj2 based adj2 medicine).ti,ab. 14440 
11 exp Technology Assessment, Biomedical/ 11795 
12 Decision Making, Organizational/ 140609 
13 (international adj2 comparison*).ab,ti. 3209 
14 (international adj2 cooperation*).ab,ti. 1965 
15 health policy.ab,ti. 17242 
16 (european adj2 cooperation*).af. 533 
17 (european adj2 collaboration*).af. 314 
18 Health Policy/ 139998 
19 International Cooperation/ 51926 
20 1 or 2 or 3 or 4 or 5 or 7 or 8 or 9 or 10 or 11 73628 
21 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 329992 
22 20 and 21 3625 
23 limit 22 to yr="2012 - 2016" 588 
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Search strategy Cinahl 
 
Search date: 11.11. 2016  
Databases: Cinahl 
 
 
 
 
Search strategy Econlit 
 
Search date: 11.11. 2016  
Databases: Econlit 
S4 ( AB (Health AND Technology AND Assessment*) OR AB 
(European public assessment report) OR AB (relative 
effectiveness assessment*) OR AB (outcome 
assessment) OR AB (clinical assessment) OR AB (health 
services research) OR AB (evidence-based medicine) OR 
AB (joint assessment) ) AND ( AB ( international AND 
comparision* ) OR AB ( international AND cooperation* ) 
OR AB ( health AND polic* ) OR AB ( european AND 
cooperation* ) OR AB ( european AND collaboration* ) )  
Limiters - Published 
Date: 2012_01_01-
2016_12_31 
Results (31) 
S3 ( AB (Health AND Technology AND Assessment*) OR AB 
(European public assessment report) OR AB (relative 
effectiveness assessment*) OR AB (outcome 
assessment) OR AB (clinical assessment) OR AB (health 
services research) OR AB (evidence-based medicine) OR 
AB (joint assessment) ) AND ( AB ( international AND 
comparision* ) OR AB ( international AND cooperation* ) 
OR AB ( health AND polic* ) OR AB ( european AND 
cooperation* ) OR AB ( european AND collaboration* ) )  
Results (124) 
S6 (S2 OR S3) AND (S1)  
Limiters - Published 
Date: 2012_01_01-
2016_12_31  
Results (180) 
S5 (S2 OR S3) AND (S1)  Results (898) 
S4 S2 OR S3  Results (62,545) 
S3 
AB ( international AND comparision* ) OR AB ( 
international AND cooperation* ) OR AB ( health AND 
polic* ) OR AB ( european AND cooperation* ) OR AB ( 
european AND collaboration* )  Results (28,582) 
S2 
(MH "Decision Making, Organizational") OR (MH "Health 
Policy") OR (MH "International Relations")  Results (39,135) 
S1 
AB (Health AND Technology AND Assessment*) OR AB 
(European public assessment report) OR AB (relative 
effectiveness assessment*) OR AB (outcome assessment) 
OR AB (clinical assessment) OR AB (health services 
research) OR AB (evidence-based medicine) OR AB (joint 
assessment)  Results (42,545) 
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S2 AB ( international AND comparision* ) OR AB ( 
international AND cooperation* ) OR AB ( health AND 
polic* ) OR AB ( european AND cooperation* ) OR AB ( 
european AND collaboration* )  
Results (12,913) 
S1 AB (Health AND Technology AND Assessment*) OR AB 
(European public assessment report) OR AB (relative 
effectiveness assessment*) OR AB (outcome 
assessment) OR AB (clinical assessment) OR AB (health 
services research) OR AB (evidence-based medicine) OR 
AB (joint assessment)  
Results (36,876) 
 
 
Search strategy Scopus 
 
Search date: 11.11. 2016  
Databases: Scopus 
 
( TITLE-ABS ( health PRE/2 technology PRE/2 assessment ) OR ( 
INDEXTERMS ( health technology assessment ) ) OR TITLE-ABS ( 
european PRE/2 public PRE/2 assessment report ) OR TITLE-ABS ( 
relative PRE/2 effectiveness PRE/2 assessment* ) OR ( INDEXTERMS ( 
relative effectiveness assessment ) ) OR TITLE-ABS ( outcome PRE/2 
assessment ) OR TITLE-ABS ( clinical PRE/2 assessment ) OR TITLE-
ABS ( evidence PRE/2 based PRE/2 medicine ) OR ( INDEXTERMS ( 
evidence based medicine ) ) OR TITLE-ABS ( joint PRE/2 assessment ) )  
AND ( TITLE-ABS ( international PRE/2 comparision* ) OR ( 
INDEXTERMS ( international comparison ) ) OR TITLE-ABS ( 
international PRE/2 cooperation* ) OR ( INDEXTERMS ( international 
cooperation) ) OR TITLE-ABS ( health PRE/2 polic* ) OR ( INDEXTERMS 
( health policy ) ) OR TITLE-ABS ( european PRE/2 cooperation* ) OR 
TITLE-ABS ( european PRE/2 collaboration* ) ) OR ( INDEXTERMS ( 
european collaboration ) ) 
AND NOT INDEX ( medline )  
AND NOT INDEX (embase)  
AND ( LIMIT-TO ( PUBYEAR , 2016 ) OR LIMIT-TO ( PUBYEAR , 2015 ) 
OR LIMIT-TO ( PUBYEAR , 2014 ) OR LIMIT-TO ( PUBYEAR , 2013 ) OR 
LIMIT-TO ( PUBYEAR , 2012 ) ) 
83 
document 
results 
 
  
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
 22 
Annex 3: Questionnaire addressed to Public administration and 
others 
 
Introduction to the survey 
 
Purpose of the survey 
The European Commission (EC) is exploring options for a new and sustainable 
mechanism for Health Technology Assessment (HTA) in Europe after 2020. 
Consequently, the Directorate General for Health and Food Safety (DG SANTE) of the 
European Commission started an impact assessment process. In the framework of this 
process, the EC commissioned the consortium of Sogeti, the Austrian Public Health 
Institute (GÖ FP) and the London School of Economics and Political Science (LSE Health) 
to provide data and evidence to identify the impact of policy options for strengthened 
EU cooperation on HTA in order to support the Impact Assessment process of the EC. 
This survey is part of the data collection process, which focuses on the insights of key 
stakeholders (HTA bodies, healthcare providers, public healthcare payers and competent 
authorities as well as patients/consumers). There is an additional version of the survey 
for completion by industry stakeholders. 
 
Aim  
We would like you to assess, from your perspective, the potential impacts of different 
policy options for strengthened EU cooperation on HTA after 2020.  
 
Outline of the questionnaire 
The survey is split into four parts: 
Part 1: General questions on your institution. 
Part 2: Questions regarding the costs incurred as a result of the HTA process  
Part 3: Information about the preliminary policy options. Assessment of possible impacts 
of 5 policy options (scenarios) for strengthened EU cooperation on HTA after 2020 
Part 4: Indicating your option with regard to the relevance of defined impacts and scope 
 
How we will process the information you provide 
The results will be gathered and clustered and will finally feed into a Multi-Criteria 
Decision Analysis (MCDA) model. The MCDA is a method, based on mathematical 
algorithms, for evaluating individual, often conflicting, criteria. The criteria are then 
combined into one matrix for general assessment to help decision-makers consider 
multiple conflicting factors, or “impacts”, in a rational and consistent manner. The 
objective of the MCDA is to identify policy options which take into account the 
preferences of the involved stakeholders as well as account for the conflicting nature of 
related impacts.  
 
Confidentiality clause 
We would like to assure you that the European Commission's statuary obligation of 
confidentiality is in place. The final report will only present aggregated or anonymized 
data.  
If you include confidential information/business secrets, please clearly identify/mark the 
section; non-marked sections are assumed to be not confidential. A non-confidential 
version is also welcome. According to the framework contract with the consortium, the 
European Commission may request the data gathered by the contractor. 
 
Deadline for the survey 
This online survey will be active until January 22 2017. 
In case you have questions or need any support please contact: 
Gesundheit Österreich Forschungs- und Planungs GmbH (GÖ FP) 
Stubenring 6, 1010 Vienna (Austria) 
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E-Mail: EU.HTA@goeg.at 
Phone: 0043 (0)151561 – 285 
 
Part 1: General Questions 
 
Please fill in the name of the organisation/association and your function within:  
Organisation/association:   
Role:   
Your contact details (E-Mail):   
 
Operational level 
Please indicate the operational level of your organisation/association (one answer 
possible): 
o International (e.g. representative at EU level) 
o National (e.g. national agency)  
o Regional (e.g. representative of a specific region).  
 
Country: 
Please indicate the country where your organization is based.  
(List of countries will be available) 
 
Personal /institutional capacity: 
We kindly ask you to fill out the questionnaire from your organisational/institutional point 
of view. If this is not possible, please state that your answers represent your personal 
perspective.  
o Personal perspective 
o Organisational perspective 
 
Organisation 
Please state your main field of work:  
o Government 
o Public Administration 
o HTA Body/Organisation  
o Payer 
o Pricing/reimbursement body 
o Healthcare provider 
o Patient/patient advocate 
o Other (please specify)   
 
Is your organization performing or commissioning an health technology 
assessment process? 
o Yes 
o No 
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Part 2: Questions regarding the status quo  
 
Costs of performing a health technology assessment (HTA) (this will only be asked to 
organisations/association that perform HTAs) 
General instructions: 
o Please refer to the timeframe that is stated within the question.  
o Please use € if available, otherwise use your local currency 
o All figures should be in the Continental European format (e.g. 3,4.) 
o All dates should be given in the format YYMMDD 
 
Please specify the activities undertaken by your Agency (please tick all that apply): 
o HTA 
o Production of clinical guidance  
o Development of quality standards 
o Evidence generation 
o Early engagement  
o Horizon scanning 
o Other 
 
General Costs 
Q4: Is there a fixed budget on an annual basis allocated to your agency for HTA 
activities? 
A. €  
 
B. % of total budget 
 
Q5: What proportion of your budget is expended on operating costs? 
 
% of total budget 
 
Q6: What are the annual audit costs?  
 
% of 
For the purpose of the study internal audit is defined as follows: an internal audit is used 
to assess operational efficiencies and resource management. It is often compulsory for 
public bodies to verify cost records and adherence to acceptable cost accounting 
procedures. 
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Q7: Approximately what overall expenses are associated with an HTA process, per 
technology?  
A. REA (if applicable) 
 
B. Full HTA 
 
a. Single technology assessment 
 
b. Multiple technology assessment 
 
 
Q8: Are there any other essential costs related to HTA process? Please specify 
 
Workforce allocation related to the HTA process 
Q10_1: How many staff do you employ in your agency exclusively for the purpose of 
HTA? 
 
Q10_2: If possible, please state how many person months are invested in one HTA 
process on average (person month meaning one person working full time for one 
month). 
 
Q11: What are the costs associated with REA process? 
A. Staff costs 
 
B. Outside consultancy/sub-contracting 
 
C. Other general expenses (i.e. travel costs) 
 
Q12: What are the costs associated with full HTA process? 
A. Staff costs 
 
B. Outside consultancy/sub-contracting 
 
C. Other general expenses (i.e. travel costs) 
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Stakeholder costs 
Q13: What are the approximate costs of stakeholder involvement in the HTA process? 
A. Fees for participation (e.g. per diem) 
 
B. Travel costs 
 
C. Interview/ workshop expenses 
 
D. Other expenses (please specify) 
 
Implementation and Dissemination of HTA recommendations 
Q14: Approximately how much do you spend on the dissemination of the final report?  
A. Reports (paper format) 
 
B. Guidelines (paper format) 
 
C. Digital services (e.g. website maintenance) 
 
Q15: Are there any expenses associated with the monitoring/implementation process of 
HTA recommendations?  
A. Yes 
 
If yes, please specify: 
 
B. No 
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Part 3: Information about the preliminary policy options on  
HTA cooperation after 2020 
 
In this part, we provide you with key information to assess the impact of the different 
preliminary policy options.  
Please read carefully through the short description of each policy option in 
order to understand the scope of the questions asked in part 3.   
 
 
 
 
 
 
 
 
 
 
 
Key characteristics 
The different policy options for cooperation on HTA after 2020 are defined along several 
key characteristics focusing on 1. HTA output, 2. Participation and uptake from Member 
States' perspectives, 3. Organizational aspects, 4. Funding aspects as well as 5. 
Timelines. These are explained in the following:   
 
1) The scope of the cooperation is defined by several outputs(14) created by a joint 
collaboration, comprising of: 
 Common tools and procedures, including common submission templates, an IT 
system with planned and ongoing assessments, common methodologies (e.g 
EUnetHTA Core Model), a joint prioritization process, and cooperation on data 
requirements, including Horizon Scanning  
 Performing joint Early Dialogues 
 Performing joint Relative Effectiveness Assessments (REA can take place at time 
of market launch, or later (re-assessment))  
 Performing joint Full Health Technology Assessments (Full HTA can take place at 
time of market launch, or later (re-assessment)) 
 
2) The engagement in participation and uptake(15) of jointly produced outputs can be 
either voluntary or mandatory:  
                                   
(14) The scope of the activities may differ between pharmaceuticals, medical devices and other technologies. 
Please note:  
For assessing the impacts of the various options and the various implementation mechanisms /business models, 
fine-tuned options were created within the course of the study. These combine the options with the 
implementation mechanisms (for details see below).  
The fine-tuned options in this section are provisional. They are merely examples of the possible combinations of 
the IIA options with the IIA implementation mechanisms that were developed in order to facilitate the analysis. 
In any event, they do not represent the preferred combinations of the European Commission nor the contractor 
and other combinations are possible. Furthermore, the policy options may need to be revised following the input 
of Member States and stakeholders through public consultation and discussions. The final policy option does not 
have to be exactly in line with one that was analysed, but it can combine elements. (E.g. it is possible to have 
option X, but combine it with the implementation mechanism of option Y.) 
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 Voluntary participation/ voluntary uptake (V/V): Member States can decide if they 
wish to participate in the production of outputs and take up the respective output; 
cooperation is entirely voluntary.  
 Voluntary participation/mandatory uptake (V/M): The participation in the creation 
of joint work is voluntary, meaning that Member States can decide to opt-in(16) to 
the joint cooperation. However, once a Member State has opted-in the uptake of 
the joint work into the national setting is mandatory.  
 Mandatory participation/mandatory uptake (M/M): Both participation in the 
production of outputs and the uptake of these into the national setting are 
mandatory. 
For each of the policy options, different combinations of voluntary or mandatory 
participation and uptake per Output are possible. 
3) For organizing the creation of these joint HTA outputs a number of different 
organizational mechanisms are conceivable: 
 
 Project based cooperation: The secretariat is set up by the Member States that 
participate (similar to EUnetHTA). 
 EU/MS secretariat: A permanent Secretariat is established.  
 Existing EU agency: A permanent Secretariat is integrated in an already existing 
EU agency. This Secretariat will coordinate the work of national experts in HTA 
bodies in carrying out the assessments.  
 New EU agency: A permanent Secretariat is integrated in a NEW EU agency. This 
Secretariat will coordinate the work of national experts in HTA bodies in carrying 
out the assessments.  
 
4) For financing the joint cooperation several funding mechanisms are conceivable: 
 
 EU funding, either through a Public Health program or another financial 
instrument 
 Funding by Member States joining the collaboration 
 Funding through industry fees 
 
5) Timelines: 
Timelines for implementation of the proposed policy options after 2020 range from 
immediately, without delay, for option 1 (i.e. 2021) to transitional periods for 
implementing options 4 or 5 in a new legal framework). 
Table 4 provides an overview of each policy option and the envisaged 
implementation/funding mechanism. A short summary for each policy option can be 
found afterwards.  
                                                                                                             
(15) Please note that Up-take concerns using or considering the results and findings of the HTA cooperation, reaching from jointly 
developed submission templates to outcomes in full HTA. The subsequent pricing and reimbursement decision would remain purely 
on national level. Also providers / developers need to adhere to this process. 
(16) Opt-in by MS is by output, not by individual products e.g. once a MS has opted in for joint REA, they take part in all joint REAs – 
but not necessarily as an author.  
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Table 4: Overview of Policy Options 
                                   
(17) Assuming that 50% of the Member States participate, a mix between high/low income, large/small MS.  
(18) Early Dialogue: Here mandatory uptake means that the MS cannot repeat an ED that was done at EU level. Technology providers initiate Early Dialogues. 
(19) Either at time of market or re-assessment 
(20) A gradual introduction of products during a transitory period that allows to manage the workload while the structures/implementation model are being developed. 
 Baseline Non-legislative Legislative 
 PO 1 PO 2 PO 3 PO 417 PO 5 
No EU action 
after 2020 
 
Voluntary 
cooperation 
through Public 
Health 
Programme 
Legislation 
covering 
common tools and 
early dialogues 
 
Legislation covering  
Joint work on REA  
Plus 
common tools and early dialogues 
Legislation covering  
Joint work on Full HTA 
(incl. REA) 
Plus 
common tools and early 
dialogues 
4.1 
REA V/M 
4.2 
REA M/M 
O
u
tp
u
ts
 
Common tools, 
incl. templates, 
methodology 
V/V V/M M/M M/M M/M M/M 
Early dialogue(18) V/V V/M V/M V/M M/M M/M 
Joint REA(19) V/V V/M V/V V/M M/M M/M 
Joint Full HTA(6) 
V/V V/V V/V V/V V/V V/M 
Implementation No EU input Project based  
cooperation 
EU/MS secretariat  Existing EU 
agency 
Existing EU agency New EU agency 
Financing None from EU EU+MS EU+MS+fees from industry for early dialogues, joint REA and full HTA 
 Scope  All medicines, 
medical and other 
technologies 
Tools: all 
medicines, medical 
technologies, other 
technologies 
(phasing in), ED: 
industry submission 
Tools and ED see PO 3. REA: certain 
categories of medicines (e.g. centrally 
authorised, high value/budget impact, 
agreement between MS), certain 
categories of medical technologies(e.g. 
high risk, high value products) and other 
technologies (agreement and prioritisation 
between MS) – phasing in(20) 
Tools and ED see PO 3, 
REA see PO4. For others: 
ad hoc agreement and 
prioritisation between MS 
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Short description of policy options: 
Policy Option 1. Baseline scenario - No EU action after 2020: 
 Non-regulatory framework 
 Participation/uptake entirely voluntary 
 No EC action & no EU funding. MS are free to cooperate in any kind 
Policy Option 2. Voluntary cooperation supported by the Public Health 
Programme: 
 Non-regulatory framework 
 Participation entirely voluntary 
 Mandatory uptake of (some of the) common (IT-) tools, templates, methodologies 
+ Early Dialogue + joint REA. EU contribution can only be obtained if contractually 
agreed by the participants.  
 Voluntary uptake of joint Full HTA 
 Coordination organised on a project basis 
 EU & MS funding: long term commitment of funding, (minimum 4, maximum 7 
years), annual budget(21)  
 Scope: All medicines, medical and other technologies 
Policy Option 3. Legislation covering Common Tools and Early Dialogues: 
 Regulatory framework will be established 
 Mandatory participation and uptake in common (IT-) tools, templates, 
methodologies, etc.  
 Opt-in (foreseen in legislation) in early dialogues and reassessments, mandatory 
uptake for those who opted in   
 Voluntary participation in and uptake of joint REA + joint Full HTA  
 Coordination organised by a secretariat run by EC or MSs 
 Funding by EU, MS and by other sources (e.g. company fees for early dialogues or 
registries for reassessment) 
 Scope: for tools: all medicines, medical technologies, other technologies (phasing 
in), for early dialogue:  industry submission 
Policy Option 4.1. Opt-in for Joint REA plus option 3: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies – see option 3 
 Opt-in (foreseen in legislation) in joint REA and early dialogues and mandatory 
uptake by those who opted in. It is assumed that 50% of the Member States 
participate, a mix between high/low income, large/small MS. 
 Voluntary participation and uptake of joint Full HTA  
 Coordination organised in an existing EU agency 
 Funding by EU, MS and other sources (e.g. company fees – including for joint EDs 
and REAs)  
 Scope: Tools and ED see PO 3. REA: certain categories of medicines (e.g. 
centrally authorised, high value/budget impact, agreement between MS), certain 
categories of medical technologies (e.g. high risk, high value products) and other 
technologies (agreement and prioritisation between MS) – phasing in 
 
                                   
(21) Through the Multiannual Financial framework (MFF) 
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Policy Option 4.2. Mandatory Joint REA plus option 3: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies + early dialogues +  joint REA 
 Voluntary participation in and uptake of joint Full HTA. It is assumed that 50% of 
the Member States participate, a mix between high/low income, large/small MS. 
 Coordination organised in an existing EU agency 
 Funding by EU, MS and other sources (e.g. company fees – including for joint EDs 
and REAs) 
 Scope: Tools and ED see PO 3. REA: certain categories of medicines (e.g. 
centrally authorised, high value/budget impact, agreement between MS), certain 
categories of MDs (e.g. high risk, high value products) and other technologies 
(agreement and prioritisation between MS) – phasing in 
Policy Option 5: Option 4.2 and Opt-in for Full HTA: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies + Early Dialogue +  joint REA – option 4.2 
 Opt-in (foreseen in legislation) participation in joint Full HTA and mandatory 
uptake for those who opted in 
 Coordination organised in a new EU agency  
 Funding by EU, MS and other sources (e.g. company fees – including for Full HTA) 
 Scope: for tools and ED see policy option 3. For REA see policy option 4. For 
others: ad hoc agreement and prioritisation between MS. 
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Part 4: Assessment of policy options 
 
In the following part of the questionnaire, we kindly ask you to assess each of the policy 
options described above according to their economic and social/health impacts.  
 
Compared to the status quo, how do you estimate the different policy options’ 
may impact on the economic indicators in the table below?  
Please indicate for each question on a range (from -100 to +100) whether the 
indicator may decrease (-) or increase (+) for each policy option. 
 
Example: If you expect that for option 4.2 the total number of HTA submission 
across Europe will be cut by half, you should put -50. 
  
Costs 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on your average costs per product?  
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+) for each policy option, with the status quo (=the current situation) set at 
zero (0).  
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the costs 
for horizon 
scanning (all 
costs)? 
 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the total 
costs for early 
dialogues? 
(Total costs including 
costs for staff, 
administrative costs, 
etc.) 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the total 
costs of a REA 
submission (if 
applicable)? 
(Total costs including 
costs for staff, 
(re)submission costs, 
administrative cost, 
costs for including 
stakeholder etc.) 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the total 
costs of a full HTA 
submission? 
(Total costs including 
costs for staff, 
(re)submission costs, 
administrative costs, 
travel costs, costs for 
including 
stakeholder) 
 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
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Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on HTA 
submission fees? 
(Fees that have to be 
paid for submitting 
an HTA/REA to the 
respective 
institution) 
 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the costs 
for additional data 
requested by HTA 
bodies? 
(Referring to all 
studies performed in 
addition to clinical 
studies conducted for 
regulatory approval  
) 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the needs 
for Human 
Resources (full time 
equivalents including 
consultants)? 
 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the costs 
for HTA re-
assessment (all 
costs)? 
 
 
range 
-
100/+10
0 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
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Administrative burden  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on your administrative burden?  
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+), with the status quo set at zero (0). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do you 
expect each policy option 
to impact on the overall 
administrative burden 
associated with HTA 
submissions?(Administrati
ve burden arising from the 
information obligations 
imposed on industry  with 
regard to HTA processes) 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+1
00 
 
To what extent do you 
expect each policy option 
to impact on the number 
of HTA submissions for 
the same product and 
indication across European 
countries? 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+1
00 
 
To what extent do you 
expect each policy option 
to impact on the time 
needed for an HTA 
process?(The time span 
of the whole assessment 
procedure) 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+1
00 
 
To what extent do you 
expect each policy option 
to impact on the 
complexity of HTA 
assessment processes? 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+10
0 
 
range 
-
100/+1
00 
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Competitiveness of EU health technology sector  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding the competitiveness of EU health 
technology sector? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+), with the status quo set at zero (0). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do you expect 
each policy option to impact on 
the predictability of the HTA 
system in Europe?    
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the competitiveness of SME?  
(SME is defined by staff 
headcount, )<250 and either 
turnover ≤ 50m or balance sheet 
total     ≤ 43m) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
your revenues?    
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
 
Innovation and research  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding Innovation and research? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+), with the status quo set at zero (0). 
 
  
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the 
research climate in 
the European 
market?  
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the actual 
innovation for the 
European market? 
(i.e. focus on 
predictability and 
deduction of 
fragmentation as key 
factors for favorable 
business climate for 
industry facilitating 
innovation thrive ) 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
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International Trade 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on international trade? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+), with the status quo set at zero (0). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
PO 5 
 
Comments 
To what extent do you expect 
each policy option to impact on 
international trade related to 
pharmaceuticals/ medical 
technologies?  
(Possibility to import and/or 
export)  
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
 
Functioning of the internal market and competition  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding the functioning of the internal market 
and competition? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+), with the status quo set at zero (0). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do you expect 
each policy option to impact on 
the fragmentation of the HTA 
system in Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the convergence of HTA 
methodologies in Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the attractiveness of the EU 
market for Industry? 
(Reduction of fragmentation of 
HTA systems) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
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Consumer and households 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding consumer and households? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+), with the status quo set at zero (0). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do you expect 
each policy option to impact on 
the number of health 
technologies available 
(consumer choice – mainly for 
medical technologies) in Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the number of health 
technologies assessed in 
Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
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Macroeconomic environment 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following macroeconomic environment? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+), with the status quo set at zero (0). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do you expect 
each policy option to impact on 
the overall economic growth 
and labor market? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the health technology sector? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the health care sector 
(including providers)? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
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Assessment of Social/health impacts 
In the following part of the questionnaire, we kindly ask you to assess each of the policy 
option described according to their social/health impacts. 
 
Compared to the status quo, how do you estimate the different policy options’ 
may impact on the social/health indicators in the table below?  
Please indicate for each question on a range (from -100 to +100) whether the 
indicator may decrease (-) or increase (+) for each policy option. 
Example: If you expect that for option 4B the total number of HTA submission 
across Europe will be cut by half, you should put -50. 
 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
Employment (labor market) 
To what extent do you expect 
each policy option to impact on 
the number of staff employed at 
your company (full time 
equivalents including 
consultants)? 
(Number of full time equivalents 
(including consultants), which are 
involved in HTA and on the payroll 
of your organization) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
Governance, participation and good administration 
To what extent do you expect 
each policy option to impact on 
the involvement of stakeholder 
groups in HTA processes? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the responsibilities of public 
institutions and 
administrations in HTA on MS 
level? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the uptake of joint outputs 
(HTA reports, early dialogues, 
tools, etc.)? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the resource efficiency of HTA 
processes? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the sustainability of EU HTA 
cooperation? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
Access to and effects on social protection and health systems 
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Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do you expect 
each policy option to impact on 
the access to innovative 
treatments? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
Sustainability of health systems 
To what extent do you expect 
each policy option to impact on 
the financing of expensive 
treatments with little or no 
added value? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact on 
the negotiation power of MS in 
setting prices? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
Public health 
To what extent do you expect 
each policy option to impact on 
the availability of health 
technologies on the market? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do you expect 
each policy option to impact 
overall public health? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
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Part 4 - Assessment of Preferences 
 
Q.1. Please indicate which relevance/importance you attribute to the impacts on HTA 
cooperation after 2020 listed below. Please rate the impacts from low priority = 1 to high 
priority = 10. 
 
Impacts Importance (0 to 10) 
E
c
o
n
o
m
ic
 i
m
p
a
c
ts
 
 
Costs Range 1/10 
Administrative burden Range 1/10 
Competitiveness of EU health technology sector Range 1/10 
Innovation and research  Range 1/10 
International Trade Range 1/10 
Functioning of the internal market and 
competition 
Range 1/10 
Consumers and households Range 1/10 
Macroeconomic environment Range 1/10 
 
S
o
c
ia
l/
h
e
a
lt
h
 i
m
p
a
c
ts
 
 
Employment (labour market) Range 1/10 
Governance, participation and good  
administration 
Range 1/10 
Access to social protection and health systems Range 1/10 
Sustainability of health systems Range 1/10 
Public health and safety  Range 1/10 
 
Q.2. The part on policy options included an example of what sub-categories of 
pharmaceuticals and medical technologies could be included in the scope of HTA 
cooperation.  
Please indicate which sub-categories you would find particularly useful to 
include in the EU HTA cooperation.  
 
 
 
Please be sure you want to submit the questionnaire, once submitted answers 
cannot be altered! 
 
Thank you very much for participating and filling in the questionnaire! 
  42 
Annex 4: Industry Questionnaire 
 
Introduction to the survey 
 
Purpose of the survey 
The European Commission (EC) is exploring and assessing options for a new and 
sustainable mechanism for Health Technology Assessment (HTA) in Europe after 2020. 
Consequently, the Directorate General for Health and Food Safety (DG SANTE) of the 
European Commission started an impact assessment process.    
 
In the framework of this process, the EC commissioned the consortium of Sogeti, the 
Austrian Public Health Institute (GÖ FP) and the London School of Economics and Political 
Science (LSE Health) to provide data and evidence to identify the impact of policy 
options for strengthened EU cooperation on HTA in order to support the Impact 
Assessment process of the EC. 
 
This survey is part of the data collection process, which focuses on the insights of key 
stakeholders, and is to be completed by industry stakeholders. There is an additional 
version of the survey for completion by non-industry stakeholders, in particular public 
bodies.   
 
Aim  
We would like you to assess, from your perspective, the potential impacts of different 
policy options for strengthened EU cooperation on HTA after 2020.  
 
Outline of the questionnaire 
The survey is split into four parts: 
Part 1: General questions. 
Part 2: Questions regarding the costs incurred as a result of the HTA process. 
Part 3: Information about the (preliminary) policy options. Assessment of possible 
impacts of 5 policy options (scenarios) for strengthened EU cooperation on HTA after 
2020. 
Part 4: Your assessment on how relevant the defined impacts and scope are.  
 
How we will process the information you provide 
The results will be gathered and clustered and will finally feed into a Multi-Criteria 
Decision Analysis (MCDA) model. The MCDA is a method, based on mathematical 
algorithms, for evaluating individual, often conflicting, criteria. The criteria are then 
combined into one matrix for general assessment to help decision-makers consider 
multiple conflicting factors, or “impacts”, in a rational and consistent manner. The 
objective of the MCDA is to identify policy options which take into account the 
preferences of the involved stakeholders as well as account for the conflicting nature of 
related impacts.  
 
General instructions 
If your company is a subsidiary of another company, we recommend that the 
questionnaire is transferred to the ultimate parent company for completion of the 
questionnaire for all subsidiaries. 
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Confidentiality clause 
We would like to assure you that the European Commission's statuary obligation of 
confidentiality is in place. The final report will only present aggregated or anonymized 
data.  
If you include confidential information/business secrets, please clearly identify/mark the 
section; non-marked sections are assumed not to be confidential. A non-confidential 
version is also welcome. According to the framework contract with the consortium, the 
European Commission may request the data gathered by the contractor. 
 
Deadline for the survey 
This online survey will be active until January 22nd 2017. 
 
In case you have questions or need any support please contact: 
Gesundheit Österreich Forschungs- und Planungs GmbH (GÖ FP) 
Stubenring 6, 1010 Vienna (Austria) 
E-Mail: EU.HTA@goeg.at 
Phone: 0043 (0)151561285 
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Part 1: General Questions 
 
Organization 
Please fill in the name of the organisation/association and your function within:  
Organisation/association:  
Role:   
Your contact details (E-Mail):   
 
Operational level 
Please indicate the operational level of your organisation/association (one answer 
possible): 
o International (e.g. representative at EU level) 
o National  
 
Country: 
Please select the country (if national or regional operational level) or countries (if 
international operational level) in the EU your organization is represented/working in.  
 
Please note that you will be asked to provide more detailed information regarding the 
costs for the countries selected. 
 
Size of company 
Please indicate the size of the organisation you are working for: 
o Large 
o Medium 
o Small  
 
Product Scope 
Please indicate which category of product your organisation specializes in (please tick all 
that apply): 
o Pharmaceuticals 
o Medical technologies 
o Other technology (please specify)  
 
Personal /organizational capacity: 
We kindly ask you to fill out the questionnaire from your organisational point of view. If 
this is not possible, please state that your answers represent your personal perspective.  
o Personal perspective 
o Organisational perspective 
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Question regarding the HTA system within a country: 
Please indicate whether in your country, HTA / REA reports are performed in-house 
within your company (preparation by staff or consultants) or if data for assessment (e.g. 
clinical studies, economic models) is delivered to HTA bodies?  
o In-house performance 
o Delivering data to HTA agency 
 
Please state whether you are working at a trade association or at a manufacturer:  
o Trade association  
o Manufacturer 
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Part 2: Questions regarding the status quo 
 
Please answer the following questions related to the costs of performing and 
undergoing a health technology assessment for the technology developer. 
When answering the questions please refer to the timeframe that is stated within the 
question. 
General instructions: 
 Please refer to the timeframe that is stated within the question.   
 Please use € if available, otherwise use your local currency  
 All figures should be in the Continental European format (e.g. 3,4.) 
 All dates should be given in the format YYMMDD 
 
 
Q1: If one or more of your products was a subject of Horizon Scanning, were any costs 
incurred as a result of this process within the last 5 years? 
A. Yes                          
If yes, please specify what costs these were and give an approximate figure (in 
Euros):  
 
 
B. No 
 
For this survey, Horizon Scanning is defined as “The systematic identification of health 
technologies that are new, emerging or becoming obsolete and that have the potential to 
effect health, health services and/or society”. 
 
Q2: Have you participated to an Early Dialogue process within the past 5 years?   
A. Yes (fill in Q2_1 till Q2_4) 
B. No (jump to part Q3_1) 
 
For this survey early dialogue is defined as follows: Early Dialogues are undertaken with 
the aim of helping pharmaceutical and MedTech companies to understand the evidence 
and information needs of the HTA organisations and reimbursement bodies to improve 
the quality and adequacy of early evidence generation   
Q2_1: With which institution did you undergo an Early Dialogue process? 
 European Medicines Agency (EMA) 
 EUnetHTA 
 Individual HTA Body 
 Other   
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Q2_2: What was the disease area? 
 
Q2_3: What is the approximate cost (in Euros) of your participation in one Early 
Dialogue process?  
 User/submission fees    
 Administration costs   
 Human resources costs  
(Please indicate in Full Time Equivalents)  
 Other expenses, please specify   
 
 
Q2_4:  Did Early Dialogue lead to a reduction in the overall costs of a full HTA process 
within the past 5 years?  
A. Yes 
If yes, please specify by how much (in Euros):  
 
B. No 
 
For this survey full HTA is defined as follows: Full HTA Assessment not only addresses the 
medical/therapeutic added value of a new technology (assessment of clinical domains) 
but also covers the assessment of aspects such as cost-effectiveness, budget impact, 
ethical aspects, legal considerations and impact on patients as well as on the health care 
systems. 
 
Q3_1: How many of your staff work on HTA submissions currently? 
            Please indicate for your country / all countries applicable. 
  
Q3_2: Is HTA performed centrally in your organisation? If yes, how many staff work on 
HTA             submissions centrally? 
 
Q3_3: If possible, please state how many person months are invested in one HTA 
submission on average (person month meaning one person working full time for one 
month). 
 
For this survey HTA submission is defined as follows: HTA submission refers to 
submitting evidence (report or clinical/economic data and studies) to an HTA 
Body/regulatory body for assessing the value of a health technology 
 
Q4: What are the average costs associated with one HTA submission? 
A. Staff costs  
B. In-house model (clinical and economic assessment) and evidence generation  
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C. External model (clinical and economic assessment) and evidence generation   
 
D. Outside consultancy/sub-contracting    
E. Dissemination costs (printing, binding, distributing) 
F. Other, please specify   
 
Q5: Please insert the information on the submission and re-submission fees paid to HTA 
bodies in the last year: 
 
HTA 
Body 
Submission fees Re-submission fees 
   
 
Q6: Are there any other fees/expenses that have not been included? 
A. Yes 
If yes, please specify (with figures in Euros):  
 
B. No 
 
Q7: Looking at your HTA submissions over the past five years have you incurred costs 
related to additional evidence generation? 
A. Yes (fill in Q8 – Q13) 
B. No (jump to part 3) 
 
Q8: What are the costs (on average) for generating additional clinical evidence 
required by the HTA body? 
A. Health surveys:   
B. Supplement to randomised controlled trial:   
C. Practical clinical trials:  
D. Registry data:   
E. Electronic health records/medical chart review:   
F. Administrative data:   
G. Other please specify: 
 
For the purpose of this survey additional evidence generation is defined as follows: 
Generation of additional clinical evidence refers to all studies and provision of data in 
addition to clinical studies performed for marketing authorization within the course of an 
HTA process 
For the purpose of this survey health survey is defined as follows: Health surveys are 
designed to collect descriptions of health status and well-being, health-care utilization, 
treatment patterns, and health-care expenditures from patients, providers, or individuals 
in the general population, which are representative of the target population. Health 
surveys are methodologically rigorous, for example, relying on complex sample survey 
designs.  
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For the purpose of this survey supplement to randomised controlled trial is defined as 
follows: To provide additional data alongside standard clinically focused randomized 
controlled trials, researchers often gather information on variables such as patient 
reported outcomes, medical resource use, and costs. Such efforts can add valuable 
evidence on treatment patterns for common events, e.g., such as the doses of drugs 
used to treat rejection in kidney transplantation 
For the purpose of this survey practical clinical trials is defined as follows: practical or 
pragmatic clinical trials (also called large simple trials) involve prospective, randomized 
assignment but are aimed at larger, more diverse real world populations. Practical or 
pragmatic clinical trials have the important strength of randomization, which minimizes 
bias in the estimation of treatment effects. These trials are by design larger than 
conventional randomized controlled trials. For this reason, they are more likely to have 
sufficient power to capture significant differences in key outcomes of interest, such as 
hospitalizations. 
 
For the purpose of this survey registry data is defined as follows: Registries are 
prospective, observational cohort studies of patients who have a particular disease 
and/or are receiving a particular treatment or intervention. They can be used for 
understanding natural history, assessing or monitoring real world safety and 
effectiveness, assessing quality of care and provider performance, and assessing cost-
effectiveness 
For the purpose of this survey administrative data is defined as follows: administrative 
data (typically retrospective or real-time, if possible) are collected primarily for 
reimbursement, but contain some clinical diagnosis and procedure use with detailed 
information on charges. Claims databases lend themselves to retrospective longitudinal 
and cross-sectional analyses of clinical and economic outcomes at patient, group, or 
population level. 
For the purpose of this survey electronic health records/medical chart reviews is defined 
as follows: electronic health records/medical chart reviews, such as the UK General 
Practice Research Database, contain more detailed, longitudinal information including 
disease-specific symptoms at the personal level and should greatly expand the use of this 
type of information.  
 
Q.9. What are the costs (on average) for generating additional evidence on non-clinical 
domains?  
 
 
 
Definition Non-clinial domains (Please see EUnetHTA core model): Costs and economic 
evaluation; Ethical analysis; Organizational aspects; Patients and Social aspects;  Legal 
aspects)  
 
Q10: Please give us an example where additional evidence was required over the past 
five years and state the associated costs: 
A. Health Technology for which additional evidence was required:   
B. Indication for which this Health technology is used:   
C. Type of additional evidence requested:   
D. Costs for this additional evidence:   
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Q11: Which countries were more likely to request additional evidence?  
          Please refer to your experience over the past five years  
 
 
Q12: Did the additional evidence requested by the country, result in: 
A. Supplementary submission 
a. Yes 
b. No 
 
B. Re-submission 
a. Yes 
b. No 
 
C. Withdrawal of submission 
a. Yes 
b. No 
 
D. What was the impact on costs? 
 
a. Staff   
 
b. HTA related costs   
 
c. Real word evidence generation   
 
E. What was the impact on the time until the final HTA report was available? 
 
 
Q13: Have any of your products undergone a re-assessment?  
If yes, please indicate how much extra costs it incurred (in Euros). 
a. Yes 
b. No 
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Part 3: Information about the preliminary policy options on  
HTA cooperation after 2020 
 
In this section, we provide you with key information to assess the impact of the different 
preliminary policy options.  
Please read carefully through the short description of each policy option in 
order to understand the scope of the questions asked in Section 3.   
 
 
 
 
 
 
 
 
 
 
 
Key characteristics 
The different policy options for cooperation on HTA after 2020 are defined along several 
key characteristics focusing on 1. HTA output, 2. Participation and uptake from 
Member States' perspectives, 3. Organizational aspects, 4. Funding aspects as well as 5. 
Timelines. These are explained in the following:   
 
1) The scope of the cooperation is defined by several outputs(22) created by a joint 
collaboration, comprising of: 
 Common tools and procedures, including common submission templates, an IT 
system with planned and ongoing assessments, common methodologies (e.g 
EUnetHTA Core Model), a joint prioritization process, and cooperation on data 
requirements, including Horizon Scanning  
 Performing joint Early Dialogues 
 Performing joint Relative Effectiveness Assessments (REA can take place at time 
of market launch, or later (re-assessment))  
 Performing joint Full Health Technology Assessments (Full HTA can take place at 
time of market launch, or later (re-assessment)) 
 
 
2) The engagement in participation and uptake(23) of jointly produced outputs can be 
either voluntary or mandatory:  
                                   
(22) The scope of the activities may differ between pharmaceuticals, medical devices and other technologies. 
Please note:  
For the purpose of assessing the impacts of the various options and the various implementation mechanisms 
/business models, fine-tuned options were created within the course of the study. These combine the options 
with the implementation mechanisms (for details see below).  
The fine-tuned options in this section are provisional. They are merely examples of the possible combinations of 
the IIA options with the IIA implementation mechanisms that were developed in order to facilitate the analysis. 
In any event, they do not represent the preferred combinations of the European Commission nor the contractor 
and other combinations are possible. Furthermore, the policy options may need to be revised following the input 
of Member States and stakeholders through public consultation and discussions. The final policy option does not 
have to be exactly in line with one that was analysed, but it can combine elements. (E.g. it is possible to have 
option X, but combine it with the implementation mechanism of option Y.) 
  52 
 Voluntary participation/ voluntary uptake (V/V): Member States can decide if they 
wish to participate in the production of outputs and take up the respective output; 
cooperation is entirely voluntary.  
 Voluntary participation/mandatory uptake (V/M): The participation in the creation 
of joint work is voluntary, meaning that Member States can decide to opt-in24 to 
the joint cooperation. However, once a Member State has opted-in the uptake of 
the joint work into the national setting is mandatory.  
 Mandatory participation/mandatory uptake (M/M): Both participation in the 
production of outputs and the uptake of these into the national setting are 
mandatory. 
 
For each of the policy options, different combinations of voluntary or mandatory 
participation and uptake per Output are possible. 
3) For organizing the creation of these joint HTA outputs a number of different 
organizational mechanisms are conceivable: 
 Project based cooperation: The secretariat is set up by the Member States that 
participate (similar to EUnetHTA). 
 EU/MS secretariat: A permanent Secretariat is established.  
 Existing EU agency: A permanent Secretariat is integrated in an already existing 
EU agency. This Secretariat will coordinate the work of national experts in HTA 
bodies in carrying out the assessments.  
 New EU agency: A permanent Secretariat is integrated in a NEW EU agency. This 
Secretariat will coordinate the work of national experts in HTA bodies in carrying 
out the assessments.  
 
4) For financing the joint cooperation several funding mechanisms are conceivable: 
 EU funding, either through a Public Health program or another financial 
instrument 
 Funding by Member States joining the collaboration 
 Funding through industry fees 
 
5) Timelines: 
Timelines for implementation of the proposed policy options after 2020 range from 
immediately, without delay, for option 1 (i.e. 2021) to transitional periods for 
implementing options 4 or 5 in a new legal framework). 
 
Table 1 provides an overview of each policy option and the envisaged 
implementation/funding mechanism. A short summary for each policy option can be 
found afterwards.  
                                                                                                             
(23) Please note that Up-take concerns using or considering the results and findings of the HTA cooperation, reaching from jointly 
developed submission templates to outcomes in full HTA. The subsequent pricing and reimbursement decision would remain purely 
on national level. Also providers / developers need to adhere to this process. 
(24) Opt-in by MS is by output, not by individual products e.g. once a MS has opted in for joint REA, they take part in all joint REAs – 
but not necessarily as an author.  
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Table 5: Overview of Policy Options 
 
                                   
(25) Assuming that 50% of the Member States participate, a mix between high/low income, large/small MS.  
(26) Early Dialogue: Here mandatory uptake means that the MS cannot repeat an ED that was done at EU level. Technology providers initiate Early Dialogues. 
(27) Either at time of market or re-assessment 
(28) A gradual introduction of products during a transitory period that allows to manage the workload while the structures/implementation model are being developed. 
 Baseline Non-legislative Legislative 
 PO 1 PO 2 PO 3 PO 425 PO 5 
No EU action 
after 2020 
 
Voluntary 
cooperation 
through Public 
Health 
Programme 
Legislation 
covering 
common tools and 
early dialogues 
 
Legislation covering  
Joint work on REA  
Plus 
common tools and early dialogues 
Legislation covering  
Joint work on Full 
HTA (incl. REA) 
Plus 
common tools and 
early dialogues 4.1 
REA V/M 
4.2  
REA M/M 
O
u
tp
u
ts
 
Common tools, 
incl. templates, 
methodology 
V/V V/M M/M M/M M/M M/M 
Early dialogue(26) V/V V/M V/M V/M M/M M/M 
Joint REA(27) V/V V/M V/V V/M M/M M/M 
Joint Full HTA(6) 
V/V V/V V/V V/V V/V V/M 
Implementation No EU input Project based  
cooperation 
EU/MS secretariat  Existing EU 
agency 
Existing EU 
agency 
New EU agency 
Financing None from EU EU+MS EU+MS+fees from industry for early dialogues, joint REA and full HTA 
 Scope  All medicines, 
medical and other 
technologies 
Tools: all 
medicines, medical 
technologies, other 
technologies 
(phasing in), ED: 
industry submission 
Tools and ED see PO 3. REA: certain 
categories of medicines (e.g. centrally 
authorised, high value/budget impact, 
agreement between MS), certain 
categories of medical technologies(e.g. 
high risk, high value products) and 
other technologies (agreement and 
prioritisation between MS) – phasing 
in(28) 
Tools and ED see PO 
3, REA see PO4. For 
others: ad hoc 
agreement and 
prioritisation between 
MS 
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Short description of policy options: 
Policy Option 1. Baseline scenario - No EU action after 2020: 
 Non-regulatory framework 
 Participation/uptake entirely voluntary 
 No EC action & no EU funding. MS are free to cooperate in any kind 
Policy Option 2. Voluntary cooperation supported by the Public Health 
Programme: 
 Non-regulatory framework 
 Participation entirely voluntary 
 Mandatory uptake of (some of the) common (IT-) tools, templates, methodologies 
+ Early Dialogue + joint REA. EU contribution can only be obtained if contractually 
agreed by the participants.  
 Voluntary uptake of joint Full HTA 
 Coordination organised on a project basis 
 EU & MS funding: long term commitment of funding, (minimum 4, maximum 7 
years), annual budget(29)  
 Scope: All medicines, medical and other technologies 
Policy Option 3. Legislation covering Common Tools and Early Dialogues: 
 Regulatory framework will be established 
 Mandatory participation and uptake in common (IT-) tools, templates, 
methodologies, etc.  
 Opt-in (foreseen in legislation) in Early Dialogues and reassessments, mandatory 
uptake for those who opted in   
 Voluntary participation in and uptake of joint REA + joint Full HTA  
 Coordination organised by a secretariat run by EC or MSs 
 Funding by EU, MS and by other sources (e.g. company fees for Early Dialogues 
or registries for reassessment) 
 Scope: For tools: all medicines, medical technologies, other technologies (phasing 
in), for Early Dialogue:  industry submission 
Policy Option 4.1. Opt-in for Joint REA plus option 3: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies – see option 3 
 Opt-in (foreseen in legislation) in joint REA and Early Dialogues and mandatory 
uptake by those who opted in. It is assumed that 50% of the Member States 
participate, a mix between high/low income, large/small MS. 
 Voluntary participation and uptake of joint Full HTA  
 Coordination organised in an existing EU agency 
 Funding by EU, MS and other sources (e.g. company fees – including for joint EDs 
and REAs)  
 Scope: Tools and ED see PO 3. REA: certain categories of medicines (e.g. 
centrally authorised, high value/budget impact, agreement between MS), certain 
categories of medical technologies (e.g. high risk, high value products) and other 
technologies (agreement and prioritisation between MS) – phasing in 
 
 
                                   
(29) Through the Multiannual Financial framework (MFF) 
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Policy Option 4.2. Mandatory Joint REA plus option 3: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies + Early Dialogues +  joint REA 
 Voluntary participation in and uptake of joint Full HTA. It is assumed that 50% of 
the Member States participate, a mix between high/low income, large/small MS. 
 Coordination organised in an existing EU agency 
 Funding by EU, MS and other sources (e.g. company fees – including for joint EDs 
and REAs) 
 Scope: Tools and ED see PO 3. REA: certain categories of medicines (e.g. 
centrally authorised, high value/budget impact, agreement between MS), certain 
categories of MDs (e.g. high risk, high value products) and other technologies 
(agreement and prioritisation between MS) – phasing in 
Policy Option 5: Option 4.2 and Opt-in for Full HTA: 
 Regulatory framework will be established 
 Mandatory participation in and uptake of common (IT-) tools, templates, 
methodologies + Early Dialogue +  joint REA – option 4.2 
 Opt-in (foreseen in legislation) participation in joint Full HTA and mandatory 
uptake for those who opted in 
 Coordination organised in a new EU agency  
 Funding by EU, MS and other sources (e.g. company fees – including for Full HTA) 
 Scope: For tools and ED see policy option 3. For REA see policy option 4. For 
others: ad hoc agreement and prioritisation between MS. 
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Part 4: Assessment of policy options 
 
In the following sections of the questionnaire, we kindly ask you to assess each of the 
policy options described above according to their economic and social/health impacts.  
 
Compared to the status quo, how do you estimate the different policy options’ 
may impact on the economic indicators in the table below?  
Please indicate for each question on a range (from -100 to +100) whether the indicator 
may decrease (-) or increase (+) for each policy option. 
 
Example: If you expect that for option 4.2 the total number of HTA submission 
across Europe will be cut by half, you should put -50. 
 
Costs 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on your average costs per product?  
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+) for each policy option.  
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the costs 
for Horizon 
Scanning (all 
costs)? 
 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the total 
costs for Early 
Dialogues? 
(Total costs including 
costs for staff, 
administrative costs, 
etc.) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the total 
costs of a REA 
submission (if 
applicable)? 
(Total costs including 
costs for staff, 
(re)submission 
costs, administrative 
cost, costs for 
including stakeholder 
etc.) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the total 
costs of a full HTA 
submission? 
(Total costs including 
costs for staff, 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
  57 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
(re)submission 
costs, administrative 
costs, travel costs, 
costs for including 
stakeholder) 
To what extent do 
you expect each 
policy option to 
impact on HTA 
submission fees? 
(Fees that have to 
be paid for 
submitting an 
HTA/REA to the 
respective 
institution) 
 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the costs 
for additional data 
requested by HTA 
bodies? 
(Referring to all 
studies performed in 
addition to clinical 
studies conducted 
for regulatory 
approval  ) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the needs 
for Human 
Resources (Full 
time equivalents 
including 
consultants)? 
 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the costs 
for HTA re-
assessment (all 
costs)? 
 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
 
 
 
 
 
 
Administrative burden  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on your administrative burden?  
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
  58 
overall 
administrative 
burden associated 
with HTA 
submissions? 
(Administrative 
burden arising from 
the information 
obligations imposed 
on industry  with 
regard to HTA 
processes) 
To what extent do 
you expect each 
policy option to 
impact on the 
number of HTA 
submissions for the 
same product and 
indication across 
European countries? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the time 
needed for an HTA 
process? 
(The time span of 
the whole 
assessment 
procedure) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
complexity of HTA 
assessment 
processes? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
 
Competitiveness of EU health technology sector  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding the competitiveness of EU health 
technology sector? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the 
predictability of 
the HTA system in 
Europe?    
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
competitiveness of 
SME?  
(SME is defined by 
staff headcount<250 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
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and either turnover 
≤ 50m or balance 
sheet total     ≤ 
43m) 
To what extent do 
you expect each 
policy option to 
impact on your 
revenues?    
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
 
 
Innovation and research  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding Innovation and research? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the 
research climate 
in the European 
market?  
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
actual innovation 
for the European 
market?  
(I.e. focus on 
predictability and 
deduction of 
fragmentation as 
key factors for 
favorable business 
climate for 
industry 
facilitating 
innovation thrive ) 
 
 
 
 
 
 
 
 
range 
-
100/+100 
 
 
 
 
 
 
 
 
range 
-
100/+100 
 
 
 
 
 
 
 
 
range 
-
100/+100 
 
 
 
 
 
 
 
 
range 
-
100/+100 
 
 
 
 
 
 
 
 
range 
-
100/+100 
 
 
 
 
 
 
 
 
range 
-
100/+100 
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International Trade 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on international trade? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on 
international trade 
related to 
pharmaceuticals/ 
medical 
technologies?  
(Possibility to import 
and/or export)  
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
range 
-
100/+100 
 
 
Functioning of the internal market and competition  
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding the functioning of the internal market 
and competition? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the 
fragmentation of 
the HTA system in 
Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
convergence of 
HTA 
methodologies in 
Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
attractiveness of 
the EU market for 
Industry? 
(Reduction of 
fragmentation of 
HTA systems) 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
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Consumer and households 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following indicators regarding consumer and households? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the 
number of health 
technologies 
available 
(Consumer choice – 
mainly for medical 
technologies) in 
Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
number of health 
technologies 
assessed in Europe? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
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Macroeconomic environment 
Compared to the status quo, how do you estimate the different policy options’ may 
impact on the following macroeconomic environment? 
Please indicate on a range (from -100 to +100) whether the indicator may decrease (-) 
or increase (+). 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
To what extent do 
you expect each 
policy option to 
impact on the 
overall economic 
growth and labor 
market? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
health technology 
sector? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
health care sector 
(including 
providers)? 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
 
range 
-
100/+100 
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Assessment of Social/health impacts 
In the following section of the questionnaire, we kindly ask you to assess each of the 
policy option described according to their social/health impacts. 
Compared to the status quo, how do you estimate the different policy options’ 
may impact on the social/health indicators in the table below?  
Please indicate for each question on a range (from -100 to +100) whether the 
indicator may decrease (-) or increase (+) for each policy option. 
Example: If you expect that for option 4B the total number of HTA submission 
across Europe will be cut by half, you should put -50. 
Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
Employment (labor market) 
To what extent do 
you expect each 
policy option to 
impact on the 
number of staff 
employed at your 
company (full time 
equivalents including 
consultants)? 
(Number of full time 
equivalents 
(including 
consultants), which 
are involved in HTA 
and on the payroll of 
your organization) 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-
100/+100 
 
Governance, participation and good administration 
To what extent do 
you expect each 
policy option to 
impact on the 
involvement of 
stakeholder groups 
in HTA processes? 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
responsibilities of 
public institutions 
and 
administrations in 
HTA on MS level? 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
uptake of joint 
outputs (HTA 
reports, Early 
Dialogues, tools, 
etc.)? 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-
100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
resource efficiency 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-
100/+100 
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Indicator 
(impact on) 
PO 1 
 
PO 2 
 
PO 3 
 
PO 4.1 
 
PO 4.2 
 
PO 5 
 
Comments 
of HTA processes? 
To what extent do 
you expect each 
policy option to 
impact on the 
sustainability of EU 
HTA cooperation? 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-
100/+100 
 
Access to and effects on social protection and health systems 
To what extent do 
you expect each 
policy option to 
impact on the 
access to 
innovative 
treatments? 
 
 
range 
-
100/+1
00 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
Sustainability of health systems 
To what extent do 
you expect each 
policy option to 
impact on the 
financing of 
expensive 
treatments with 
little or no added 
value? 
 
range 
-
100/+1
00 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact on the 
negotiation power 
of MS in setting 
prices? 
 
range 
-
100/+1
00 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
Public health 
To what extent do 
you expect each 
policy option to 
impact on the 
availability of 
health 
technologies on 
the market? 
 
range 
-
100/+1
00 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
To what extent do 
you expect each 
policy option to 
impact overall 
public health? 
 
range 
-
100/+1
00 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
 
range 
-100/+100 
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Part 4 - Assessment of Preferences 
 
Q.1. Please indicate which relevance/importance you attribute to the impacts on HTA 
cooperation after 2020 listed below. Please rate the impacts from low priority = 1 to high 
priority = 10. 
 
Impacts Importance (0 to 10) 
E
c
o
n
o
m
ic
 i
m
p
a
c
ts
 
 
Costs Range 1/10 
Administrative burden Range 1/10 
Competitiveness of EU health technology sector Range 1/10 
Innovation and research  Range 1/10 
International trade Range 1/10 
Functioning of the internal market and 
competition 
Range 1/10 
Consumers and households Range 1/10 
Macroeconomic environment Range 1/10 
 
S
o
c
ia
l/
h
e
a
lt
h
 i
m
p
a
c
ts
 
 
Employment (labour market) Range 1/10 
Governance, participation and good  
administration 
Range 1/10 
Access to social protection and health systems Range 1/10 
Sustainability of health systems Range 1/10 
Public health and safety  Range 1/10 
 
Q.2. The section on policy options included an example of what sub-categories of 
pharmaceuticals and medical technologies could be included in the scope of HTA 
cooperation.  
Please indicate which sub-categories you would find particularly useful to 
include in the EU HTA cooperation.  
 
 
 
Please be sure you want to submit the questionnaire, once submitted answers 
cannot be altered! 
 
Thank you very much for participating and filling in the questionnaire! 
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Annex 5: List of agencies performing HTA agencies operating at EU level 
 
Country HTA Agency Scope of 
Recommendations 
Technologies Appraised Role of 
HTA Body 
Publicly 
Available 
HTA 
Reports 
Austria GÖG 
LBI-HTA 
Hauptverband 
National Pharmaceuticals, medical devices and 
other technologies 
Advisory Yes 
Belgium KCE National Pharmaceuticals and other technologies Advisory Yes 
Bulgaria NCPHA 
Centre for 
Health Technology Assessment 
and 
Analysis 
National Pharmaceuticals Advisory No 
Croatia Azz National Pharmaceuticals and medical devices Advisory No 
Cyprus MoH National Pharmaceuticals Advisory No 
Czech 
Republic 
MoH National Pharmaceuticals Advisory No 
Estonia Centre for Health Technology 
Assessment-University of Tartu 
Estonian Health Insurance Fund 
(EHIF) 
National Pharmaceuticals Advisory Yes 
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Country HTA Agency Scope of 
Recommendations 
Technologies Appraised Role of 
HTA Body 
Publicly 
Available 
HTA 
Reports 
Finland FIMEA 
KELA 
National Pharmaceuticals, medical devices and 
other technologies 
Advisory Yes 
France HAS National Pharmaceuticals, medical devices, hospital 
medical technologies 
Advisory Yes 
Germany IQWIG 
G-BA 
National Pharmaceuticals Advisory 
(IQWIG) 
Regulatory 
(G-BA) 
Yes 
Hungary OGYEI National Pharmaceuticals, medical devices, hospital 
medical technologies 
Advisory No 
Ireland NCPE 
HIQA 
National Pharmaceuticals, medical devices and 
other technologies 
Advisory Yes partly 
Italy AIFA (national) 
UVEF (regional) 
AGENAS (regional) 
REGIONE EMILIA ROMAGNA 
(regional) 
National and 
Regional 
Pharmaceuticals and medical devices Regulatory 
(AIFA) 
Advisory 
(UVEF & 
AGENAS) 
Yes 
Latvia ZVA National Pharmaceuticals Regulatory No 
Lithuania VASPVT National Medical Devices Advisory Yes 
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Country HTA Agency Scope of 
Recommendations 
Technologies Appraised Role of 
HTA Body 
Publicly 
Available 
HTA 
Reports 
Malta Directorate of Pharmaceutical 
Affairs-MoH 
National Pharmaceuticals Advisory No 
Netherlands ZiN National Pharmaceuticals, medical devices and 
other technologies 
Advisory Yes partly 
Poland AOTMiT National Pharmaceuticals, medical devices and 
other technologies 
Advisory Yes 
 
Portugal Infarmed National Pharmaceuticals and medical devices Advisory Yes 
Romania NAMMD National Pharmaceuticals Regulatory Yes 
Slovakia MoH National Pharmaceuticals and medical devices    Advisory No 
Slovenia MoH National Pharmaceuticals     
Advisory 
No 
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Spain CADIME (regional) 
AQuAS (regional) 
ISCII (national) 
OSTEBA (regional) 
AETSA (regional) 
SECS (Regional) 
Regional Pharmaceuticals and medical devices Advisory Yes 
Sweden TLV National Pharmaceuticals and medical devices Regulatory Yes 
United 
Kingdom 
NICE 
SMC 
National Pharmaceuticals, medical devices and 
other technologies 
Advisory Yes 
EU level  EUnetHTA European Level Pharmaceuticals, medical devices and 
other technologies 
  
 
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; GÖG: 
Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; NCPHA: The National Center of Public Health and 
Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and 
Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health 
Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts 
agentura; VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional 
da Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de Medicamentos; AquAS: Agència de Qualitat i 
Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for Health Technology Assessment; SECS: 
Servicio de Evaluacion del Servicio Canario de salud. 
Source: The Authors 
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Annex 6: Minutes Focus Group Pharma  
 
Pharmaceutical Industry focus group 
Date: 02/05/2017 
Location: DG SANTE offices 
 
Participants 
Pharmaceutical companies: The company representatives that participated in the 
online survey related to Health Technology Assessment (HTA) (“the survey") were 
attending in order to provide additional information on the survey results. The survey is 
part of a "Study on impact analysis of policy options for strengthened EU cooperation on 
HTA" ("the study") - run by the Austrian Public Health Institute (GO FP) and the  London 
School of Economics on behalf of DG SANTE/CHAFEA. The following companies were 
represented: 
 
Biogen International GmbH 
Johnson & Johnson  
Pfizer 
Novo Nordisk Region Europe Pharmaceuticals A/S 
Eli Lilly & Co 
CelgenE 
Teva Pharma 
 
DG SANTE: Dominik Schnichels, Head of Unit, Medical products: quality, safety, 
innovation;  F. Giorgio, N.Orsi, C. Larsson Lindqvist, K. Valkova, N. Suleiman  
 
The Austrian Public Health Institute (GO-FP): Anja Laschkolnig 
London School of Economic (LSE): Panos Kanavos, Erica Visintin  
Purpose of the meeting 
Discussion, interpretation and validation of the survey results with industry experts 
regarding costs and impacts of the policy options. 
 
Discussion 
General observations 
Industry participants agreed that the results of the survey are useful to understand 
preferences of the pharma industry regarding the HTA policy options. The survey results 
should however not be over-interpreted as precise quantifications of the impacts (e.g. 
 
EUROPEAN COMMISSION 
DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY 
 
 
Directorate B - Health systems, medical products and innovation 
Unit B4 - Medical products: quality, safety, innovation 
 
  71 
cost increases by x%). The survey results should rather be taken as a general indication 
of trends. The respondents also noted that exact quantification of certain impacts has 
been difficult as many factors had to be taken into consideration for one indicator. Also 
the impacts will depend on how the policy options would be implemented and for some 
participants this was not defined sufficiently when answering the questionnaire.  
To compensate for the above limitations, it was recommended to triangulate the results 
with additional data sources and complement by the outcome of the focus group 
discussion. DG SANTE clarified that the online survey is one part of the data gathering 
exercise to support the analysis of the impacts of the policy options. The survey is further 
supported by the literature review and a set of case studies. In addition, it was also 
clarified that the study is one input to the impact assessment process along with the 
results of the public consultation, the outcome of the ongoing additional stakeholders' 
consultation and further data gathering which is currently ongoing via additional studies 
which aim to map processes and procedures of HTA systems across the EU.  
Largely, the representatives of pharma companies expressed a preference for policy 
options 4.1 and 4.2. Both of them having provisions for a centralised REA with a varying 
degree of uptake – respectively voluntary participation and mandatory uptake; and 
mandatory participation and uptake. The stated reasoning was that pharmaceutical 
companies could use the results from an EU-wide REA as supporting the various pricing 
and reimbursement discussions which normally follow the HTA process and these options 
would further increase the business predictability across Member States providing for a 
better investment as well as research and innovation environment.   
Participants expressed strong concerns towards policy option 5. As option it is considered 
to bring the most substantial (structural) changes by moving decisions from the local 
towards EU level. They agreed that a joint European full HTA is not feasible due to the 
specificities, e.g. in the organisational care or economic domains and so policy option 5 
would lead to a duplication of demands for pharmaceutical companies – first at EU level, 
and then at national level, in the cases where Member States do not find the EU demands 
sufficient enough. This leads to duplications and even higher unpredictability, which 
strongly affects the responses to all indicators.  
EC1 Costs 
The participants confirmed that the general trend for costs is plausible. Discussing the 
results for policy option 2 to 4 the industry representatives explained that they do not 
expect any significant changes in their current costs, yet the overall consistency of HTA 
processes and outcomes would increase resulting in better business predictability having 
positive effects on investment as well as research and innovation.  
The participants explained that they usually prepare a central/global value dossier for 
each product. This dossier is then used as a main source of input by the HTA teams 
across the countries where the products is foreseen to be launched. One estimation was 
that a joint HTA report could replace 20-25% of the local HTA costs if there is no 
requirement for translation/adaptation. At the same time, even if there is an EU-
centralised REA at the time of market launch, companies would still have to go through 
national reimbursement procedures. While this could result in a reduction of some costs 
(see above), the companies would still have significant and possibly increased 
expenditure for the national requirements, which are outside the EU cooperation (eg 
“economic evaluation”). That is why industry believes that the increases and decreases in 
costs would just balance each other out.  
Furthermore, it was explained that today there are certain risks when performing 
evidence generation. Should the company align to the market that requires the highest 
level of evidence or can a lower standard be sufficient. In that regard, companies take 
risks when deciding for a lower or medium standard. Following that logic it is perceived 
likely that a framework for an EU HTA may provide a compromise between data needs.  
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The key driver for HTA-related costs is the evidence generation. It is mainly in the largest 
markets that companies perform additional clinical trials requested by HTA bodies. 
Otherwise, the existing knowledge gaps are often covered with post-marketing studies 
(investigator-initiated trial). The companies also explained that the requests for evidence 
by smaller countries might be more difficult to address – taking into account the market 
size. 
Harmonisation of data requirements was perceived positive. It reduces risks but does not 
necessarily result in overall cost reduction as the data needs at EU level will likely not 
end up at the level of the lowest denominator.  
 
Comments on the costs reported 
The costs for industry (absolute figures) were considered to be realistic, but erring on the 
conservative side. The actual costs would depend on what is included in the cost factors 
(such as costs related to RCTs, which were not included by the study team on purpose). 
It was also noted that many indirect costs may not have been reported and that 
establishing the costs for additional evidence generation is particularly difficult (different 
budget lines, data may also serve other – regulatory/pricing and reimbursement - 
purposes etc.)  
Participants agreed to follow up on the issue of additional evidence generation and to 
provide further information to DG SANTE. 
EC2 Administrative Burden 
The industry representatives reiterated that the recurrent sharp rise of expected costs 
between policy option 4 and 5 can be explained with the aforementioned multiplication of 
national requirements – in addition to the harmonisation achieved at EU level. Industry 
also argued that option 5 does not appear feasible in practice due to the different 
economic situations of Member States.  
EC 3 Competitiveness of the EU health technology sector 
The pharma representatives clarified that, overall, they could expect an increase in 
competitiveness in the EU with the reduction of the heterogeneity of the markets and the 
potential shortening of timelines that stronger cooperation in HTA on EU level would 
achieve. However, less heterogeneity among EU markets would not necessarily translate 
immediately into higher revenues since the negotiations on the pricing and 
reimbursement of pharmaceuticals will still take place and the overall budget for 
pharmaceuticals is not expected to increase.  
EC 4 Innovation and Research 
The main driver is the improved predictability of the HTA process which could lead to 
increased efforts to innovate, since operating in an environment with less variability 
between markets, would lead to less risks and thus, to more investments. Joint REA in 
parallel with market authorisation should shorten the market access process – at least in 
certain countries. If the process is shortened, there would cost savings and earlier 
revenues. Participants also pointed out the value in accessing the first markets quickly. 
This could be particularly relevant for SMEs.  
Meanwhile, additional efforts would be needed from the small and medium enterprises 
(SMEs) to keep up with new requirements and stay competitive on the market. These 
trends are reflected in the answers for the respective policy options.  
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SH 4 Sustainability of health systems and SH 5 Public Health 
Most of the participants did not provide input to this question, since they deemed the 
question out of their reach. According to them, one of the positive aspects of HTA is the 
value-based approach for treatments and products.   
Follow up 
DG SANTE thanked the participants of the focus group and asked them to provide 
clarification on the occasions when they have been performed additional evidence 
generation by 12th May.   
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Annex 7: Minutes Focus Group MedTech Minutes 
 
HTA Focus Group: Medical Technologies (incl. diagnostics) 
Date: 02/05/2017 
Location: DG SANTE offices 
 
Participants 
Medical technologies industry:  
Company representatives that participated in the online survey related to Health 
Technology Assessment (HTA) (“the survey") were attending in order to provide 
additional information on the survey results. The survey is part of a "Study on impact 
analysis of policy options for strengthened EU cooperation on HTA" ("the study") - run by 
the Austrian Public Health Institute (GO FP) and the  London School of Economics on 
behalf of DG SANTE/Chafea. The following companies were represented:  
 
Beckman Coulter 
GE Healthcare Europé 
Baxter World Trade 
Johnson & Johnson Medical 
Roche Diagnostics 
B.Braun Melsungen AG 
Philips Healthcare  
Biocartis 
Fresenius SE & Co. KGaA 
 
DG SANTE: Dominick Schnichels, Head of Unit, Medical products: quality, safety, 
innovation; F. Giorgio, N.Orsi, C. Larsson Lindqvist, K. Valkova, N. Suleiman. 
The Austrian Public Health Institute (GO-FP): Anja Laschkolnig 
London School of Economic (LSE): Panos Kanavos, Erica Visintin  
Purpose of the meeting 
Discussion,interpretation and validation of the survey results with industry experts 
regarding costs and impacts of the policy options. 
 
Discussion  
The majority of participants to the focus group had relevant HTA experience, either in 
their current function or in their past professional career.  
 
 
 
EUROPEAN COMMISSION 
DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY 
 
 
Directorate B - Health systems, medical products and innovation 
Unit B4 - Medical products: quality, safety, innovation 
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General observations 
Industry participants agreed that the results of the survey are useful to understand 
preferences of the medtech industry regarding the HTA policy options. The survey results 
should however not be over-interpreted as precise quantifications of the impacts (e.g. 
cost increases by x%). Certain values are rather the expression of significant concerns 
that the market access path for medtech products might change substantially – over and 
above the new legislation for medical technologies that was just adopted. The survey 
results should rather be taken as a general indication of trends. The respondents also 
noted that exact quantification of certain impacts has been difficult as many factors had 
to be taken into consideration for one indicator. Also the impacts will depend on how the 
policy options would be implemented and for some participants this was not defined 
sufficiently when answering the questionnaire.  
To compensate for the above limitations, it was recommended to triangulate the results 
with additional data sources and complement by the outcome of the focus group 
discussion. DG SANTE clarified that the online survey is one part of the data gathering 
exercise to support the analysis of the impacts of the policy options. The survey is further 
supported by the literature review and a set of case studies. In addition, it was also 
clarified that the study is one input to the impact assessment process along with the 
results of the public consultation, the outcome of the ongoing additional stakeholders' 
consultation and further data gathering which is currently ongoing via additional studies 
which aim to map processes and procedures of HTA systems across the EU.  
Many industry participants explained that their responses for Policy Option 2 are based 
on the assumption that the collaboration is expected to be demand driven, from the 
‘bottom upwards’ and the overall number of HTAs for medical technologies would remain 
stable. Whilst in options 3 to 5 the collaboration would become more top-down and the 
number of (joint) HTA reports would increase significantly – leading to additional costs 
for industry and delays in market launch. Also some participants indicated that in their 
responses they considered that Option 2 is fully aligned with the proposal of the 
European medtech association, where clusters of Member States (MS) that are interested 
in a given technology can agree to cooperate on a voluntary basis.  
DG SANTE explained that in its view the main difference between Policy Options 2 and 3 
is the cooperation framework for HTA bodies. In Policy Option 2 the cooperation of HTA 
bodies is based on a contractual arrangement (like EUnetHTA). In Policy Option 3 the 
cooperation is based on legislation. In this sense the risk of diverging submission 
templates, diverging data requirements etc. is less pronounced in Policy Option 3. Joint 
Assessments can be done under both Policy Options alike, in both cases on a voluntary 
basis. Industry participants had different understanding of Policy Option 3 had been clear 
to them – they would have replied differently by giving more favourable marks to Policy 
Option 3.  
Participants also clarified that they had interpreted Policy Options 3-5 as legally 
mandating REA (or full HTA) at the time of launch, and as such they felt it would 
substantially increase HTA activities in MS for medical technologies. Ultimately it would 
fundamentally change the current business model, which is based largely on public 
procurement at local level. In their view the creation of a legal framework, even if it did 
not impose a legal obligation on REA or Full HTA, would provide a driver for further 
increase of HTA activities in MS. Some participants also argued that the market access 
path for medical products typically does not foresee setting prices or reimbursement 
levels at national level. This would question the value of HTA at time of launch (no 
impact on “decision making”) and could delay market access. For the majority of 
technologies it might therefore be preferable to allow immediate market access and 
foresee a demand-driven reassessment based on real world evidence (value based 
pricing) at a later stage (e.g. on clinical uncertainty after a period of clinical experience). 
This would also maintain the first mover advantage.  
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Industry participants also indicated that there is a perceived risk that even though an EU 
Assessment would be implemented, there would be duplications on national and local 
level. In the view of the industry it will still be essential to capture the specific elements 
present at local level which have to be part of the assessment related to the use of the 
technologies in the local settings. Therefore HTA bodies are considered likely to continue 
to ask additional information, including for generation of evidence, which are particularly 
costly for the industry.  
The discussion also touched upon the difference between regulatory and HTA 
requirements; where industry pointed out that they should remain separate. The 
regulatory framework, currently in transition, aims to ensure that products are safe, and 
that label claims are correct. HTA, on the other hand, intends to assess the clinical 
benefit of an intervention. These purposes are complementary but different, and should 
not be confused. It would instead make more sense to align HTA requirements with 
needs of market access decision-makers / payers, to increase the relevance of HTAs. 
When defining the value of a technology, one particular challenge for medical 
technologies are the large variability in service delivery models across Member States 
and the fact that the costs and benefits are often realised in health and social budgets 
(e.g. less invasive surgeries and other technologies shifting care from hospitals to social 
settings) and they are not fully captured in the assessment. Moreover, it is particularly 
dependent on the local specificities and would be impossible to capture it in a single EU 
full HTA.  
EC1 Costs 
The participants confirmed that the general trend visible is plausible.  
In response to the question how to explain the major differences between Policy Options 
2 and 3, participants explained that the main driver for increased costs from policy option 
3 to 5 is the legal nature of the cooperation. A described earlier (see "general 
observations"), participants expect a legal system to significantly increase HTA activities 
across Member States and between Member States in the field of medical devices and 
IVDs at the time of the market launch of the product, where currently there are limited 
activities (if at all).  
The key cost factor is the generation of evidence. Companies noted that currently 
efficacy data is not required (and in the revised regulation it will only be required for a 
limited number of technologies). The cost of regulatory and HTA data generation differs; 
HTA evidence generation is estimated to be four times more expensive. It was also 
discussed that for products requiring additional clinical data, it may be beneficial to align 
requirements, if possible to maximise the use of data and reduce duplication.   
Comments on the costs reported:  
 The large variation reported on the costs related to HTA is a good reflection of 
large variation of real-life costs of different technologies. Costs are considered to 
be realistic yet slightly conservative, depending on what is included in the cost 
factors. 
 
 For the number companies involved in early dialogues: of the participants that 
responded “yes”, they clarified that they only had undergone one ED process 
respectively (i.e. do not routinely engage in early dialogues for medical devices), 
so the number overestimates the importance of EDs for medical technologies. This 
is explained by the short life cycle of medical technologies (including fast 
development phase) and the limited requirements for clinical evidence, according 
to the current regulatory framework.   
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EC2 Administrative Burden 
Industry reiterated that they expect a legally mandated REA at the time of launch to 
substantially increase HTA activities in MS, and so fundamentally change the business 
model. This explains the sharp increase from policy option 2 to 3. At the same time, once 
evidence needs to be generated for HTA there is little difference in terms of 
administrative burden, if this additional data should focus on effectiveness or on 
economic aspects. This accounts for the relative stability of the curve from policy option 3 
to 5.  
EC3 and EC4 Innovation, Competitiveness 
If HTA is conducted at the time of market launch and the first mover needs to generate 
comprehensive evidence, which can then be used for the early followers, a situation is 
created where the first mover has a considerable disadvantage. In the view of 
participants this explains the sharp expected decline for these impacts form a voluntary 
cooperation to a mandatory one. More general/academic HTAs, which are not fully 
recognized by each Member State and hence informing decision making to a less 
effective extend create extra cost with a less clear link to a potential return. This would 
be harmful for investment decisions of all companies, but companies with a weaker cash 
position (i.e. many innovating SMEs) might be forced to change strategic direction away 
from the riskier/more innovative IVDs. 
In addition, if the EU market is not attractive (limited growth opportunities, difficult 
entry) industry would prioritise other markets. Ultimately all products would arrive on the 
EU market, but just delayed. It was further emphasised that the growth in the European 
medical technologies market is already quite low and that any additional burden might 
jeopardise it further. Additional legislation and slower market access in particularly for 
first movers/innovators with no clear link to pricing and reimbursement might reduce the 
attractiveness of the EU market.  
Particular challenges for SMEs relate to the fact that increased harmonisation can delay 
the first revenues, which are particularly challenging due to the higher costs of financing. 
So even if harmonization means access to more countries, losing the quick access to the 
first market overrides the advantage of accessing some countries (quicker). This can 
already be seen today where focus is given to launch products in certain markets with 
earlier access to provide the first additional revenues. At the same time participants 
expressed understanding that Member States have a legitimate interest to ensure the 
sustainability of their national health systems and to favour effective treatments over 
ineffective treatments.  
Furthermore, one participant indicated that an EU system might lead to a higher demand 
for costly quality evidence, which does not inform decisions and does not improve 
patients' situations. Moreover, SMEs might not be able to handle such increased costs 
(extra burden of adapting to any new harmonised tools or assessments). Therefore, 
private equity investors might be more inclined to find other opportunities for investment 
and/or larger companies would take over of SMEs. Large companies would probably be 
able to cope with the additional costs, but SMEs would have a very difficult time in an 
already competitive market.  
EC6 Internal Market 
Respondents mentioned a number of factors through which legislation can in fact 
increase fragmentation and complexity:  
 In particular in the first years of the new regulatory framework, due to the 
exceptions the landscape may paradoxically become more fragmented.  
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 It was also considered that a joint submission template may even increase 
complexity if it adds a high number of general fields which are not relevant in 
local settings.   
 Voluntary cooperation on the other hand would still enable HTA bodies and/or 
decision makers and Industry to work together/ facilitate evidence generation (eg 
cooperation with different research centres testing the new product). This is 
perceived to share the risk of evidence generation rather than provide additional 
hurdles. These reasons would explain the expected positive impact of policy 
option 2.  
SH4 Sustainability 
Participants considered that due to the weak link between health technology assessments 
and pricing and reimbursement decisions for medical technologies, the changes in the 
HTA processes would not affect the negotiation power or the funding of technologies with 
little or no added value in this sector.  
It was also mentioned that there were difficulties in answering to the indicator on 
“financing of expencive treatments with little or no added value” (whether a higher score 
meant more technologies with little or no added value funded or an improved situation 
i.e. reduced number of technologies with little or no added value funded).  
It was also stated by certain participants that they do not necessarily see that financing 
of medical technologies with little or no added value is a major issue, as the sector is 
very competitive and having large number of technologies on the market drives price 
down. But participants conceded that Member States might be concerned for ensuring 
sustainability.  
SH5 Public Health 
In general, if the number of medical technologies available decreases as consequence of 
any changes in the HTA sector, this is expected to translate to lower level of public 
health. Participants accepted on the other hand that Member States might want to favour 
those treatments where the added value is particularly high for patients.  
Product scope 
In certain responses it was assumed that legal cooperation implies a broad scope of 
medical technologies (potentially all devices), which has been an important factor in the 
responses relating to policy option 3 to 5. There was a general agreement that currently 
the topic selection for joint assessment is not defined and would benefit from further 
input. Also, when defining the product scope, it the purpose of the HTA needs to be 
clarified. In response to two posed questions on potential product scope and timing of 
assessments the following was relayed: 
Suggestions for product scope in the future:  
- Respond to decision-makers' needs and/or feed into access decisions 
- Transformative technologies 
- High budget impact 
- Unmet medical needs 
Timing of assessment:  
- Anytime when there is a need from decision-makers/ local request 
- Should allow for sufficient evidence to be gathered. 
- Transformative technologies in need of real-life evidence 
- Later, for disinvestment decisions  
It was also mentioned that when a common technology is adopted and further 
comparisons are needed with available alternatives of the technology also known as Multi 
Technology Assessment; EU cooperation and in particular Joint REA, could provide a 
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benefit where different health care providers might have adopted different alternatives 
and would jointly be able to deliver evidence to support comparisons between 
alternatives.    
Follow up 
DG SANTE, LSE and GO FP thanked the participants of the focus group and asked them 
to provide clarification on defining transformative health technologies as well as to 
provide examples on these by 12th May.  
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Annex 8: Minutes Focus Group Public Administration and others  
 
 
EUnetHTA Joint Action Executive Board Meeting- 
Focus group with Public authorities  
Summary of discussion results from the online survey for the "Study on impact analysis 
of policy options for strengthened EU cooperation on HTA" 
Date: 03/05/2017 
Location: DG SANTE offices  
Participants 
EUnetHTA Joint Action Executive Board  
G-BA - Pharmaceutical Dpt. Germany 
Belgian Health Care Knowledge Centre (KCE) Belgium 
Onassis Cardiac Surgery Centre (OCSC)  Greece 
NICE National Institute for Health and Care Excellence United Kingdom 
ZIN - Zorginstituut Nederland The Netherlands 
AETS - Health Technology Assessment Agency 
Carlos III Institute for Health 
Spain 
ZIN - Zorginstituut Nederland Netherlands 
Health Care Knowledge Centre (KCE) Belgium 
Haute Autorité de Sante (HAS) France 
Fimea - Finnish Medicines Agency Finland 
Health Information and Quality Authority  Ireland 
Norwegian Institute of Public Health (NIPHNO) Norway 
INFARMED  (National Authority of Medicines and Health 
Products) 
Portugal 
Comenius University - Faculty of Pharmacy Slovakia 
DG SANTE 
Austrian Public Health Institute (GO-FP): Anja Laschkolnig, Katharina Habimana  
 
EUROPEAN COMMISSION 
DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY 
 
 
Directorate B - Health systems, medical products and innovation 
Unit B4 - Medical products: quality, safety, innovation 
 
  81 
Purpose of the meeting 
Discussion, interpretation and validation of the survey results HTA experts (members of 
the EUnetHTA executive board) regarding costs and impacts of the policy options. 
 
Discussion  
This report only refers to the  first part of the Executive Board meeting, which was 
dedicated to the discussion of the results from the online survey for the "Study on impact 
analysis of policy options for strengthened EU cooperation on HTA", Anja Laschkolnig and 
Katharina Habimana (GO-FP) presented the results, which was followed by a discussion.  
General observations 
It was clarified in advance that the results represent the expectations of the respondents. 
The results do not allow precise quantification, but should be taken as general indications 
on the overall trends. The survey results should therefore not be over-interpreted as 
precise quantifications of the impacts (e.g. cost increases by x%). The respondents also 
noted that the quantification of the impacts has been difficult as many factors had to be 
taken into consideration for one indicator and some of these factors would also depend 
on how the policy options would be implemented.  
To compensate for the above limitations, it was recommended to triangulate the results 
with additional data sources and complement by the outcome of the focus group 
discussion (as already planned by the study team). DG SANTE clarified that the online 
survey is one part of the data gathering exercise to support the analysis of the impacts of 
the policy options. The survey is further supported by the literature review and of the 
case studies done by London School of Economics. In addition, it was also clarified that 
the study is one input to the impact assessment process along with the results of the 
public consultation, the outcome of the ongoing additional stakeholders' consultation and 
further data gathering which is currently ongoing via additional studies mapping 
processes and procedures of HTA systems across the EU.  
There was a discussion on to which extent and how the different indicators can be 
interpreted. The interpretation has to be done with caution, as the number of different 
factors affects the impacts. For example for "costs impact" the answer would depend 
whether an activity is already done or not in the country responding, whether fees are 
charged to support a specific activities etc. Therefore it was underlined that the different 
baselines also affect results, which is however natural since respondents were asked 
answer the questionnaire from their respective position. The contractor explained that 
this point was already made by the expert group, which is supporting the study and a 
number of actions have been put in place to address this issue. An example will be 
provided during the presentation in relation to costs, where for example a comparison 
between the estimation on cost development will be displayed separated for HTA 
institutes that stated experience with Early Dialogues and the ones not performing Early 
Dialogues.  
One additional suggestion aiming at increasing the comparability of data was to 
distinguish HTA bodies with research focus and the ones which need to give advice for 
pricing and reimbursement decision as the timelines for their assessments as well as the 
criteria used may differ.   
It was also pointed out that where there is a high variation of responses (high standard 
deviation), the results are less conclusive and a simple average does not reflect a trend. 
The contractor was aware of this and will be transparent about this limitation, when this 
is the case. Grouping respondents according to their functions may address also this 
issue. It was also clarified that the focus group may help to explain the reasoning behind 
answers and large variations, when these occur. 
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EC1 Cost indicators:  
In the discussion, there was consensus that stronger EU cooperation would lead to cost 
decreases per products, rather than increases, as indicated in the online survey. This is 
mainly due to reduced duplication of efforts and increased efficiency. Current experience 
suggests that sharing the work lowers the costs for agencies very significantly (in one 
case where only two agencies agreed to cooperate on clinical guidelines they were able 
to save 30% respectively). Whilst there are higher overheads, which are particularly 
important in the beginning, this would be more than compensated by work-sharing 
arrangements. It was suggested that for smaller agencies, with currently limited HTA 
activities, cooperation could increase the scope of activities – albeit with a relatively 
small investment. This could explain some of the answers. In conclusion participants 
agreed that the results as presented were not in line with their expectations based on 
their experience in the cooperation. 
DG SANTE confirmed that for the calculations of costs within the Impact Assessment, the 
primary input will be calculations based on the first part of the survey, and the follow up 
interaction with EUnetHTA Board in subsequent meetings (December 2016 and February 
2017). The availability of the data regarding the baseline costs of HTA is not as extensive 
as it was hoped for. On the other hand, since the first follow up meeting with EUnetHTA 
Board, availability of data increased and is considered acceptable. In any event it is the 
best available evidence. It was also noted that for the respondents of the survey it was 
difficult to estimate the costs per product (considering overheads or the methodology 
used for assessment). It was noted that the wage difference across MS will also explain 
some of the differences in the variations of costs declared for national HTA products.  
GO-FP presented the costs for HTA processes conducted by LSE. The HTA institutions 
were categorised in two ways. The first categorisation aimed to reflect the institutional 
differences. The second categorisation aimed to capture the differences in the costs of 
REA and single technology full HTAs.  
It was agreed that the costs from the Joint Actions on the joint products would be a very 
important input.  Further efforts will be made using data available from Joint Action 2 
and Joint Action 3 and work within EU funded project (i.e. SEED for early dialogues). 
When considering these data the relevant assumptions will be made to reflect the 
learning curves and the number of countries involved.   
EC2 Administrative burden:  
It was considered that this is an example in which the overall expected variations of 
administrative burden may not be significant between the different policy options. Policy 
option 1 to 4 are all in rather close range, policy option 5 would foresee a more relevant 
increase, which was considered to be plausible due to the increased complexity of 
reaching a common agreement on economic aspects of the HTA reports which will be 
more context specific. 
It was however also mentioned that while administrative complexity may increase from 
policy option 1 to 5, the resources for research may be spent more efficiently, which can 
ultimately lead to a more neutral effect.  
EC3 Competitiveness of the EU health technology sector, EC4 Innovation and 
research, EC5 Internal market and competition:  
These impacts and some of the sub-indicators are more applicable for industries, 
nevertheless the survey aimed at gathering the expectations of HTA bodies as key 
players in the HTA sector. It was agreed that the sub-indicator "revenue" is ambiguous in 
relation to HTA bodies and it was recommended to be discarded.  
On other impacts, with the caveat mentioned above, the general trends outlined in the 
graph were confirmed as plausible. The following comments were made: 
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- The predictability is an important component also for academic research institutions. 
- It was noted and confirmed that stronger cooperation should reduce significantly 
fragmentation of the HTA.  
- Stronger EU cooperation may increase overall evidence needs, which are costly for the 
industry, in particular for medical technologies. Nevertheless there would be a significant 
benefit for public health.  
SH4 Sustainability of Health Systems 
It was agreed that a joint perspective on the added value can improve sustainability. 
There was consensus that stronger cooperation would improve the negotiation power to 
achieve lower prices for technologies with limited added value. Nonetheless, it would be 
more difficult to discontinue the financing of such technologies alltogether. This is mainly 
due to the fact that final decisions on availability of technologies will remain a 
national/local decision based on additional considerations than HTA assessments.  
SH5 Effect on Public Health  
It was noted that the availability of the technologies also depends on other factors, in 
particular the marketing authorisation and pricing and reimbursement systems. 
Therefore it is difficult to quantify with precision the impact of HTA cooperation. 
Nevertheless it was considered that increased convergence of HTA methods would 
increase the availability of health technologies with added benefits, and as such benefits 
public health. Variations between expectations reported between PO3 and PO4 were not 
considered significant.  
It was noted that in particular for medical technologies the regulatory framework is less 
stringent in the EU than in the US. 
Follow up  
It was agreed that it would be useful to look at the cost structures established for Joint 
Action 2. DG SANTE encouraged participants to engage with the HTA team if there would 
be any further comments or information to be sent in relation to costs and perceived 
impacts in relation to the preliminary identified policy options.   
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Annex 9: Sample of 20 Pharmaceutical products 
TECHNOLOGY GENERIC 
NAME 
TECHNOLOGY 
BRANDED NAME  
INDICATION M.A Holder 
Abiraterone Zytiga® Treatment of metastatic castration-resistant prostate cancer in adult men whose disease has 
progressed on or after a docetaxel- based chemotherapy regimen. 
Janssen-Cilag International N.V. 
Aclidinium Bromidum Eklira Genuair® Genuair is a treatment Bretaris 
maintenance bronchodilator for 
relieving symptoms in adults with illness chronic obstructive pulmonary disease (COPD). 
AstraZeneca AB 
Alemtuzumab Lemtrada®  For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by 
clinical or imaging features. 
Genzyme Therapeutics Ltd 
Apremilast  Otezla® Treating moderate to severe plaque psoriasis Celgene Europe Limited 
Ataluren  Translarna® Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense 
mutation in the dystrophin gene, in ambulatory patients aged 5 years and older 
PTC Therapeutics International Limited 
Canagliflozin Invokana® Treatment of Diabetes Mellitus Type 2 Janssen-Cilag International N.V. 
Dapagliflozin  Forxiga® Forxiga is indicated in Adults aged 18 years and over, diabetes type II, for improve glycemic control 
in the form of: monotherapy 
AstraZeneca AB 
Defibrotide Defitelio® Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as 
sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. 
It is indicated in adults and in adolescents, children and infants over 1 month of age. 
Gentium S.r.l. 
Ivacaftor Kalydeco® For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation Vertex Pharmaceuticals (Europe) Ltd 
Mirabegron Betmiga® Mirabegron for treating symptoms of overactive bladder Astellas Pharma Europe B.V. 
Nivolumab Opdivo® OPDIVO® is indicated as a monotherapy in adults for the treatment of advanced (non-resectable or 
metastatic) melanoma. 
Bristol-Myers Squibb 
Nintedanib Ofev® Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Boehringer Ingelheim International 
GmbH 
Ocriplasmin Jetrea® Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT). ThromboGenics NV 
Ofatumumab Arzerra® Arzerra in combination with chlorambucil or bendamustine for the treatment of chronic lymphocytic 
leukemia (CLL) in patients for these disease not previously treated and which are not eligible eligible 
for a treatment based on fludarabine.  
Novartis Europharm Ltd 
Omalizumab Xolair® Xolair is indicated in adults, adolescents and children (Aged 6 to <12 years). Xolair treatment should 
be considered only in patients with asthma-mediated certainty of IgE (immunoglobulin E). 
Novartis Europharm Ltd 
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TECHNOLOGY GENERIC 
NAME 
TECHNOLOGY 
BRANDED NAME  
INDICATION M.A Holder 
Pasireotide Signifor® For the treatment of adult patients with Cushing’s Disease for whom surgery is not an option or for 
whom surgery has failed 
Novartis Europharm Limited 
Ramucirumab Cyramza® Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated 
with chemotherapy 
Eli Lilly Nederland B.V. 
Rilpivirine in combination 
with other antiretroviral 
medicinal  
Edurant® Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment 
of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult 
patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml. 
Janssen-Cilag International N.V.    
Riociguat Adempas® Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with 
inoperable CTEPH, persistent or recurrent CTEPH after surgical treatment, to improve exercise 
capacity  
Bayer Pharma AG 
Sofosbuvir Solvaldi® In combination with other medicines, indicated in the treatment of Chronic hepatitis C (HCC) in 
adults 
Gilead Sciences International Ltd 
Tolvaptan Jinarc® Tolvaptan for treating autosomal dominant polycystic kidney disease Otsuka Pharmaceutical Europe Ltd 
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Annex 10: Sample of 15 Medical devices 
 
TECHNOLOGY GENERIC NAME INDICATION Main companies marketing the MD and specific nomenclature of the Medical device 
 Endovascular stents Endovascular repair of aortic aneurysms Talent stent–graft (Medtronic), Excluder AAA endoprosthesis (WL Gore), Aorfix AAA stent–
graft (Lombard Medical), Zenith AAA endovascular graft (Cook Medical) and Endologix 
Powerlink Systems (Le Maitre). 
Home haemodialysis device Renal replacement therapy in chronic kidney disease  NxStage System One NX1000-1 ( NxStage Medical ) 
Transcatheter implantable devices Transcatheter implantable devices for mitral valve repair in adults with 
chronic mitral valve regurgitation  
 CARILLON® Mitral Contour System®  (Cardiac Dimensions, Inc.) and , MitraClip®  System 
(Abbott Vascular) 
 Balloon Eustachian Tuboplasty  Balloon Eustachian tuboplasty for the treatment of Eustachian tube 
dysfunction 
 “Bielefelder Ballonkatheter”/ TubaVent® by Spiggle and Theis, and AERATM by Acclarent 
Inc. (Johnson and Johnson).  
 Oscillometric blood pressure monitor Diagnosis and monitoring of hypertension  Watch BP Home ® Microlife 
High intensity focused ultrasound 
(HIFU) 
High intensity focused ultrasound in oncologic indications Mixed producers depending on country 
Gene expression profiling 
diagnostics 
Gene expression profiling and expanded immunohistochemistry tests for 
guiding adjuvant chemotherapy decisions in early breast cancer management 
MammaPrint (Agendia) and Oncotype DX (Genomic Health) 
Positron emission tomography 
(PET)  
PET in oncological indications  Mixed producers depending on country 
Cochlear implants Cochlear implants for children and adults with severe to profound hearing 
loss. 
 Clarion CII Bionic Ear System and the HiResolution Bionic Ear System (Advanced Bionics 
UK)  
Nucleus Freedom cochlear implants (Cochlear Europe)  
Pulsar CI-100 (MED-EL UK) 
Digisonic SP (Neurelec)  
Left ventricular assist devices  Mechanical pump that's used to support heart function and blood flow in 
people who have weakened hearts. 
  Mixed producers depending on country 
LASER KTP Laser treatment for treating benign prostatic hyperplasia GreenLight XPS (Boston Scientific)  
Self-monitoring coagulometers Self-monitoring system for self-monitoring (self-testing or selfmanaging) 
coagulation status in people with atrial fibrillation or heart valve disease for 
whom long-term vitamin K antagonist therapy is intended 
CoaguChek XS system and the INRatio2 PT/INR monitor (   International Technidyne 
Corporation and Alere 
) and other depending by countries.  
Nucleic acid amplification tests 
(NAATs) 
 Detecting system for Neisseria gonorrhoeae (NG), by a nucleic acid 
amplification test (NAAT) in symptomatic patients, asymptomatic patients 
(screening of persons at risk) and in other clinical situations. 
 Roche's Amplicor (PCR), Becton Dickinson's ProbeTec (SDA), and Gen-Probe's APTIMA 
Combo 2 (AC2) 
Duodenal-jejunal bypass sleeve  Treatment  of obesity  GI Dynamics (GI Dynamics, Inc., Lexington, Massachusetts, USA) 
Vitro fertilisation (IVF)  Fertilization of Egg in laboratory Mixed producers depending on country 
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Annex 11: Sample of 5 ‘Other technologies’ 
 
 
  
Name of the intervention Description of the intervention 
HPV Vaccination Role of vaccination against human papillomavirus in reducing the risk of cervical cancer. 
Colorectal cancer screening Screening program aiming to identify people who appear healthy but may be at increased risk of a colorectal cancer. 
Pneoumococcla vaccination    Pneumococcal vaccination in children 
Rotavirus vaccination  Rotavirus vaccination is usually part of the childhood vaccination programme for babies aged 8 weeks and 16 weeks.  
Cervical cancer 
Screening programme.  
 Evaluation of seasonal influenza vaccines practices and programs 
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Annex 12: Indicators 
 
Indicator / 
Information 
Scope of information to be gathered 
per technology and MS 
Variables DEFINITIONS 
Basic information 
 Name, active substance/mode of action 
Molecules name Name of the molecules under review 
Branded name Branded name of the molecules under review 
Clinical pharmacology Therapeutic class of the drugs considered 
 Producer/sponsor of the technology Manufacturer The pharmaceutical company presenting the request for the HTA 
Description of the technology 
Route of administration Oral/intravenous etc 
Mechanism of action How does the active substance act 
Available Dosage The dosage(s) available on the market 
DDD Recommended daily dose by WHO  (http://www.whocc.no/ddd/definition_and_general_considera/) 
Indication(s) and target population of the 
marketing authorization 
M.A. Indication(s) 
Medical condition that a medicine is used for approved by EMA. This can include the treatment, 
prevention and diagnosis of a disease. 
M.A. Indication(s) for other diseases (if 
applicable) 
List If Other Medical condition that a medicine is used for approved by EMA 
Indication(s) and target population of the HTA 
body (if appraised) 
Exact indication under review of the HTA 
(e.g. specific stage of a disease such as 
RRMS) 
State indication under assessment (if applicable) or the therapeutic category under review (e.g. 
Belgium breast-cancer in metastatic setting) 
Dosage under review  Recommended dosage by the manufacturer (SPC leaflet) 
Dosage recommended The dosage recommended by the HTA body after the assessment  
Therapeutic area(s) 
ICD-10 classification Code 
Disease area State the disease area identified by the ICD-10 code 
Price (actual price) Actual price by country based on DDD Market price weighted on the DDD 
Timeliness/ Timing 
from regulatory 
approval to market 
launch 
Date of marketing authorization or other form of 
market approval 
Date of M.A Date of Marketing Authorization retrieved by the EMA website 
Type of Authorisation procedure Centralized/ Decentralized/mutual-recognition procedure 
Date on which the HTA dossier was submitted 
including a differentiation between REA and Full 
HTA and different involved bodies if applicable  
HTA body HTA body performing the assessment 
Date of the submission to the HTA body (If available) 
HTA body HTA body performing the REA (if applicable)  
Date of the submission of the REA (If applicable and available)  
date on which the HTA body issued its report (or 
reports if different reports are submitted or 
different bodies involved) 
Date of the decision   
Date of publication of the report    
if applicable the date on which an application for 
price and reimbursement status was submitted  
Date on which the price application was 
submitted  
  
Date on which the reimbursement 
application was submitted (if different 
from the price) 
  
date on which the decision on prices and 
reimbursement status were communicated to the 
company 
If applicable (or calculate based on the 
guidelines instructions) 
  
Date on which the product was launched on the 
market (1st sale/effective market access) 
Availability on the market When it is available to patient  
the length of the actual HTA process (from first 
formal submission to final report including stop 
the clock periods, if applicable) in days 
Actual length  (days)  
Length calculated between the date of the submission of the report and the HTA decision 
(detracting the stop of the clock) 
Estimated time (days) by the HTA body   
Number of stop of the clock were given   
Length of stop of the clock given How many days were allowed to the company  
  
Dates of  possible reassessment of the 
technology after the market launch in terms of 
the date and the outcome 
If rejected (or accepted with restrictions) 
Length of resubmission process (if 
applicable) 
Length calculated between the date of the resubmission of the report and the HTA decision  
If accepted/ restricted 
Days forecasted for the reassessment of 
the technology by the HTA 
  
Lag time between the first approval and 
the reassessment (if applicable) 
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Indicator / 
Information 
Scope of information to be gathered 
per technology and MS 
Variables DEFINITIONS 
Date and year of an early dialogue with the HTA 
body, if applicable  
Date and year of an early dialogue with 
the HTA body, if applicable  
Date and year of an early dialogue with the HTA body, if applicable  
 Reasons / relevant contributions to the duration 
of the process 
  
List of legislative delays with records and, if not confidential information, reasons given by the 
industry or HTA bodies  
Type/typology of 
procedure 
Information on the number of clinical and 
economic studies which need to be submitted to 
the HTA bodies  
Number of clinical studies needed for the 
submission  (If applicable) 
Minimum number of clinical studies requested by the HTA body for a complete submission 
Number of economic evaluation needed for 
the submission  (If applicable) 
Minimum number of economic evaluation  requested by the HTA body for a complete submission 
Information on the number of additional clinical 
and economic studies/submissions which took 
place during the process specifically for HTA (if 
these has been submitted at Market 
Authorization this will be indicated) 
Number of studies submitted by the 
manufacturer at the first submission   
Final Number of studies submitted by the 
manufacturer (accounting for all the stop 
of the clock information)   
 if applicable information on the number of “stop 
the clocks” 
Documentation requested to the 
manufacturer once the stop of the clock 
was granted 
e.G.more clinical evidence, different/additional comparators, different Indirect comparisons 
overview on how many different studies were 
requested across Member states 
Differences in the number of studies 
considered and requested by different HTA 
bodies   
Type of clinical study preferred by the HTA 
body 
  
Type of economic study preferred by the 
HTA body 
  
Type of other evidence requested (if 
applicable ) 
e.g. RWE 
Stakeholder involvement  
Type of stakeholders involved  e.g. patients group, clinicians, health economists 
Level of Involvement Mandatory or voluntary  
  Information’s on full HTA 
Outcomes of HTA 
Information on recommendation (recommended, 
not recommended, recommended with 
restrictions) and where not applicable 
information on the benefit given (e.g. minor, 
medium or major) 
Decision (if applicable) Listed /Listed with restrictions/ Rejected 
Benefit Identified (if applicable) 
ASMR I-V   
No proof of added benefit  Major added benefit/ Hint of added benefit 
Information on possible restrictions or conditions 
for each technology classified by macro areas 
(economic restrictions and clinical restrictions)  
Clinical Restrictions Clinical restrictions are applied. E.g. subgroup or first line therapy 
Economic restrictions    PAS, Improvement of Cost-effectiveness , Lower price, Other financial provisions 
Information on quantitative assessment  
Type of Economic evaluation considered  Cost-utility, cost minimization, cost-comparison or cost consequences 
Comparator(s) Comparator(s) included 
ICER - Base case ICER submitted by the Manufacturer 
ICER - Accepted  Final ICER calculated by the HTA 
Cost-minimization (saving costs)  Cost saving or final cost for the cost-minimization 
Final cost  Final cost accepted for the cost-comparison. 
Other quantitative results steaming by 
different type of analysis (e.g. cost-
consequences) 
If applicable for "other technologies" 
Number of studies 
Number of study  considered for 
supporting clinical benefit  
  
Number of studies/clinical evidence 
considered  for supporting  the economic 
analysis 
  
Type of the clinical evidence submitted 
Observational (cross sectional, case series, case-control studies, cohort studies) vs experimental 
comparative trials (controlled or head to head), randomised trials) or indirect comparison (naive 
indirect comparison, network meta-analysis 
Number of economic evaluation considered  Number of studies submitted by the Manufacturer to the HTA company 
Clinical benefit  Achieved/ not achieved/ statistically significant/not statistically significant 
Economic results Cost-effective/Cost-saving/not cost-effective not cost-saving  
Information’s on REA (if applicable) 
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Indicator / 
Information 
Scope of information to be gathered 
per technology and MS 
Variables DEFINITIONS 
Information on recommendation (recommended, 
not recommended, recommended with 
restrictions) and where not applicable 
information on the benefit given (e.g. minor, 
medium or major) 
Decision (if applicable) Listed /Listed with restrictions/ Rejected 
Benefit Identified (if applicable) 
ASMR I-V   
No proof of added benefit  Major added benefit/ Hint of added benefit 
Information on possible restrictions or conditions 
for each technology classified by macro areas 
(economic restrictions and clinical restrictions)  
Clinical Restrictions Clinical restrictions are applied. E.g. subgroup or first line therapy 
Economic restrictions    PAS, Improvement of Cost-effectiveness , Lower price, Other financial provisions 
Information on quantitative assessment  
Type of Economic evaluation considered  Cost-utility, cost minimization, cost-comparison or cost consequences 
Comparator(s) Comparator(s) included 
ICER - Base case ICER submitted by the Manufacturer 
ICER - Accepted  Final ICER calculated by the HTA 
Cost-minimization (saving costs)  Cost saving or final cost for the cost-minimization 
Final cost  Final cost accepted for the cost-comparison. 
Other quantitative results steaming by 
different type of analysis (e.g. cost-
consequences or budget impact analysis) 
If applicable for "other technologies" 
Number of studies 
Number of study  considered for 
supporting clinical benefit  
  
Number of studies/clinical evidence 
considered  for supporting  the economic 
analysis 
  
Type of the clinical evidence submitted 
Observational (cross sectional, case series, case-control studies, cohort studies) vs experimental 
comparative trials (controlled or head to head), randomised trials) or indirect comparison (naive 
indirect comparison, network meta-analysis 
Number of economic evaluation considered  Number of studies submitted by the Manufacturer to the HTA company 
information’s on the clinical and economic 
reasons for the recommendations  
Clinical benefit  Achieved/ not achieved/ statistically significant/not statistically significant 
Economic results Cost-effective/Cost-saving/not cost-effective not cost-saving  
 Information on special arrangements in place 
that influence the outcome (e.g. EoL) 
Elicited 
Elicited Social value judgements 
considered in the guidelines? 
Eol, severity and National priority in France  
Considered for the technology under 
review? 
  
Non elicited  
Severity High/low 
Rarity  Rare/not rare  
Unmet need for treatments Yes/no (if no list the other treatments mentioned) 
Special conditions considered End of life criteria/humanitarian dignity principle solidarity principle/ the human value principle 
Burden on family and carers emotional 
well being 
Yes/no 
Impact on work and everyday life activities Yes/no 
Wider societal Benefits  Yes/no 
Equality issues Yes/no 
Small population Yes/no (for NICE to be considered only if they account for it outside EoL) 
Significant innovation   
Life expectancy  
Short-Life threatening-Chronic disease(for NICE to be considered only if they account for it outside 
EoL) 
Impact of HTA 
recommendation on 
market launch 
Information on how the HTA recommendation 
had an impact on the steps towards market 
launch  
If accepted in how many days the 
reimbursement is implemented.   
If rejected what was the next step taken 
by the company? 
Resubmission, withdrawal, extension of studies (RCTs phase 4) or appeal  
Information regarding impact on pricing and 
reimbursement level (e.g. patient access scheme 
in UK) 
Presence of Managed entry agreements or 
any other provisions implemented for the 
reimbursement   
Information on time to market launch  
Date on which the Drug was launched in 
the market (exact date of availability of 
the drug to suppliers)   
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Indicator / 
Information 
Scope of information to be gathered 
per technology and MS 
Variables DEFINITIONS 
Information on budget impact on the health 
system as a whole 
Percentage of the technology 
reimbursement cost over country 
pharmaceutical expenditure   
Information on eligible population in order to 
assess the impact regarding patient access 
Breakdown of Prevalence data and socio-
economics data on the indication under 
review   
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Annex 13: Cost indicators 
 
Indicator Sub-indicator Variable* Definition of the variable 
Costs of performing a health 
technology assessment for the 
technology developer 
Costs for early dialogues 
(without considering the 
clinical trials costs) 
Travel costs/Locum Costs/ general expenses connected to the procedures 
/ meeting expenses 
All the costs incurred for meetings with HTA agencies  
Submission fees Fees asked by the HTA body to participate to the evaluation process  
Administrative costs  
All the expenses incurred in controlling and directing an organization, but not 
directly identifiable with financing marketing or production operations. This will 
not include any salary costs.  
Human resource costs 
All the costs related to hiring experts/sub-contractors employees or permanent 
employee 
Costs for clinical studies 
additional to market 
authorization 
Costs by clinical trial phase    
Costs by therapeutic area    
Pre-study costs    
Costs for human 
resources to handle the 
procedure (including fees 
to consultants) 
Permanent Staff costs    
Consultant costs   
Sub-contractor costs    
Travel costs/Locum Costs/ general expenses connected to the procedures 
- 
  
Fees to be paid to the 
HTA bodies (if applicable) 
Submission fees   
Re-submission fees   
Nature and cost of 
additional data 
requirement requested 
during the HTA phases of 
market launch and post 
market authorization 
Costs by clinical trial phase/ type of clinical evidence Additional cost of studies explicitly requested by the HTA body  
Costs by therapeutic area    
Pre-study costs    
Costs associated to perform again the economic analysis Consultant 
Re-evaluation of the HTA decision costs Associated costs for further assessment 
In case of early 
dialogues: did it lead to a 
reduction of overall costs 
for performing a HTA for 
the technology developer 
and if so how 
HTA costs when early dialogue is in place - HTA complete assessment 
costs.  (If applicable) 
  
Costs of performing a  health 
technology assessment for the HTA 
body 
Operating Costs 
Premises & fixed plants/rentals/establishment expenses/Supplies and 
Services/Education &training/Recruiting costs/Non-cash items 
(Depreciation, Amortisation, Provisions and profit/loss on disposal) 
  
Audit Costs Auditor's remuneration/ Audit Reports   
Full time equivalents and 
expenditure for human 
resources costs in order 
to perform the 
assessments (taking 
account the differences 
between a Full HTA and 
an REA-Report) 
REA 
Permanent Staff costs  
Salary and wages/ performance-related pay/benefits in kind/severance pay/ 
pension contributions-social security costs 
Consultant costs/ External contractors costs 
e.g.: NICE recruits external contractors for systematic literature searching and 
quality assurance 
Sub-contractor costs  
Associated costs with any external contractors such as academic units, other 
organisations 
Travel costs/Locum Costs/ general expenses connected to the procedures 
- 
  
FULL HTA 
Permanent Staff costs  
Salary and wages/ performance-related pay/benefits in kind/severance pay/ 
pension contributions-social security costs 
Consultant costs 
e.g.: NICE recruits external contractors for systematic literature searching and 
quality assurance 
Sub-contractor costs  
Associated costs with any external contractors such as academic units, other 
organisations 
Travel costs/Locum Costs/ general expenses connected to the procedures 
- 
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Stakeholders involvement 
Interview costs( Including Staff, experts in the health 
and care system, industry representatives, patients and c charitable groups, 
and international bodies)/Workshop expenses/ Costs for Programs engaging 
stakeholders 
Horizon Scanning 
Associated Costs 
Costs associated with the process of horizon scanning, identifying and 
recording new technologies 
e.g.: NICE uses UK PharmaScan database as a primary-source of horizon 
scanning information 
 Other costs (specify) 
Iterative approach-other costs that maybe HTA bodies will highlight as 
important 
  
Information on to which 
extent they cover the 
costs 
Fees charged - Overall expenditure per drug for the process per drug    
Cost of involvement of 
stakeholders  
Fees for participation HTA to set up stakeholders groups 
Travel costs/Locum Costs/ general expenses connected to the procedures    
Dissemination costs 
Publication costs such as reports/ Digital services' costs such as web 
development and maintenance 
  
Implementation Costs Enforce implementation/ monitoring implementation associated costs   
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Annex 14: Ten concrete examples  
 
Ten concrete examples indicators  
Influence of the regulatory 
framework on technology developer 
investment behavior / decision 
 
(Information on the underlying 
motivations of the developers) 
Country setting 
The scope of the recommendations of the HTA body. If the recommendation has national or regional or local applicability 
Did the scope of the recommendations of the HTA body have an influence 
on business strategy of the company? 
It will be asked to the Manufacturer if the level of scope of the HTA have a clear 
influence in shaping their business strategy, and if yes if they can give an 
example. 
Legal status of the HTA advice Are recommendations by the HTA body legally binding in its country? 
Did Legal status of the HTA body have an influence on business strategy of 
the company? If yes how? 
It will be asked to the Manufacturer if the legal status of the HTA have a clear 
influence in shaping their business strategy, and if yes if they can give an 
example. 
Role of the HTA body Advisory vs. regulatory vs. co-ordinatroy 
Did the role of the HTA body have an influence on business strategy of the 
company? If yes how? 
It will be asked to the Manufacturer if the role of the HTA have a clear influence in 
shaping their business strategy, and if yes if they can give an example. 
Allowed to resubmit/re-evaluate Yes/No 
Did the Possibility of re-submission/re-evaluation have an influence on 
business strategy of the company? If yes how? 
It will be asked to the Manufacturer if possibility of re-submission/re-evaluation 
have a clear influence in shaping their business strategy, and if yes if they can 
give an example. 
 Presence of an appeal process Yes/No 
 Did the appeal process have an influence on business strategy of the 
company? If yes how? 
It will be asked to the Manufacturer if the presence of an appeal process have a 
clear influence in shaping their business strategy, and if yes if they can give an 
example. 
 Special arrangements  
 Did the any special arrangements have an influence on business strategy of 
the company? If yes how? 
It will be asked to the Manufacturer if the presence of a specific special 
arrangements   have a clear influence in shaping their business strategy, and if 
yes if they can give an example. 
REA Presence of a REA process Yes/No 
Did presence of REA process had an influence on business strategy of the 
company? 
It will be asked to the Manufacturer if the presence of the possibility of REA have a 
clear influence in shaping their business strategy, and if yes if they can give an 
example. 
Time-frame Did the time length of the process to assess the technology have an 
influence on the company business decisions? If yes, how? 
It will be asked to the Manufacturer if the length of the full HTA assessment had 
an influence in the business strategy, investment decisions (country/therapeutic 
area). 
Costs Did the costs of the process to assess the technology have an influence on 
the company business decisions? 
It will be asked to the Manufacturer if the costs 
* All the costs in different currency than Euro will be converted at the historic rate of the data retrieved. 
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Annex 15: Semi-structured interview guide 
 
EUROPEAN COMMISSION DG SANTE - HTA PROJECT 
Semi-structured interview questions for industry participants 
 
Topic 1: Impact of HTA setting 
Aim: To understand if and how HTA settings affect the decision-making process of 
manufacturers. How do the legal status, the scope and the role of HTA bodies influence 
investment behaviours and which are the HTA best practices from an industry 
perspective?  
Legal status of HTA bodies 
 Did the legal status (if it is legally binding or not) of the HTA bodies have an 
influence on the business strategy of your company so far?  
o If yes, how did you shape your market access strategy?  
o Did you prioritize settings where HTA has a legally binding status?  
 Is it possible to give us a concrete example of whether your business strategy was 
affected positively or negatively by the HTA legal framework? 
Scope and role of HTA bodies 
 Did the scope (national, regional or local) of the recommendations of HTA bodies 
have an influence on business strategy of the company?  
o How did you deal with the presence of a regional HTA body (e.g. in Spain)? 
o Could you give us a concrete example of how your company shaped its 
market strategy based on the different scope of an HTA body? 
o How did you handle HTA submissions for different HTA bodies (NICE and 
SMC) in the UK?  
o Did you have a single department that coordinated both submissions? 
 Did the role (advisory vs. regulatory vs. co-ordination) of HTA bodies have an 
influence on the company’s business strategy? 
o If yes, in what way?  
o How did you deal differently with an advisory HTA body rather than a 
regulatory one?  
o Would you prioritise a submission to a regulatory HTA body rather than a 
submission to an advisory one? 
Resubmission and re-evaluation  
 Did the possibility of resubmission/re-evaluation have an influence on the 
company’s business strategy? Did you shape your submission strategy differently 
knowing that you have the possibility of re-submission or re-evaluation?  
 If yes, in what way?  
Appeal process 
 Did the existence of an appeal process have an influence on business strategy of 
your company?  
o If yes, how did this shape your company’s strategy?  
o Did you prioritise launch in settings with a well-established appeal process? 
Costs 
 Did the costs of the product’s assessment process have an influence on the 
company’s business decisions?   
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o For instance, did the submission fees charged by HTA bodies affect the 
company’s strategy?  
o To what extent the cost of the generation of additional evidence required 
by the HTA body affected the company’s market strategy? 
Product-specific questions 
 Did the product (referring to the product(s) listed in our case study) face specific 
issues related to the HTA processes across the member states?  
o Is it possible to give us some examples?   
 How did the company deal with these issues?  
o Did your company change marketing decisions after facing these issues? 
 If this is not applied to the product(s) selected in our case study, is it possible to 
give us another product-specific example? 
 
Topic 2: Delays related to full HTA submissions 
Aim: To understand to what extent the timelines of HTA bodies might affect the 
manufacturer’s market strategy. Could a shorter review period have a positive impact? 
How do manufacturers deal with delays related to the submission of further evidence 
(clock stop) and any other delays caused by administrative issues (legislative delays)? 
Are there any best practices worth noting in this context? 
Standard length of full HTA submission  
 Did the time length of the process to assess the technology have an influence on 
the company’s business decisions (country/therapeutic area)?   
o If yes, in what way? 
o Did you prioritise submissions due to a faster process? 
Common delays  
 What are the common delays that your company is facing when submitting an 
HTA dossier (e.g. clock stop, request of additional evidence, or other legislative 
delays)?  
 How has your company overcome issues stemming from HTA-related delays?  
o For instance, if the delay was due to a legislative issue, how did your 
company change its strategy? 
 Has your company faced any legislative delays during the HTA process in the last 
three years?  
o If yes, could you please specify what kind of legislative issues emerged and 
how did these affect your market strategy?  
Product-specific questions 
 Did the product have a clock stop or a request of submission of further evidence?  
o If not, can you give us another product-specific example?  
 
Topic 3: Early dialogue/rapid assessment 
Aim: To understand if and how the possibility of having engaged in early dialogue or 
undergone a rapid evaluation assessment (REA) has influenced the manufacturer’s 
decisions and market strategy. Were there any best practices worth noting in this 
context?  
Early dialogue 
 Did the possibility of engaging in early dialogue influence your market strategy 
positively?  
o If yes, was your market strategy shaped accordingly?  
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o Could you give us a country-specific example?   
 If you engaged in an early dialogue in the past, how did it influence the HTA 
submission?   
o Did it lead to a reduction of overall costs?  
o Did it lead to a shortening of the timeline for the full HTA submission?  
Rapid evaluation assessment (REA) 
 Did the possibility to undergo a REA have any impact on or shape your market 
strategy?  
o If yes, in what way?  
o Did you prioritise launch in settings where a REA was present? 
 In the last three years, did a REA process lead to a change in your market strategy? 
o If yes, in what way?  
o Could you give a specific example?  
Special arrangements  
 Did any specific special arrangements influence the business strategy of the 
company?  
o If yes, in what way?  
o Could you give a specific example? 
Product-specific questions  
 Were you involved in an early dialogue with any HTA body in Europe?  
o If yes, could you give us an example? 
 How did this affect your business strategy? 
 Did the early dialogue have any effect on the company’s 
submission/market strategy? 
o If not, could you give us another example related to any other product? 
Topic 4: Specific product information 
In the table below, please provide any available information related to the selected case 
study product(s). 
 
Country Launch 
date 
 
HTA 
submission 
date 
Reimbursement 
and pricing 
decision date 
Number of 
clock stops 
(if 
applicable) 
Time length 
of clock stop 
Legislative 
delays 
HTA submission-
related costs 
 
France (HAS)        
UK (NICE)        
UK (SMC)        
Ireland (NCPE)        
Germany 
(IQWIG) 
       
Germany (G-
BA) 
      
Spain (ISCII)        
Portugal 
(INFRAMED) 
       
Sweden (TLV)        
The 
Netherlands 
(ZIN) 
       
Belgium (KCE)        
Poland (AOTM)        
Lithuania        
Estonia         
Latvia        
Hungary         
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Annex 16: Availability of data Pharmaceuticals products – Kappa score 
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UK-NICE   
0  
[0.341
6; 0-
0.669
5] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.341
6; 0-
0.669
5] 
0.0441  
[0.1568
;0- 
0.3515] 
0.0909 
[0.166;
0-
0.4162] 
0.3056 
[0.269;
0-
0.8327] 
0.16 
[0.2592
;0-
0.6681] 
0  
[0.3416
; 0-
0.6695] 
0.0441 
[0.1568
;0-
0.3515] 
0.0909 
[0.166;
0-
0.4162] 
0.1304 
[0.2381
;0-
0.5971] 
N/A N/A 
0.0909 
[0.166;
0-
0.4162] 
0.0769 
[0.2568
;0-
0.5802] 
0.2045 
[0.2424
;0-
0.6796] 
0.0741 
[0.207;
0-
0.4799] 
0.1176 
[0.3014
;0-
0.7083] 
0  
[0.341
6; 0-
0.669
5] 
UK-SMC 
0  
[0.341
6; 0-
0.6695
] 
  
0  
[0.341
6; 0-
0.669
5] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.5323
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.5323
; 0-1] 
0  
[0.3416
; 0-
0.6695] 
0  
[0.3416
; 0-
0.6695] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.2739
; 0-
0.5368] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.5323
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.4472
; 0-
0.8765] 
0  
[0.3047
; 0-
0.5972] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.6708
; 0-1] 
0  
[0.341
6; 0-
0.669
5] 
Ireland-
NCPE 
0  
[0.341
6; 0-
0.6695
] 
0  
[0.341
6; 0-
0.669
5] 
  
0  
[0.341
6; 0-
0.669
5] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.5323
; 0-1] 
0  
[0.5323
; 0-1] 
0  
[0.6708
; 0-1] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.2739
; 0-
0.5368] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.4472
; 0-
0.8765] 
0  
[0.3047
; 0-
0.5972] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.6708
; 0-1] 
0  
[0.341
6; 0-
0.669
5] 
France-
HAS 
0  
[0.341
6; 0-
0.6695
] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.341
6; 0-
0.669
5] 
  
0  
[0.5323
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.5323
; 0-1] 
0  
[0.3416
; 0-
0.6695] 
0  
[0.3416
; 0-
0.6695] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.2739
; 0-
0.5368] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.5323
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.4472
; 0-
0.8765] 
0  
[0.3047
; 0-
0.5972] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.6708
; 0-1] 
0  
[0.341
6; 0-
0.669
5] 
Belgium-
KCE* 
0.0441  
[0.156
8;0- 
0.3515
] 
0  
[0.532
3; 0-
0.100
5] 
0  
[0.051
3; 0-
0.100
5] 
0  
[0.532
3; 0-
0.100
5] 
  N/A 
0.0184 
[0.1097
; 0-
0.2335] 
0.0184 
[0.1097
; 0-
0.2335] 
0.0116 
[0.0928
; 0-
0.1936] 
1 
0 
[0.0745
, 0-
0.1461] 
0.0678 
[0.1885
; 0-
0.4373] 
N/A N/A N/A 
0.026 
[0.1257
; 0-
0.2725] 
0.0551 
[0.1725
;0-
0.3932] 
0.1463 
[0.2601
;0-
0.6561] 
0.0116 
[0.0928
; 0-
0.1936] 
0  
[0.051
3; 0-
0.100
5] 
Italy- UVEF 
0.0909 
[0.166;
0-
0.4162
] 
0  
[0.074
5; 0-
0.146
1] 
0  
[0.074
5; 0-
0.146
1] 
0  
[0.074
5; 0-
0.146
1] 
N/A   
0.0385 
[0.1241
;0-
0.2818] 
N/A N/A N/A N/A N/A 
0.0476 
[0.2608
; 0-
0.5588] 
N/A N/A 
0.0541 
[0.1385
;0-
0.3255] 
N/A 
0.2857 
[0.244; 
0-
0.7639] 
0.0244 
[0.1091
;0-
0.2382] 
0  
[0.670
8; 0-
1] 
Sweden- 
TLV 
0.3056 
[0.269;
0-
0.8327
] 
0  
[0.532
3; 0-1] 
0  
[0.532
3; 0-1] 
0  
[0.532
3; 0-1] 
0.0184 
[0.1097
; 0-
0.2335] 
0.0385 
[0.1241
;0-
0.2818] 
  
0.2157 
[0.3508
; 0-
0.9032] 
0.2157 
[0.3508
; 0-
0.9032] 
0.0184 
[0.1097
;0-
0.2335] 
0.0385 
[0.1241
;0-
0.2818] 
0.186 
[0.248;
0-
0.6721] 
0.2105 
[0.1952
;0-
0.593] 
N/A 
0.0385 
[0.1241
;0-
0.2818] 
0.4828 
[0.2753
;0-1] 
0.1064 
[0.2486
; 0-
0.5015] 
0.2105 
[0.1952
;0-
0.593] 
N/A 
0  
[0.532
3; 0-
1] 
Germany-
IQWIG 
0.16 
[0.259
2;0-
0.6681
] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.532
3; 0-1] 
0  
[0.341
6; 0-
0.669
5] 
0.0184 
[0.1097
; 0-
0.2335] 
N/A 
0.2157 
[0.3508
; 0-
0.9032] 
  
0.3182 
[0.3629
;0-1] 
0.0184 
[0.1097
;0-
0.2335] 
0.0385 
[0.1241
; 0-
0.2818] 
0.186 
[0.248;
0-
0.6721] 
0.0351 
[0.1952
;0-
0.4176] 
N/A 
0.0385 
[0.1241
; 0-
0.2818] 
0.1379 
[0.3339
; 0-
0.7923] 
0.2405 
[0.2594
;0-
0.7489] 
N/A N/A 
0  
[0.532
3; 0-
1] 
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Germany-
G-BA 
0  
[0.341
6; 0-
0.6695
] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.670
8; 0-1] 
0  
[0.341
6; 0-
0.669
5] 
0.0116 
[0.0928
; 0-
0.1936] 
N/A 
0.2157 
[0.3508
; 0-
0.9032] 
0.3182 
[0.3629
;0-1] 
  
0.0184 
[0.1097
;0-
0.2335] 
0.0385 
[0.1241
; 0-
0.2818] 
0.186 
[0.248;
0-
0.6721] 
0.0351 
[0.1952
;0-
0.4176] 
N/A 
0.0385 
[0.1241
; 0-
0.2818] 
0.1379 
[0.3339
; 0-
0.7923] 
0.2405 
[0.2594
;0-
0.7489] 
N/A N/A 
0  
[0.532
3; 0-
1] 
Croatia-
Azz 
0.0441 
[0.156
8;0-
0.3515
] 
0  
[0.051
3; 0-
0.100
5] 
0  
[0.051
3; 0-
0.100
5] 
0  
[0.051
3; 0-
0.100
5] 
1 N/A 
0.0184 
[0.1097
;0-
0.2335] 
0.0184 
[0.1097
;0-
0.2335] 
0.0184 
[0.1097
;0-
0.2335] 
  N/A 
0.0678 
[0.1885
; 0-
0.4373] 
N/A N/A N/A 
0.026 
[0.1257
;0-
0.2725] 
0.0551 
[0.1725
;0-
0.3932] 
0.1463 
[0.2601
; 0-
0.6561] 
0.0116 
[0.0928
; 0-
0.1936] 
0  
[0.051
3; 0-
0.100
5] 
Finland- 
Fimea 
0.0909 
[0.166;
0-
0.4162
] 
0  
[0.074
5; 0-
0.146
1] 
0  
[0.074
5; 0-
0.146
1] 
0  
[0.074
5; 0-
0.146
1] 
0 
[0.0745
, 0-
0.1461] 
N/A 
0.0385 
[0.1241
;0-
0.2818] 
0.0385 
[0.1241
; 0-
0.2818] 
0.0385 
[0.1241
; 0-
0.2818] 
N/A   
0.1379 
[0.1928
; 0-
0.5157] 
N/A N/A 
0.4444 
[0.3727
;0-1] 
N/A 
0.1129 
[0.1794
; 0-
0.4646] 
N/A 
0.0244 
[0.1091
;0-
0.2382] 
0  
[0.074
5; 0-
0.146
1] 
Spain-
AEMPS 
0.1304 
[0.238
1;0-
0.5971
] 
0  
[0.273
9; 0-
0.536
8] 
0  
[0.273
9; 0-
0.536
8] 
0  
[0.273
9; 0-
0.536
8] 
0.0678 
[0.1885
; 0-
0.4373] 
N/A 
0.186 
[0.248;
0-
0.6721] 
0.186 
[0.248;
0-
0.6721] 
0.186 
[0.248;
0-
0.6721] 
0.0678 
[0.1885
; 0-
0.4373] 
0.1379 
[0.1928
; 0-
0.5157] 
  
0.2308 
[0.2107
; 0-
0.6437] 
N/A 
0.1379 
[0.1928
; 0-
0.5157] 
0.0909 
[0.249;
0-
0.5789] 
0.2553 
[0.2269
;0-
0.7001] 
N/A 
0.0476 
[0.2608
;0-
0.5588] 
0  
[0.273
9; 0-
0.536
8] 
Spain-
AQuAs 
N/A 
0  
[0.182
6; 0-
0.357
8] 
0  
[0.182
6; 0-
0.357
8] 
0  
[0.182
6; 0-
0.357
8] 
N/A 
0.0476 
[0.2608
; 0-
0.5588] 
0.2105 
[0.1952
;0-
0.593] 
0.0351 
[0.1952
;0-
0.4176] 
0.0351 
[0.1952
;0-
0.4176] 
N/A N/A 
0.2308 
[0.2107
; 0-
0.6437] 
  N/A 
0.0476 
[0.2608
; 0-
0.5588] 
0.2857 
[0.1956
; 0 
0.6691} 
N/A N/A N/A 
0  
[0.182
6; 0-
0.357
8] 
Austria-
LBI-HTA 
N/A 
0  
[0.532
3; 0-
0.100
5] 
0  
[0.051
3; 0-
0.100
5] 
0  
[0.532
3; 0-
0.100
5] 
N/A N/A N/A N/A N/A N/A N/A N/A N/A   N/A 
0.026 
[0.1257
; 0-
0.2725] 
N/A N/A 
0.0116 
[0.0928
;0-
0.1936] 
0  
[0.051
3; 0-
0.100
5] 
EUnetHTA 
0.0909 
[0.166;
0-
0.4162
] 
0  
[0.074
5; 0-
0.146
1] 
0  
[0.074
5; 0-
0.146
1] 
0  
[0.074
5; 0-
0.146
1] 
N/A N/A 
0.0385 
[0.1241
;0-
0.2818] 
0.0385 
[0.1241
; 0-
0.2818] 
0.0385 
[0.1241
; 0-
0.2818] 
N/A 
0.4444 
[0.3727
;0-1] 
0.1379 
[0.1928
; 0-
0.5157] 
0.0476 
[0.2608
; 0-
0.5588] 
N/A   
0.0541 
[0.1385
;0-
0.3255] 
0.1129 
[0.1794
; 0-
0.4646] 
N/A 
0.0244 
[0.1091
; 0-
0.2382] 
0  
[0.074
5; 0-
0.146
1] 
Netherlda
ns-ZIN 
0.0769 
[0.256
8;0-
0.5802
] 
0  
[0.447
2; 0-
0.876
5] 
0  
[0.447
2; 0-
0.876
5] 
0  
[0.447
2; 0-
0.876
5] 
0.026 
[0.1257
; 0-
0.2725] 
0.0541 
[0.1385
;0-
0.3255] 
0.4828 
[0.2753
;0-1] 
0.1379 
[0.3339
; 0-
0.7923] 
0.1379 
[0.3339
; 0-
0.7923] 
0.026 
[0.1257
;0-
0.2725] 
N/A 
0.0909 
[0.249;
0-
0.5789] 
0.2857 
[0.1956
; 0 
0.6691} 
0.026 
[0.1257
; 0-
0.2725] 
0.0541 
[0.1385
;0-
0.3255] 
  N/A 
0.1071 
[0.1996
;0-
0.4984] 
N/A 
0  
[0.447
2; 0-
0.876
5] 
Romania-
NAMMD 
0.2045 
[0.242
4;0-
0.6796
0  
[0.304
7; 0-
0.597
0  
[0.304
7; 0-
0.597
0  
[0.304
7; 0-
0.597
0.0551 
[0.1725
;0-
0.3932] 
N/A 
0.1064 
[0.2486
; 0-
0.5015] 
0.2405 
[0.2594
;0-
0.7489] 
0.2405 
[0.2594
;0-
0.7489] 
0.0551 
[0.1725
;0-
0.3932] 
0.1129 
[0.1794
; 0-
0.4646] 
0.2553 
[0.2269
;0-
0.7001] 
N/A N/A 
0.1129 
[0.1794
; 0-
0.4646] 
N/A   N/A 
0.0789 
[0.2807
;0-
0.629] 
0  
[0.304
7; 0-
0.597
  100 
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] 2] 2] 2] 2] 
Portugal- 
Infarmed 
0.0741 
[0.207;
0-
0.4799
] 
0  
[0.182
6; 0-
0.357
8] 
0  
[0.182
6; 0-
0.357
8] 
0  
[0.182
6; 0-
0.357
8] 
0.1463 
[0.2601
;0-
0.6561] 
0.2857 
[0.244; 
0-
0.7639] 
0.2105 
[0.1952
;0-
0.593] 
N/A N/A 
0.1463 
[0.2601
; 0-
0.6561] 
N/A N/A N/A N/A N/A 
0.1071 
[0.1996
;0-
0.4984] 
N/A   N/A 
0  
[0.182
6; 0-
0.357
8] 
Poland-
AOTMiT 
0.1176 
[0.301
4;0-
0.7083
] 
0  
[0.670
8; 0-1] 
0  
[0.670
8; 0-1] 
0  
[0.670
8; 0-1] 
0.0116 
[0.0928
; 0-
0.1936] 
0.0244 
[0.1091
;0-
0.2382] 
N/A N/A N/A 
0.0116 
[0.0928
; 0-
0.1936] 
0.0244 
[0.1091
;0-
0.2382] 
0.0476 
[0.2608
;0-
0.5588] 
N/A 
0.0116 
[0.0928
;0-
0.1936] 
0.0244 
[0.1091
; 0-
0.2382] 
N/A 
0.0789 
[0.2807
;0-
0.629] 
N/A   
0  
[0.670
8; 0-
1] 
Italy-
AIFA** 
0  
[0.341
6; 0-
0.6695
] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.341
6; 0-
0.669
5] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.6708
; 0-1] 
0  
[0.5323
; 0-1] 
0  
[0.5323
; 0-1] 
0  
[0.5323
; 0-1] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.2739
; 0-
0.5368] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.0513
; 0-
0.1005] 
0  
[0.0745
; 0-
0.1461] 
0  
[0.4472
; 0-
0.8765] 
0  
[0.3047
; 0-
0.5972] 
0  
[0.1826
; 0-
0.3578] 
0  
[0.6708
; 0-1] 
  
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: 
Haute Autorité de Santé; GÖG: Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care 
Knowledge Centre; NCPHA: The National Center of Public Health and Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj 
skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: 
Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: 
Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts agentura; 
VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: 
Instituto Nacional da Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información 
de Medicamentos; AquAS: Agència de Qualitat i Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology 
Assessment; AETSA: Andalusian Agency for Health Technology Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud. *KCE does not have a mandate for 
Pharmaceuticals but it performed an economic evaluation of the Hepatitis C treatments comprising also Sofusbuvir ** For AIFA the reports were not publicly available but 
the decision was published in Gazzetta Ufficiale  
Note: Countries with no HTA reports publically available have been excluded from this table (e.g. Hungary, Bulgaria, Cyprus, Slovenia, Latvia, etc.) The confidence level, 1 
– α, has the following interpretation. If thousands of samples of N items are drawn from a population using simple random sampling and a confidence interval is calculated 
for each sample, the proportion of those intervals that will include the true value of kappa is 1 – α 
Source: The Authors 
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Annex 17: Availability of data – Medical devices– Kappa score 
Kappa 
scores 
[Standard 
error (SE); 
95% 
confidence 
intervals]  
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I 
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EU
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N
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h
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d
s-
Zi
N
 
UK-NICE 
  
N/A 
0.0351 
[0.1502; 
0-
0.3296] 
0.1667 
[0.356
8; 0-
0.866] 
0.3333 
[0.285
4; 0-
0.8928
] 
0.1667 
[0.263
5; 0-
0.6832
] 
N/A N/A 
0.1176 
[0.186; 
0-
0.4822
] 
N/A N/A 
0.1176 
[0.186; 
0-
0.4822
] 
N/A N/A 
0.0741 
[0.1691; 
0-
0.4054] 
N/A 
0.1176 
[0.186;0
-0.4822] 
N/A N/A 
UK- SHTG N/A   N/A 
0.0741 
[0.169
1; 0-
0.4054
] 
N/A N/A N/A N/A N/A N/A N/A N/A 
0.4231 
[0.3798; 
0-1] 
0.2857 
[0.368
9; 0-1] 
N/A 
0.2857 
[0.3689; 
0-1] 
0.2857 
[0.3689; 
0-1] 
0.2857 
[0.3689; 
0-1] 
N/A 
Ireland-
NCPE 
0.0351 
[0.1502
; 0-
0.3296] 
N/A 
  
N/A 
0.069 
[0.196
3; 0-
0.4537
] 
N/A N/A 
0.25 
[0.321
1; 0-
0.8794
] 
N/A 
0.3284 
[0.346
8; 0-1] 
N/A N/A N/A N/A N/A N/A 
0.4444 
[0.3657;
0-1] 
  
0.0909 
[0.2196; 
0-0.5212] 
France-
HAS 
0.1667 
[0.3568
; 0-
0.866] 
0.0741 
[0.169
1; 0-
0.4054
] 
N/A 
  
0 
[0.316
2; 0-
0.6198
] 
N/A 
0.1176 
[0.186; 
0-
0.4822
] 
N/A N/A N/A N/A 
0.1176 
[0.186; 
0-
0.4822
] 
N/A 
0.1176 
[0.186; 
0-
0.4822
] 
0.0741 
[0.1691; 
0-
0.4054] 
0.1176 
[0.186; 
0-
0.4822] 
N/A N/A 
0.2424 
[0.2766; 
0-
0.7846] 
Belgium-
KCE 
0.3333 
[0.2854
; 0-
0.8928] 
N/A 
0.069 
[0.1963; 
0-
0.4537] 
0 
[0.316
2; 0-
0.6198
]   
N/A N/A 
0.16 
[0.231
9; 0-
0.6144
] 
N/A 
0.3077 
[0.218
9; 0-
0.7368
] 
0.1429 
[0.207; 
0-
0.5487
] 
0.2222 
[0.214
7; 0-
0.643] 
N/A 
0 
[0.210
8; 0-
0.4132
] 
0.1429 
[0.207; 
0-
0.5487] 
0 
[0.2108; 
0-
0.4132] 
0 
[0.2108; 
0-
0.4132] 
N/A 
0 
[0.276; 
0-0.541] 
Italy-
AGENAS 
0.1667 
[0.2635
; 0-
0.6832] 
N/A N/A N/A N/A 
  
N/A N/A 
0.1026 
[0.247
7; 0-
0.5881
] 
N/A N/A N/A N/A 
0.1026 
[0.247
7; 0-
0.5881
] 
N/A N/A 
0.1026 
[0.2477; 
0-
0.5881] 
N/A N/A 
Sweden-
TLV 
N/A N/A N/A 
0.1176 
[0.186; 
0-
0.4822
] 
N/A N/A 
  
0 
[0.316
2; 0-
0.6198
] 
N/A 
0.0741 
[0.338
1; 0-
0.7368
] 
0.2857 
[0.368
9; 0-1] 
N/A N/A 
0.1667 
[0.356
8; 0-
0.866] 
0.2857 
[0.3689; 
0-1] 
N/A N/A N/A 
0.0476 
[0.23; 0-
0.4984] 
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Germany-
IQWIG 
N/A N/A 
0.25 
[0.3211; 
0-
0.8794] 
N/A 
0.16 
[0.231
9; 0-
0.6144
] 
N/A 
0 
[0.316
2; 0-
0.6198
]   
N/A 
0.5263 
[0.244
6; 
0.0469
-1] 
0.1176 
[0.322
2; 0-
0.7491
] 
0 
[0.316
2; 0-
0.6198
] 
0.1176 
[0.3222; 
0-
0.7491] 
0 
[0.316
2; 0-
0.6198
] 
0.1176 
[0.3222; 
0-
0.7491] 
0.3333 
[0.2854; 
0-
0.8928] 
0 
[0.3162; 
0-
0.6198] 
N/A 
0.25 
[0.2372; 
0-
0.7148] 
Croatia-Azz 
0.1176 
[0.186; 
0-
0.4822] 
N/A N/A N/A N/A 
0.1026 
[0.247
7; 0-
0.5881
] 
N/A N/A 
  
N/A N/A 
0.1667 
[0.356
8; 0-
0.866] 
N/A N/A N/A N/A 
0.1667 
[0.3568; 
0-0.866] 
0.5833 
[0.2743; 
0.0457-
1] 
0.0476 
[0.23; 0-
0.4984] 
Finland-
Fimea 
N/A N/A 
0.3284 
[0.3468; 
0-1] 
N/A 
0.3077 
[0.218
9; 0-
0.7368
] 
N/A 
0.0741 
[0.338
1; 0-
0.7368
] 
0.5263 
[0.244
6; 
0.0469
-1] 
N/A 
  
0.5946 
[0.266
9; 
0.0715
-1] 
0.0741 
[0.338
1; 0-
0.7368
] 
0.1892 
[0.3472; 
0-
0.8696] 
N/A 
0.1892 
[0.3472; 
0-
0.8696] 
0.0741 
[0.3381; 
0-
0.7368] 
0.0741 
[0.3381; 
0-
0.7368] 
N/A 
0.1463 
[0.2356; 
0-
0.6081] 
Spain-
AQuAs 
N/A N/A N/A N/A 
0.1429 
[0.207; 
0-
0.5487
] 
N/A 
0.2857 
[0.368
9; 0-1] 
0.1176 
[0.322
2; 0-
0.7491
] 
N/A 
0.5946 
[0.266
9; 
0.0715
-1]   
N/A 
0.4231 
[0.3798; 
0-1] 
N/A 
0.4231 
[0.3798; 
0-1] 
N/A N/A N/A N/A 
Spain-
Avalia 
0.1176 
[0.186; 
0-
0.4822] 
N/A N/A 
0.1176 
[0.186; 
0-
0.4822
] 
0.2222 
[0.214
7; 0-
0.643] 
N/A N/A 
0 
[0.316
2; 0-
0.6198
] 
0.1667 
[0.356
8; 0-
0.866] 
0.0741 
[0.338
1; 0-
0.7368
] 
N/A 
  
N/A N/A N/A 
0.1667 
[0.3568; 
0-0.866] 
N/A 
0.1667 
[0.3568; 
0-0.866] 
0.0476 
[0.23; 0-
0.4984] 
Spain-
OSTEBA 
N/A 
0.4231 
[0.379
8; 0-1] 
N/A N/A N/A N/A N/A 
0.1176 
[0.322
2; 0-
0.7491
] 
N/A 
0.1892 
[0.347
2; 0-
0.8696
] 
0.4231 
[0.379
8; 0-1] 
N/A 
  
N/A N/A 
0.2857 
[0.3689;
0-1] 
N/A 
0.2857 
[0.3689;
0-1] 
N/A 
Estonia- 
University 
of Tartu 
and EHIF 
N/A 
0.2857 
[0.368
9; 0-1] 
N/A 
0.1176 
[0.186; 
0-
0.4822
] 
0 
[0.210
8; 0-
0.4132
] 
0.1026 
[0.247
7; 0-
0.5881
] 
0.1667 
[0.356
8; 0-
0.866] 
0 
[0.316
2; 0-
0.6198
] 
N/A N/A N/A N/A N/A 
  
N/A N/A 
0.1667 
[0.3568; 
0-0.866] 
N/A 
0.0476 
[0.23;0-
0.4984] 
Lithuania-
VASPVT 
0.0741 
[0.1691
; 0-
0.4054] 
N/A N/A 
0.0741 
[0.169
1; 0-
0.4054
] 
0.1429 
[0.207; 
0-
0.5487
] 
N/A 
0.2857 
[0.368
9; 0-1] 
0.1176 
[0.322
2; 0-
0.7491
] 
N/A 
0.1892 
[0.347
2; 0-
0.8696
] 
0.4231 
[0.379
8; 0-1] 
N/A N/A N/A 
  
0.2857 
[0.3689;
0-1] 
N/A N/A 
0.186 
[0.2247;
0-
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Kappa 
scores 
[Standard 
error (SE); 
95% 
confidence 
intervals]  
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0.6263] 
Austria-LBI N/A 
0.2857 
[0.368
9; 0-1] 
N/A 
0.1176 
[0.186; 
0-
0.4822
] 
0 
[0.210
8; 0-
0.4132
] 
N/A N/A 
0.3333 
[0.285
4; 0-
0.8928
] 
N/A 
0.0741 
[0.338
1; 0-
0.7368
] 
N/A 
0.1667 
[0.356
8; 0-
0.866] 
0.2857 
[0.3689;
0-1] 
N/A 
0.2857 
[0.3689;
0-1] 
  
N/A 
0.1667 
[0.3568; 
0-0.866] 
0.2857 
[0.3689;
0-1] 
Austria- 
GÖG 
0.1176 
[0.186;
0-
0.4822] 
0.2857 
[0.368
9; 0-1] 
0.4444 
[0.3657;
0-1] 
N/A 
0 
[0.210
8; 0-
0.4132
] 
0.1026 
[0.247
7; 0-
0.5881
] 
N/A 
0 
[0.316
2; 0-
0.6198
] 
0.1667 
[0.356
8; 0-
0.866] 
0.0741 
[0.338
1; 0-
0.7368
] 
N/A N/A N/A 
0.1667 
[0.356
8; 0-
0.866] 
N/A N/A 
  
N/A 
0.0476 
[0.23;0-
0.4984] 
EUnetHTA N/A 
0.2857 
[0.368
9; 0-1] 
  
N/A N/A N/A N/A N/A 
0.5833 
[0.274
3; 
0.0457
-1] 
N/A N/A 
0.1667 
[0.356
8; 0-
0.866] 
0.2857 
[0.3689;
0-1] 
N/A N/A 
0.1667 
[0.3568; 
0-0.866] 
N/A 
  
0.0476 
[0.23;0-
0.4984] 
Netherland
s-ZiN 
N/A N/A 
0.0909 
[0.2196; 
0-
0.5212] 
0.2424 
[0.276
6; 0-
0.7846
] 
0 
[0.276; 
0-
0.541] 
N/A 
0.0476 
[0.23; 
0-
0.4984
] 
0.25 
[0.237
2; 0-
0.7148
] 
0.0476 
[0.23; 
0-
0.4984
] 
0.1463 
[0.235
6; 0-
0.6081
] 
N/A 
0.0476 
[0.23; 
0-
0.4984
] 
N/A 
0.0476 
[0.23;0
-
0.4984
] 
0.186 
[0.2247;
0-
0.6263] 
0.2857 
[0.3689;
0-1] 
0.0476 
[0.23;0-
0.4984] 
0.0476 
[0.23;0-
0.4984] 
  
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: 
Haute Autorité de Santé; GÖG: Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care 
Knowledge Centre; NCPHA: The National Center of Public Health and Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj 
skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: 
Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: 
Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts agentura; 
VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: 
Instituto Nacional da Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información 
de Medicamentos; AquAS: Agència de Qualitat i Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology 
Assessment; AETSA: Andalusian Agency for Health Technology Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud.  Note: Countries with no HTA 
reports publically available have been excluded from this table. The confidence level, 1 – α, has the following interpretation. If thousands of samples of N items are drawn 
from a population using simple random sampling and a confidence interval is calculated for each sample, the proportion of those intervals that will include the true value of 
kappa is 1 – Source: The Authors 
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Annex 18: Availability of data- Other technologies – Kappa score 
Kappa scores 
[Standard error 
(SE); 95% 
confidence 
intervals] 
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SN
S*
**
 
Ireland** 
  
N/A 
0 
(0.8944;0-
1) 
0 
(0.3651; 
0-
0.7157) 
0 
(0.2236; 
0-
0.4383) 
0.1176 
(0.3222; 
0-
0.7491) 
0.2857 
(0.3912; 
0-1) 
N/A N/A 
0.5455 
(0.4066; 
0-1) 
N/A 
0.2857 
(0.3912; 
0-1) 
0 
(0.2236; 
0-1) 
0.1176 
(0.3222; 
0-
0.7491) 
France-HAS N/A 
  
0 
(0.5477;0-
1) 
0.4 
(0.3464; 
0-1) 
0.5 
(0.433; 
0-1) 
0.2857 
(0.3912; 
0-1) 
N/A 
0.2857 
(0.3912; 
0-1) 
N/A N/A 
1 
(0; 0-1) 
0.6154 
(0.344; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
Belgium-KCE 
0 
(0.8944;0-
1) 
0 
(0.5477;0-
1) 
  
0 
(0.5; 0-
0.95) 
0 
(0.2236; 
0-
0.4383) 
0 
(0.2236; 
0-
0.4383) 
0 
(0.3651; 
0-
0.7157) 
0 
(0.2236; 
0-
0.4383) 
0 
(0.3651; 
0-
0.7157) 
0 
(0.5477; 
0-1) 
0 
(0.5477; 
0-1) 
0 
(0.3651; 
0-
0.7157) 
0 
(0.2236; 
0-
0.4383) 
0 
(0.2236; 
0-
0.4383) 
Germany-
IQWIG 
0 
(0.3651; 
0-0.7157) 
0.4 
(0.3464; 
0-1) 
0 
(0.5; 0-
0.95)   
0.5455 
(0.4066; 
0-1) 
0.5455 
(0.4066; 
0-1) 
N/A 
0.5455 
(0.4066; 
0-1) 
0.1667 
(0.4564; 
0-1) 
N/A 
0.6154 
(0.344; 
0-1) 
0.1667 
(0.4564; 
0-1) 
0.5455 
(0.4066; 
0-1) 
N/A 
Germany-G-BA 
0 
(0.2236; 
0-0.4383) 
0.5 
(0.433; 0-
1) 
0 
(0.2236; 
0-0.4383) 
0.5455 
(0.4066; 
0-1)   
1 
(0; 0-1) 
N/A N/A N/A 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.5455 
(0.4066; 
0-1) 
1 
(0; 0-1) 
N/A 
Finland-Fimea 
0.1176 
(0.3222; 
0-0.7491) 
0.2857 
(0.3912; 
0-1) 
0 
(0.2236; 
0-0.4383) 
0.5455 
(0.4066; 
0-1) 
1 
(0; 0-1) 
  
N/A N/A N/A 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.5455 
(0.4066; 
0-1) 
1 
(0; 0-1) 
N/A 
Spain-ISCII 
0.2857 
(0.3912; 
0-1) 
N/A 
0 
(0.3651; 
0-0.7157) 
N/A N/A N/A 
  
N/A N/A N/A N/A 
0.1667 
(0.4564; 
0-1) 
N/A 
0.5455 
(0.4066; 
0-1) 
Spain- AQuAs N/A 
0.2857 
(0.3912; 
0-1) 
0 
(0.2236; 
0-0.4383) 
0.5455 
(0.4066; 
0-1) 
N/A N/A N/A 
  
0.5455 
(0.4066; 
0-1) 
N/A 
0.2857 
(0.3912; 
0-1) 
N/A N/A N/A 
Spain-Avalia N/A N/A 
0 
(0.3651; 
0.1667 
(0.4564; 
N/A N/A N/A 
0.5455 
(0.4066;   
N/A N/A N/A N/A N/A 
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Kappa scores 
[Standard error 
(SE); 95% 
confidence 
intervals] 
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0-0.7157) 0-1) 0-1) 
Estonia- 
University of 
Tartu 
0.5455 
(0.4066; 
0-1) 
N/A 
0 
(0.5477; 
0-1) 
N/A 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
N/A N/A N/A 
  
0.1667 
(0.4564; 
0-1) 
0.6154 
(0.344; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
Austria-LBI-
HTA 
N/A 
1 
(0; 0-1) 
0 
(0.5477; 
0-1) 
0.6154 
(0.344; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
N/A 
0.2857 
(0.3912; 
0-1) 
N/A 
0.1667 
(0.4564; 
0-1)   
0.6154 
(0.344; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
Austria-
Hauptverband 
0.2857 
(0.3912; 
0-1) 
0.6154 
(0.344; 0-
1) 
0 
(0.3651; 
0-0.7157) 
0.1667 
(0.4564; 
0-1) 
0.5455 
(0.4066; 
0-1) 
0.5455 
(0.4066; 
0-1) 
0.1667 
(0.4564; 
0-1) 
N/A N/A 
0.6154 
(0.344; 
0-1) 
0.6154 
(0.344; 
0-1)   
0.5455 
(0.4066; 
0-1) 
0.5455 
(0.4066; 
0-1) 
EUnetHTA 
0 
(0.2236; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0 
(0.2236; 
0-0.4383) 
0.5455 
(0.4066; 
0-1) 
1 
(0; 0-1) 
1 
(0; 0-1) 
N/A N/A N/A 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.5455 
(0.4066; 
0-1)   
N/A 
Portugal -
Infarmed and 
SNS*** 
0.1176 
(0.3222; 
0-0.7491) 
0.2857 
(0.3912; 
0-1) 
0 
(0.2236; 
0-0.4383) 
N/A N/A N/A 
0.5455 
(0.4066; 
0-1) 
N/A N/A 
0.2857 
(0.3912; 
0-1) 
0.2857 
(0.3912; 
0-1) 
0.5455 
(0.4066; 
0-1) 
N/A 
  
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; GÖG: 
Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; NCPHA: The National Center of Public Health and 
Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and 
Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health 
Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts 
agentura; VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional 
da Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de Medicamentos; AquAS: Agència de Qualitat i 
Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for Health Technology Assessment; SECS: 
Servicio de Evaluacion del Servicio Canario de salud. * shows available reports before 2006-thus, not included in the analysis. ** Different bodies are performing/requesting the assessment. (National 
Cancer Registry Ireland, Health Information and Quality Authority,National Immunisation Advisory Committee) *** In Poland, HTA assessments are also performed at county level. However, we 
considere only the national programmes Note: Countries with no HTA reports publically available have been excluded from this table. The confidence level, 1 – α, has the following interpretation. If 
thousands of samples of N items are drawn from a population using simple random sampling and a confidence interval is calculated for each sample, the proportion of those intervals that will include 
the true value of kappa is 1 – α. Source: The Authors  
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Annex 19: Outcomes 
Figure 1- Pharmaceutical products outcomes 
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; GÖG: 
Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; NCPHA: The National Center of Public Health and 
Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and 
Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health 
Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts 
agentura; VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional 
da Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de Medicamentos; AquAS: Agència de Qualitat i 
Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for Health Technology Assessment; SECS: 
Servicio de Evaluacion del Servicio Canario de salud. ND : No decision.  Source: The Authors  
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Abiraterone 
  
                      
  
            
Aclidinium 
Bromidium   
  
        
    
        
  
            
Alemtuzumab                                       
Apremilast                                      
Ataluren                                      
Canagliflozin                                      
Dapagliflozin                                       
Defibrotide Suspended                                     
Ivacaftor                                   ND   
Mirabegron                                       
Nivolumab                                  ND   
Nintedanib   ND                                  
Ocriplasmin                                   ND   
Ofatumumab   ND                                  
Omalizumab                                       
Pasireotide                                       
Ramucirumab                                  ND   
Rilpivirine                                       
Riociguat   ND                                  
Sofosbuvir                                      
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Figure 2- Pharamaceuticals products- Outcomes 
Molecules name Branded name IQWIG HAS ZIN 
Abiraterone Zytiga® 
Best supportive care population 
Mortality: There is an indication of an added benefit of abiraterone 
acetate/prednisone/BSC over prednisone/BSC for this outcome. 
Morbidity: There is an indication of an added benefit of abiraterone 
acetate/prednisone/BSC over prednisone/BSC for both outcomes. 
Docetaxel retreatment population:  An added benefit for the docetaxel retreatment 
population is not proven. 
SMR Important  
ASMR III (moderate) 
Included in 
the list 1B 
Aclidinium bromide Eklira Genuair® 
 1: Grade II: added benefit not proven;Grade III with < 2 exacerbations per year: Proof 
of considerable added benefit;Grade IV with < 2 exacerbations per year: Added benefit 
not 
proven;an added benefit for all-cause mortality is therefore not proven. ; an added 
benefit for the outcome “TDI responder” is therefore not proven.; an added benefit for 
the outcome “E-RS responder” is therefore not proven.  
2: no hint of an added benefit of aclidinium in comparison with the ACT for adult 
patients with COPD grades III and IV with 2 or more exacerbations per year; an added 
benefit is therefore not proven.  
Insufficient  
Included in 
the list 1A 
Alemtuzumab Lemtrada®  N/A 
Moderate  SMR (In patients with severe MS-RR, defined by the occurrence of two or 
more disabling sprays in one year associated with cerebral MRI inflammatory activity 
(one or more lesions enhanced after injection Of Gadolinium), despite treatment of 
1st line or 2nd line) 
Insufficient  SMR (other forms of MS) 
ASMR IV 
Intramural 
drug 
Apremilast Otezla® 
an added benefit of apremilast in comparison with the ACT (adalimumab or infliximab 
or ustekinumab) is not proven for patients with plaque psoriasis. 
Moderate SMR 
 
ASMR V 
 N/A 
Ataluren Translarna® no added benefit 
Moderate SMR 
 
ASMR IV 
 N/A 
Canagliflozin Invokana®  N/A Insufficient SMR  
mural drug, 
included in 
the list 1A + 
list 2 
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Molecules name Branded name IQWIG HAS ZIN 
Dapagliflozin Forxiga® 
Dapagliflozin monotherapy: no added benefit  
Combination therapy of dapagliflozin and metformin:  no added benefit  
Combination therapy of dapagliflozin and sulfonylureas: no added benefit 
Combination therapy of dapagliflozin and insulin: no added benefit 
Moderate 
The actual benefit of FORXIGA is : 
- moderate as dual therapy in combination with metformin or a sulfonylurea 
- moderate as triple therapy in combination with insulin and metformin 
Insufficient  
- insufficient as monotherapy for reimbursement by National Health Insurance 
Improvement in actual benefit 
V (absence)  
In the dual therapy indications, in combination with metformin or a sulfonylurea and 
triple therapy, in combination with insulin and metformin : 
Given the very modest glycaemic control observed compared with the placebo, 
doubts about the safety profile, particularly on an infectious, cardiovascular and 
carcinogenic level, and the difficulty in defining the therapeutic use, the Committee 
cannot recognise any improvement for FORXIGA. 
In addition, the Transparency Committee considers that FORXIGA does not provide 
any improvement in actual benefit (level V, non-existent) in the management of 
patients with type 2 diabetes in dual oral therapy, in combination with metformin or 
a sulfonylurea and in triple therapy, in combination with insulin and metformin. 
Sans objet  
In the monotherapy and dual therapy indications, in combination with insulin : not 
applicable 
Extramural 
drug, 
included in 
the list 1B + 
list 2 
Defibrotide Defitelio®  N/A 
Moderate SMR 
ASMR IV 
 N/A 
Ivacaftor Kalydeco®  N/A 
Major SMR 
ASMR II 
Included in 
the list 1B + 
list 2 
Mirabregon Betmiga® 
No added benefit of mirabegron can be derived in the overall assessment of morbidity 
outcomes. Moreover, there were no data on the outcomes “incontinence” and “urge 
incontinence” for the total population. 
Weak SMR  
(temporary in waiting for study versus solifenacin results) 
ASMR V 
Included in 
the list 1A 
Nintedanib Ofev®   
Moderate SMR 
ASMR IV 
Included in 
the list 1A + 
list 2 
Nivolumab Opdivo® 
Subgroup 1: no proven added benefit 
Subgroup 2: Nivolumab treatment resulted in a statistically significant prolongation of 
overall survival in comparison with dacarbazine. For morbidity and HQoL: no hint of an 
added benefit.Men: Indication of considerable added benefit. Women: Hint of minor 
added benefit 
Subgroup 3: no proven added benefit 
Major SMR 
ASMR III 
N/A 
Ocriplasmin Jetrea® 
VMT population with mild symptoms:For patients with mild visual impairment (> 60 
ETDRS letters), there is an indication of a major added benefit of ocriplasmin in 
comparison with watchful waiting. For patients with moderate visual impairment (35 
Major SMR 
ASMR IV 
 N/A 
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Molecules name Branded name IQWIG HAS ZIN 
to 60 ETDRS letters), there is an indication of a considerable added benefit of 
ocriplasmin in comparison with watchful waiting. In summary, for patients with mild 
visual impairment (> 60 ETDRS letters) there is an indication of a major added benefit 
of ocriplasmin compared with watchful waiting.In summary, for patients with 
moderate visual impairment (35 to 60 ETDRS letters) there is an indication of a 
considerable added benefit of ocriplasmin compared with watchful waiting. 
Subpopulation with asymptomatic VMT: not proven added benefit 
Subpopulation with asymptomatic VMT: not proven added benefit 
VMT population with severe symptoms: not proven added benefit 
Ofatumumab Arzerra® N/A 
Major SMR 
ASMR V 
Intramural 
drug 
Omalizumab Xolair® 
 
Moderate SMR 
ASMR IV 
 N/A 
Pasireotide Signifor®  N/A 
Moderate SMR 
ASMR V 
Included in 
the list 1B 
Ramucirumab Cyramza® 
1. no evidence for an additional benefit of ramucirumab + paclitaxel compared to the 
appropriate comparative therapy 
2.no evidence for an additional benefit of ramucirumab compared to the appropriate 
comparative therapy 
Combination with pactlixel: 
Moderate SMR 
ASMR V 
Monotherapy: 
No SMR 
Intramural 
drug 
Rilpivirine Edurant®  N/A 
Important SMR (In combination with other antiretroviral in the restricted MA 
population to patients for whom efavirenz treatment is not appropriate.) 
Insufficient SMR (all the other category of patients) 
ASMR V 
Included in 
the list 1B 
Riociguat Adempas®  N/A 
CTEPH: 
Moderate SMR 
ASMR V 
PAH: 
Moderate SMR 
ASMR IV 
Included in 
the list 1A + 
list 2 
Sofosbuvir Sovaldi® no added benefit proven  
SMR Important 
ASMR II  ( In combination with pegylated interferon alfa and / or ribavirin In the 
management of all adult patients infected with HCV, except for patients of genotype 
3 naïve antiviral treatment.)  
ASMR III ( In combination with pegylated interferon alfa and / or ribavirin  in the 
management of adult patients infected with HCV genotype 3 naïve antiviral 
treatment) 
Included in 
the list 1B 
HAS: Haute Autorité de Santé; IQWIG: Institute for Quality and Efficiency in Healthcare N/A: not applicable, not appraised; SMR: Service Médical Rendu; ASMR: Amélioration du Service Médical Rendu; 
ZiN: Zorginstituut Nederland.   
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Figure 3- Medical device outcomes 
Medical Devices 
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Endovascular stent–
grafts 
Not specified                                    
TALENT LPS                                    
Aorfix AAA stent–graft                                   
Zenith AAA endovascular 
graft 
                                  
Endologix Powerlink 
Systems 
                                  
Haemodialysis devices   ND                                 
Transcatheter 
implantable devices 
 CARILLON® Mitral 
Contour System®  
                                  
MitraClip® System                                    
NeoChord DS1000                                    
Balloon Eustachian 
Tuboplasty 
TubaVent® and AERATM®                                   
Oscillometric blood 
pressure monitor 
Not specified                                    
High intensity focused 
ultrasound (HIFU) 
Sonablate®                                    
Ablatherm®                                    
 Focal One                                   
 JC/JC200                                   
UroLift system                                    
Self-monitoring 
coagulometers 
INRatio2 PT/INR monitor                                   
CoaguChek XS system                                    
Protime®                                   
Positron emission 
tomography (PET) 
Not specified                                    
Cochlear implants Not specified                                    
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Medical Devices 
Included 
Branded name  
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Clarion CII Bionic Ear 
System and the 
HiResolution Bionic Ear 
System ® 
                
 
                
Nucleus 24® and Nucleus 
Freedom® cochlear 
implants  
                
  
                
Pulsar CI-100 ®                                   
Digisonic SP®                                   
Left ventricular assist 
devices 
HeartMate II®                 
  
                
LASER KTP GreenLight XPS®                                   
Gene expression 
profiling diagnostics 
uPA/PAI-1®                                   
MammaPrint®                                   
Oncotype DX®                                   
EndoPredict®                                   
Nucleic acid 
amplification tests 
(NAATs) 
 
                
  
  
 
            
Duodenal-jejunal 
bypass sleeve 
Not specified    
  
 
                          
EndoBarrier®                                   
In-vitro fertilisation 
(IVF)  
Not specified                  
  
                
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute 
Autorité de Santé; GÖG: Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; 
NCPHA: The National Center of Public Health and Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish 
Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos Gyógyszerészeti 
és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: 
Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts agentura; VASPVT: Valstybinė akreditavimo 
sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional da Farmácia e do 
Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de Medicamentos; AquAS: Agència de 
Qualitat i Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for 
Health Technology Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud. ND : No decision 
Source: The Authors 
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Figure 4- Other technologies outcomes 
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HPV Vaccination       N/A N/A N/A ND N/A N/A     ND N/A   
Colorectal Cancer 
Screening  
      ND     N/A N/A N/A     ND   N/A 
Pneumococcal 
Vaccination 
  N/A   N/A N/A N/A N/A N/A     N/A N/A N/A N/A 
Rotavirus Vaccination   N/A   N/A N/A N/A   N/A N/A N/A N/A N/A N/A N/A 
Cervical cancer 
screening 
N/A *   ND N/A N/A N/A   ** N/A   N/A N/A N/A 
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute 
Autorité de Santé; GÖG: Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; 
NCPHA: The National Center of Public Health and Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish 
Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos Gyógyszerészeti 
és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: 
Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts agentura; VASPVT: Valstybinė akreditavimo 
sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional da Farmácia e do 
Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de Medicamentos; AquAS: Agència de 
Qualitat i Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for 
Health Technology Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud. ND : No decision ; N/A : not assessed *  1. Smear Test:Listed 2. HPV Test: 
Rejected ; **mRNA test rejected due to insufficient evidence.  
Source: The Authors 
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Annex 20: Economic restrictions- pharmaceutical sample 
 
AOTM AQUAS CROATIA HAS* EUnHTA FINoHTA INFRAMED 
ITALY 
CRUF 
KCE 
LBI-
HTA 
NCPE NICE 
MoH 
Romania 
SMC TLV ZIN 
Abiraterone 
   
100% 
   
RSA 
  
Price 
negotion 
RSA 
 
RSA RSA RSA 
Aclidinium 
Bromidium    
NS 
            
Alemtuzumab 
   
 
NS           
RSA RSA 
Apremilast 
   
30% 
       
RSA 
    
Ataluren 
   
NS 
            
Canagliflozin 
   
65% 
      
Price 
negotion      
Dapagliflozin 
   
30% 
      
Price 
negotion      
Defibrotide 
   
NS 
            
Ivacaftor 
   
65% 
         
RSA 
  
Mirabegron 
   
15% 
           
RSA 
Nivolumab RSA 
  
100% 
        
RSA RSA 
  
Nintedanib RSA 
  
30% 
       
RSA 
 
RSA 
 
RSA 
Ocriplasmin 
   
NS 
  
Price 
negotiation          
Ofatumumab RSA 
  
NS 
       
RSA 
    
Omalizumab RSA 
  
30% 
       
RSA 
    
Pasireotide 
   
30% 
            
Ramucirumab 
   
NS 
            
Rilpivirine 
   
100% 
  
Price 
negotiation         
RSA 
Riociguat 
   
NS 
         
RSA 
  
Sofosbuvir 
   
NS 
  
Price 
negotiation       
RSA 
 
RSA 
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute 
Autorité de Santé; GÖG: Gesundheit Österreich GmbH;  LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; 
NCPHA: The National Center of Public Health and Analyses ; MoH: Ministry of Health; Azz: Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish 
Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos Gyógyszerészeti 
és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: 
Unità di valutazione dell'efficacia del farmaco ; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts agentura; VASPVT: Valstybinė akreditavimo 
sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional da Farmácia e do 
Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de Medicamentos; AquAS: Agència de 
Qualitat i Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for 
Health Technology Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud. NS: Not stated * HAS decided on the level of reimbursement to apply for each 
Pharmaceutical product.  
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HTA systems 
Arm’s length body 
Advisory 
NICE (England) 
SMC (Scotland) 
TLV (Sweden) 
OGYEI (Hungary) 
AOiTM (Poland) 
INFRAMED (Portugal) 
STGH (Scotland) 
AWTTC (Wales) 
IQWIG (Germany) 
NCPE (Ireland) 
HIQA (Ireland) 
Regulatory 
G-BA (Germany) 
FIMEA (Finland) 
Coordination 
University of Tartu (Estonia) 
KCE (Belgium) 
AEMPS (Spain) 
OESTEBA (Spain) 
AETSA (Spain) 
SECS (Spain) 
Avalia-T (Spain) 
AQUAS (Spain) 
UETS (Spain) 
IACS (Spain) 
ISCII (Spain) 
SBU (Sweden) 
AZZ (slovenia) 
HTA function 
incorporated/Integrate
d  
Develop indipendent 
HTA funciton w/in 
insurance body 
Advisory 
INAMI (Belgium) 
Hauptverband (Austria) 
Union Health Insurance 
Fund (Slovakia) 
Croatian Health 
Estonian Health 
Insurance Fund (EHIF) 
Health Insurance Institute 
of Slovenia (HIIS) 
ZIN (Netherlands) 
Use HTA to 
determine Pricing or 
coverage decisions 
Regulatory 
AIFA (Italy) 
National Center of Public 
Health and Analyses 
(Bulgaria)  
SUKL (Checz Republic) 
JAZMP (Slovenia) 
State Medicines Control 
Agency (SMCA) 
Cellule d'expertise médicale 
(Luxembourg) 
Ministry of Human Capacities, 
State Secretary of Health, 
Department for 
Pharmaceuticals and Medical 
Devices (Hungary) 
Slovakia Ministry of Health 
(Slovakia) 
VASPVT  (Latvia) 
DPA/MFH (Malta) 
Annex 21: Taxonomy of HTA systems 
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Annex 22: Average percentage of usage of mode 
 Pharma Industry MedTech Industry Public Administration 
EC1 70% 73% 26% 
EC2 76% 63% 28% 
EC3 51% 41% 34% 
EC4 69% 37% 31% 
EC5 82% 42% 38% 
EC6 72% 59% 31% 
EC7 79% 48% 43% 
EC8 28% 38% 35% 
SH1 60% 33% 43% 
SH2 81% 36% 34% 
SH3 75% 35% 39% 
SH4 84% 60% 36% 
SH5 74% 54% 33% 
all impacts 69% 52% 32% 
Source: GÖ FP / LSE survey 2017 
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Annex 23: Follow-up questionnaire regarding costs of HTA 
bodies 
Study on impact analysis of  
policy options for strengthened EU cooperation on HTA  
Costs of the current HTA system in Europe (Baseline costs) 
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To complete the data gathering exercise and in line with the discussions of the last EUnetHTA Executive Board 
meeting , we would kindly ask you to provide the main costs factors for your body in performing HTA 
activities as stated in the table below This information is needed to maximize the completeness and the 
reliability of the results and to cover as many European countries as possible regarding the costs of HTA 
processes.  
 
Nota bene:  
HTA bodies that submitted cost information in response to the online survey do not need to respond to the 
questions contained in this document. The information previously provided will be used. 
 
Background 
In the course of the study a detailed case study covering 40 health technologies including pharmaceuticals, 
medical devices and other technologies (such as screening programs) has been conducted to assess the status 
quo of HTA in Europe. Data for this case study have been retrieved by literature review and an additional 
survey process to complement information retrieved.  
Additionally, this study aims to provide an overview about the costs of HTA assessment processes in Europe 
for different stakeholder groups. Therefore, different cost components of performing HTA were requested 
through an online survey.   
The information which will be provided in response to the attached questions will be used in a strictly 
confidential manner. Only aggregated data will be presented in the report including an indication of the 
countries and HTA bodies whose information was used. The costs submitted by individual HTA bodies won´t be 
presented alone and no comparison across different bodies/countries is intended.  
 
Please send the information by 18
th
 April to EU.HTA@goeg.at.   
 
Many thanks for your kind cooperation.  
 
Comments:  
- Please fill in if relevant. If not relevant (=not done) please fill in NR. If not available please fill in NA. 
- If data are available for separate product categories (pharmaceuticals, medical technologies and other 
technologies), please provide information separately 
- Include information for 2016 or latest year available (please indicate ) 
- Please report cost data in Euro and indicate where applicable the exchange rate used.  
- Total unit cost should ideally include variable and fixed costs/overheads. The data can be provided as an 
average or as a range. If the information on total costs is not available provide an estimate or indicate to 
the extent possible what your cost data includes. 
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ITEM 
   
Total unit costs: please give an average and/or range 
per item below in Euro 
Current annual number of 
products / assessments done 
by your agency for the years 
2014 /  2015 / 2016 
Full Cost for HTA body 
in 2016  
(please state if 
overhead costs are 
included or not) 
If relevant: 
Costs for industry 
(submission fees) 
2016 
Early Dialogue (ED)1 
(see definition below)   
2014:  
2015:  
2016:   
REA / Rapid Assessment2 
see definition below 
 
 
2014:  
2015:  
2016:  
REA / Rapid Assessment incl. economic 
evaluation3 
see definition below 
  
2014:  
2015:  
2016:  
Full HTA4  
see definition below   
2014:  
2015:  
2016:  
5National adaptation of a joint REA: (Please give 
an estimation for the average costs when a 
national adaptation is done and specify what 
was done) 1. Summarizing; 2. Update of 
searches; 3. Adapting; 4.Translation to own 
language;   
  
2014:  
2015:  
2016:  
5National adaptation of a joint full HTA: 
(Please give an estimation for the average costs 
when a national adaptation is done and specify 
what was done) 
  
2014:  
2015:  
2016:  
1Early Dialogue (ED): Early Dialogues is the process offered by HTA bodies with the 
aim of helping pharmaceutical and medtech companies to understand the evidence and 
information needs of the HTA organizations and reimbursement bodies to improve the 
quality and adequacy of early evidence generation. 
2REA / rapid assessment  is the process to assess the medical/therapeutic added value 
of a new technology (assessment of clinical domains). Broadly speaking two forms exist: 
a) a Rapid Assessment produced (mainly) by an HTA-body (with no or some 
evidence/data submission provided by industry) or b) a Rapid Assessment produced 
mainly by industry and reviewed by an HTA body (please indicate). Please do not include 
EUnetHTA Joint Assessments. 
3REA / rapid Assessment incl. economic evaluations is the process to assess (1) the 
medical/therapeutic added value of a new technology (assessment of clinical domains) 
and (2) the cost-effectiveness / budget impact. Again it may take two forms (see above, 
please indicate which form corresponds best to your assessments). Please do not include 
EUnetHTA Joint Assessments. 
4Full HTA is the process to assess (1) the medical/therapeutic added value of a new 
technology (assessment of clinical domains), (2) the cost-effectiveness / budget impact, 
Total budget spent annually on HTA activities 
(approx.) in 2016 or latest available YEAR   
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and (3) other aspects, e.g. ethical aspects, legal considerations and impact on patients 
as well as on the health care systems. Please do not include EUnetHTA Joint 
Assessments. 
5National adaptation of a joint REA or a joint full HTA: includes a range of options; 
please indicate for your estimates on costs and annual numbers the most suitable option 
(according to EUnetHTA definition): 1) Summarizing: translate the summary and use this 
for background information, 2) Updating searches: using the original search strategy to 
identify any more recent evidence or adding to the search strategy and extending it. 3) 
Adapting: the systematic extraction of relevant HTA information from an existing report 
(from a whole report or from part of a report). 4) Adopting: making use of the report 
without making any changes at all (except perhaps translation into your own language).  
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Annex 24: Further impacts for Public Administration - Graphs of 
survey results  
Public Administration – perceived average effect of Policy Options on employment (30) 
 
Source: GÖ FP / LSE survey 2017 
 
Public Administration – perceived average effect of Policy Options on consumers and 
households (31) 
 
Source: GÖ FP / LSE survey 2017 
                                   
(30)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Nr of Staff 21,0 91% 22,2 33% 14% 52% 
 
(31)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Nr Health Technologies Available 22,0 96% 17,0 41% 14% 45% 
Nr Health Technologies Assessed 22,0 96% 20,1 18% 9% 73% 
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Public Administration - perceived average effect of Policy Options on competitiveness of 
EU health technology sector (32) 
 
Source: GÖ FP / LSE survey 2017  
 
 
 
 
                                   
(32)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Predictibility of HTA System 22,0 96% 28,1 5% 9% 86% 
Competitiveness of SME 15,2 66% 23,2 7% 20% 73% 
Revenues 18,0 78% 18,3 44% 17% 39% 
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Public Administration – perceived average effect of Policy Options on internal market 
and competition (33) 
 
Source: GÖ FP / LSE survey 2017 
Public Administration – perceived average effect of Policy Options on International Trade 
(34) 
 
Source: GÖ FP / LSE survey 2017  
 
                                   
(33)  
Aggregation: inverted for fragmentation of HTA system 
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Fragmentation of HTA System 22,0 96% 33,6 5% 77% 18% 
Convergence of HTA 
Methodologies 
22,0 96% 32,9 5% 9% 86% 
Attractiveness of EU Market 20,0 87% 29,3 5% 5% 90% 
 
(34)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
International Trade 18,0 78% 15,7 27% 6% 67% 
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Public Administration – perceived average effect of Policy Options on macroeconomic 
environment (35) 
 
Source: GÖ FP / LSE survey 2017 
 
                                   
(35)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Economic Growth and Labour 
Market 
17,0 74% 20,0 35% 12% 53% 
Health Technology Sector 18,0 78% 23,9 17% 11% 72% 
Health Care Sector 18,0 78% 16,8 33% 6% 61% 
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Annex 25: Further impacts for Pharmaceutical Industry - Graphs of 
survey results  
Pharma Industry – perceived average effect of Policy Options on consumers and 
households (36) 
 
Source: GÖ FP / LSE survey 2017 
 
 
Pharma Industry – perceived average effect of Policy Options on international trade (37) 
 
Source: GÖ FP / LSE survey 2017  
                                   
(36)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Nr Health Technologies Available 14,0 88% 9,2 0% 100% 0% 
Nr Health Technologies Assessed 14,0 88% 5,4 0% 100% 0% 
 
(37)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
International Trade 14,0 88% 8,0 8% 92% 0% 
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Pharma Industry – perceived average effect of Policy Options on macroeconomic 
environment(38) 
 
Source: GÖ FP / LSE survey 2017 
 
Pharma Industry – perceived average effect of Policy Options on access to social 
protection and health systems(39) 
Source: GÖ FP / LSE survey 2017 
 
                                   
(38)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Economic Growth and Labour 
Market 
13,8 86% 6,0 0% 92% 8% 
Health Technology Sector 3,0 19% 15,1 0% 100% 0% 
Health Care Sector 2,0 13% 21,0 0% 100% 0% 
 
(39)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Access to Innovative Treatments 14,0 88% 11,2 0% 92% 8% 
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Pharma Industry – perceived average effect of Policy Options on employment (40) 
 
Source: GÖ FP / LSE survey 2017 
 
Pharma Industry - perceived average effect of Policy Options on sustainability of health 
systems (41) 
 
Source: GÖ FP / LSE survey 2017  
                                   
(40)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Nr of Staff 14,0 88% 6,7 23% 0% 77% 
 
(41)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Financing of expensive treatments 
with little or no added value 
14,0 88% 5,2 92% 8% 0% 
Negotiation power of member 
states in setting prices 
14,0 88% 4,3 100% 0% 0% 
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Pharma Industry – perceived average effect of Policy Options on Public Health (42) 
 
Source: GÖ FP / LSE survey 2017 
 
Pharma Industry – perceived average effect of Policy Options on indicators for 
governance, participation and good administration (unaggregated) (43) 
 
Source: GÖ FP / LSE survey 2017 
                                   
(42)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Availability of Health Technologies 14,0 88% 8,7 0% 100% 0% 
Overall public health 14,0 88% 7,3 0% 100% 0% 
 
(43)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Stakeholder Involvement 14,0 88% 5,2 0% 0% 100% 
Responsibilities Member States 14,0 88% 5,5 0% 0% 100% 
Uptake Joint Outputs 14,0 88% 7,2 8% 0% 92% 
Resource Efficiency 14,0 88% 6,1 0% 100% 0% 
Sustainability HTA Cooperation 14,0 88% 16,8 92% 8% 0% 
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MedTech Industry – perceived average effect of Policy Options on indicators for 
governance, participation and good administration (unaggregated) (44) 
 
Source: GÖ FP / LSE survey 2017 
 
 
 
  
                                   
(44)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Stakeholder Involvement 86,5 87% 37,0 7% 82% 11% 
Responsibilities Member States 85,7 87% 24,5 20% 4% 76% 
Uptake Joint Outputs 85,5 86% 35,4 2% 82% 15% 
Resource Efficiency 85,5 86% 33,6 4% 86% 11% 
Sustainability HTA Cooperation 86,5 87% 32,6 1% 85% 14% 
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Annex 26: Further impacts for MedTech Industry - Graphs of 
survey results  
MedTech Industry – perceived average effect of Policy Options on consumers and 
households (45) 
 
Source: GÖ FP / LSE survey 2017 
 
MedTech Industry – perceived average effect of Policy Options on international trade 
(46) 
 
Source: GÖ FP / LSE survey 2017  
                                   
(45)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Nr Health Technologies Available 90,2 91% 23,4 2% 94% 3% 
Nr Health Technologies Assessed 87,8 89% 20,4 8% 4% 88% 
 
(46)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
International Trade 90,2 91% 26,2 6% 86% 8% 
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MedTech Industry – perceived average effect of Policy Options on employment (47) 
 
Source: GÖ FP / LSE survey 2017 
 
 
                                   
(47)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Nr of Staff 86,8 88% 29,6 7% 80% 13% 
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MedTech Industry – perceived average effect of Policy Options on macroeconomic 
environment (48) 
 
Source: GÖ FP / LSE survey 2017 
 
                                   
(48)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Economic Growth and Labour 
Market 
89,8 91% 29,3 5% 89% 7% 
Health Technology Sector 90,0 91% 28,9 5% 91% 5% 
Health Care Sector 89,8 91% 28,7 5% 87% 8% 
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MedTech Industry – perceived average effect of Policy Options on sustainability of health 
systems (49) 
 
Source: GÖ FP / LSE survey 2017  
 
MedTech Industry – perceived average effect of Policy Options on Public Health (50)  
 
  Source: GÖ FP / LSE survey 2017  
                                   
(49)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Financing of expensive treatments 
with little or no added value 
87,5 88% 25,7 6% 88% 6% 
Negotiation power of member 
states in setting prices 
85,8 87% 18,2 82% 6% 12% 
 
(50)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Availability of Health Technologies 87,2 88% 26,7 4% 94% 2% 
Overall public health 85,8 87% 18,7 84% 8% 8% 
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MedTech Industry – perceived average effect of Policy Options on indicators for 
governance, participation and good administration (unaggregated)(51) 
 
Source: GÖ FP / LSE survey 2017 
 
 
                                   
51  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Stakeholder Involvement 86,5 87% 37,0 7% 82% 11% 
Responsibilities Member States 85,7 87% 24,5 20% 4% 76% 
Uptake Joint Outputs 85,5 86% 35,4 2% 82% 15% 
Resource Efficiency 85,5 86% 33,6 4% 86% 11% 
Sustainability HTA Cooperation 86,5 87% 32,6 1% 85% 14% 
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MedTech Industry – perceived average effect of Policy Options on access to social 
protection and health systems (52) 
 
Source: GÖ FP / LSE survey 2017 
 
                                   
(52)  
additional information av. responses response rate av. std. dev no trend negative trend positive trend 
Access to Innovative Treatments 87,0 88% 26,3 0% 94% 6% 
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Annex 27: Medical technology example  
The product selected received EMA marketing authorization for two different indications 
for treating a chronic disease through the centralized procedure.  
The product underwent HTA assessments in 11 countries by 12 agencies. In Germany, 
we considered both the evaluation from IQWIG and G-BA, even if they do not differ in 
terms of outcome, in order to assess differences, if any, between the two agencies in the 
way they perceive and assess the submitted evidence. Indeed, the procedure for arriving 
at the overall conclusion on the extent of added benefit is a proposal from IQWiG in the 
first instance; G-BA is taking the final decision and also conducts its own evaluation; in 
some cases, the opinions of the two agencies may differ. In this case, for example, G-BA 
extended the benefit to Level two also to the other sub-population, rated at Level V by 
IQWIG. 
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Table 6- Overview of HTA recommendations  
Country 
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M.A. Date: 
XX/XX/XXXX 
Type of M.A. 
Centralized 
Decision date XX/XX/X
XXX 
XX/XX/XXXX XX/XX/XXXX XX/XX/XXXX XX/XX/XXXX XX/XX/XXXX XX/XX/XXXX XX/XX/XXXX XX/XX/XXX
X 
XX/XX/X
XXX 
XX/XX/XX
XX 
XX/XX/XXXX 
Decision LWC LWC LWC ASMR III 
SMR: 
Important 
LWC LWC LWC Sub-
population 1: 
Level 2 
Sub-
population 2: 
Level 5 
L 
(Level 2) 
L L LWC 
Clinical 
restrictions 
Not 
stated   
  
       
Economic 
restrictions 
Not 
stated            
Severity               
Rarity                 
Unmet need for 
treatments  
      
      
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Special 
conditions 
considered 
 
 End of life 
criteria 
 
Humanitaria
n aspect and  
solidarity 
principle  
 SMC 
Modifiers          
Burden on 
family and 
carers 
emotional well 
being                
Impact on work 
and everyday 
life activities                
Wider societal 
Benefits                 
Equality issues                
Small 
population                
Significant 
innovation                
             
Legend:  : presence of the variables; NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and 
Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; UVEF: Unità 
di valutazione dell'efficacia del farmaco ; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional da 
Farmácia e do Medicamento;.MoH; Minsitry of Health; NCPE: National Centre for Pharmacoeconomics.  
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The primary evidence for the clinical benefit stemmed by the same randomised, double-
blind phase-III study comparing the efficacy and tolerability of the product with placebo. 
The total number of studies submitted and evaluated by HTA agencies differed widely. In 
three cases (IQWIG, G-BA and ZIN) an indirect comparison was also included in order to 
compare the product with a direct comparator whereas NICE, TLV, AOTM and ZIN also 
included another Phase III trial in order to support the clinical effectiveness arguments. 
Finally, TLV included an observational study to support the clinical benefit and ZIN 
included the results of the EPAR report, while AOTMiT included three studies assessing 
the drug with a direct comparator. 
Considering the submission of the economic evidence, HTA agencies considered at least 
one cost-utility analysis. The comparators included in the analysis differed is some cases, 
which might lead to a different outcome. For Instance, TLV considered an analysis that 
compared the cost-effectiveness of the product against the direct comparator and partly 
against no treatment, that is, only symptomatic treatment, whereas ZIN, NICE, UVEF 
considered only comparison with the same direct comparator. INFRAMED considered the 
comparison with a direct comparator, that for example is not licensed in the UK. It is 
important to highlight also, that most of the agencies (e.g. SMC, AOTMiT and ZIN) 
considered a budget impact analysis, which, in some cases (ZIN), had a negative 
influence on the final decision.  For instance, ZIN highlighted that the budget impact on 
pharmaceutical expenditure was calculated between €9 and €13 million per year, leading 
to a higher cost than the use of the comparator currently used in clinical practice.  
A number of elicited and non-elicited social value judgments were identified in the 
reports, some of which helped shape or influence the final HTA recommendation. These 
values, comprising clinical, social, and ethical parameters, have increasingly been 
included in HTA decisions in order fully assess the value of healthcare technologies when 
making judgments regarding clinical and cost effectiveness. In some cases (e.g. End of 
life criteria by NICE in England; and SMC modifiers in Scotland), HTA agencies state 
these values explicitly in the guidelines and are captured in a consistent manner across 
all the relevant reports.  In other cases, some types of value (e.g. Degree of innovation 
or administration benefit) are taken into consideration in addition to the cost per unit of 
health gain but in a less standardized manner.  
Considering non-elicited social value judgments, seven out of 13 agencies considered 
important to include a treatment in this area because of unmet medical need. 
Specifically, TLV, ZIN and HAS highlighted the national importance of having a treatment 
for this chronic disease in late stage disease whereas SMC specifically stated an unmet 
need in this treatment category. Whereas most of the agencies consider the product as 
palliative care treatment, HAS considered that product as a ‘curative’ treatment and 
commented it could provide an additional response to public health need compared to the 
therapeutic strategy currently in place. NICE, ZIN and AOTM pointed out the 
innovativeness of the treatment in terms of its mode of administration because it is an 
oral drug taken by patients at home. This advantage is highlighted also by SMC and HAS, 
the latter stating in its report that the product under review offers an alternative, orally 
administered to other treatments, and is better tolerated with a different safety profile. 
SMC highlighted the unmet need in this area with very limited treatment options in this 
stage of the disease. The most common alternative treatment was cited by HAS and 
NICE. NICE also suggested another product considered as main treatment an alternative 
in other countries has not been licensed in UK.  
Looking at the management of the disease, HAS pointed out that the method of 
administration could have a positive impact on the organization of patient care, having a 
clear influence on the final decision. 
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For all HTA agencies, the most important “other consideration” in the decision was the 
improvement in the quality of life of patients using the product.   
Looking at the elicited social value judgments, their consideration by three agencies 
(NICE, SMC and TLV) had a considerable impact on the outcome, leading the agencies to 
accept an ICER higher than their notional threshold. Specifically, elicited social value 
judgments played a key role in the assessment by NICE.  Initially, NICE rejected the 
product because it was not considered to be cost-effective stating that the End of life 
criteria were not applicable due to the absence of the prerequisite of a no small 
population and the ICER (XX,XXX/QALY) was significantly over what it would consider 
acceptable even with the application of EoL criteria (which is in the region of XX,XXX 
/QALY). However, in February 2012 the product underwent a re-evaluation and it was 
accepted with restrictions, stating that the eligible patient population was actually small 
and the drug was suitable for the consideration of the end-of-life criteria. Interestingly, 
NICE reversed its initial decision within one month, whereas it took nearly three years for 
TLV to decide to reimburse the drug with restrictions. 
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Table 7: Medical technology example: Conclusions  
Legend: *: clinical effectiveness uncertain and not demonstrated; : improved or positively assessed clinical effective 
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Clinical effectiveness 
 
 
 
 
 
 
 
 
        
Economic analysis 
* 
 * 
N/A * * * N/A N/A  N/A  
Social  value 
judgments with an 
influence on decision 
End of life 
criteria 
SMC 
modifiers 
Human dignity 
and solidarity 
principle 
Administration 
advantage 
N/A N/A N/A N/A N/A  N/A N/A 
Risk sharing 
agreement/ Pricing 
agreements 
Commercial 
access 
arrangement 
Patient 
Access 
Scheme 
(PAS) 
Yes N/A 
Price 
negotiation 
Annex 
1b 
Yes- 
Confiden
tial 
N/A N/A N/A 
the list 
comprising 
DCI 
Cost Sharing in 
accordance with 
the contractual 
condition. List H 
[E
W
-0
5
-1
7
-0
7
3
-E
N
-N
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